Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models   new Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term:irinotecan
go back to main search page
Accession:CHEBI:80630 term browser browse the term
Definition:A member of the class of pyranoindolizinoquinolines that is the carbamate ester obtained by formal condensation of the carboxy group of [1,4'-bipiperidine]-1'-carboxylic acid with the phenolic hydroxy group of (4S)-4,11-diethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2- hydrochloride]quinoline-3,14-dione. Used (in the form of its hydrochloride salt trihydrate) in combination with fluorouracil and leucovorin, for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. It is converted via hydrolysis of the carbamate linkage to its active metabolite, SN-38, which is ~1000 times more active.
Synonyms:exact_synonym: (4S)-4,11-diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl [1,4'-bipiperidine]-1'-carboxylate
 related_synonym: Formula=C33H38N4O6;   HSDB 7607;   InChI=1S/C33H38N4O6/c1-3-22-23-16-21(43-32(40)36-14-10-20(11-15-36)35-12-6-5-7-13-35)8-9-27(23)34-29-24(22)18-37-28(29)17-26-25(30(37)38)19-42-31(39)33(26,41)4-2/h8-9,16-17,20,41H,3-7,10-15,18-19H2,1-2H3/t33-/m0/s1;   InChIKey=UWKQSNNFCGGAFS-XIFFEERXSA-N;   Irinophore C;   Irinotecan lactone;   Irinotecan mylan;   SMILES=C1(=CC=C2C(=C1)C(=C3C(=N2)C=4N(C3)C(C5=C(C4)[C@](C(OC5)=O)(CC)O)=O)CC)OC(=O)N6CCC(CC6)N7CCCCC7;   irinotecanum
 xref: CAS:97682-44-5;   DrugBank:DB00762;   Drug_Central:1482;   HMDB:HMDB0014900;   KEGG:C16641;   KEGG:D08086;   LINCS:LSM-2167
 xref_mesh: MESH:D000077146
 xref: PDBeChem:CP0;   PMID:26081596;   PMID:26352218;   PMID:26381420;   PMID:26487578;   PMID:26503200;   PMID:26526067;   PMID:26541586;   PMID:26574999;   PMID:26580826;   PMID:26739304;   Reaxys:4839096;   Wikipedia:Irinotecan
 cyclic_relationship: is_conjugate_base_of CHEBI:90895


show annotations for term's descendants           Sort by:
irinotecan term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G A2M alpha-2-macroglobulin increases expression ISO Irinotecan results in increased expression of A2M mRNA CTD PMID:20097248 NCBI chr12:9,067,708...9,116,229
Ensembl chr12:9,067,664...9,116,229 		JBrowse link
G ABCB1 ATP binding cassette subfamily B member 1 decreases response to substance
affects export
multiple interactions
affects expression
affects response to substance
affects metabolic processing		 EXP
ISO		 ABCB1 protein results in decreased susceptibility to Irinotecan
ABCB1A gene mutant form results in decreased susceptibility to Irinotecan
ABCB1 protein affects the export of Irinotecan
bis(4-nitrophenyl)phosphate inhibits the reaction [ABCB1A protein affects the metabolism of Irinotecan]; Everolimus inhibits the reaction [ABCB1A protein affects the metabolism of Irinotecan]
ABCB1 exon SNP affects the susceptibility to and affects the metabolism of Irinotecan
Irinotecan affects the expression of ABCB1A mRNA
ABCB1 gene polymorphism affects the susceptibility to Irinotecan		 CTD PMID:12960109 PMID:15655543 PMID:15801936 PMID:16815871 PMID:20097248 More... NCBI chr 7:87,503,017...87,713,295
Ensembl chr 7:87,503,017...87,713,323 		JBrowse link
G ABCB6 ATP binding cassette subfamily B member 6 (LAN blood group) decreases response to substance EXP ABCB6 protein results in decreased susceptibility to Irinotecan CTD PMID:25202056 NCBI chr 2:219,209,772...219,218,958
Ensembl chr 2:219,209,772...219,218,994 		JBrowse link
G ABCC1 ATP binding cassette subfamily C member 1 (ABCC1 blood group) decreases expression
multiple interactions
decreases response to substance		 EXP Irinotecan analog results in decreased expression of ABCC1 mRNA
[selenomethylselenocysteine co-treated with Irinotecan] results in decreased expression of ABCC1
ABCC1 protein results in decreased susceptibility to Irinotecan		 CTD PMID:15897249 PMID:16815871 PMID:18927307 NCBI chr16:15,949,143...16,143,053
Ensembl chr16:15,949,138...16,143,257 		JBrowse link
G ABCC2 ATP binding cassette subfamily C member 2 decreases response to substance
affects response to substance		 EXP
ISO		 ABCC2 protein results in decreased susceptibility to Irinotecan
ABCC2 gene mutant form results in decreased susceptibility to Irinotecan
ABCC2 gene polymorphism affects the susceptibility to Irinotecan; ABCC2 gene polymorphism affects the susceptibility to Irinotecan metabolite		 CTD PMID:16815871 PMID:18981587 PMID:32387182 NCBI chr10:99,782,640...99,852,594
Ensembl chr10:99,782,640...99,852,594 		JBrowse link
G ABCC4 ATP binding cassette subfamily C member 4 (PEL blood group) affects export EXP ABCC4 protein affects the export of Irinotecan CTD PMID:15827327 NCBI chr13:95,019,835...95,301,451
Ensembl chr13:95,019,835...95,301,475 		JBrowse link
G ABCG2 ATP binding cassette subfamily G member 2 (JR blood group) affects response to substance
increases response to substance
increases transport
affects export
decreases response to substance
multiple interactions
affects metabolic processing		 EXP
ISO		 ABCG2 affects the susceptibility to Irinotecan
ABCG2 gene mutant form results in increased susceptibility to Irinotecan
ABCG2 mRNA results in increased susceptibility to Irinotecan; ABCG2 protein results in increased susceptibility to Irinotecan
ABCG2 protein results in increased transport of Irinotecan
ABCG2 protein affects the export of Irinotecan
ABCG2 protein results in decreased susceptibility to Irinotecan; ABCG2 results in decreased susceptibility to Irinotecan
ABCG2 gene polymorphism affects the susceptibility to and affects the metabolism of Irinotecan; Porphyrins inhibits the reaction [ABCG2 protein results in decreased susceptibility to Irinotecan]; Reserpine inhibits the reaction [ABCG2 protein results in increased transport of Irinotecan]
ABCG2 protein affects the metabolism of Irinotecan
bis(4-nitrophenyl)phosphate inhibits the reaction [ABCG2 protein affects the metabolism of Irinotecan]; Everolimus inhibits the reaction [ABCG2 protein affects the metabolism of Irinotecan]		 CTD PMID:10606239 PMID:12869632 PMID:15239142 PMID:15655543 PMID:15695404 More... NCBI chr 4:88,090,264...88,231,626
Ensembl chr 4:88,090,150...88,231,628 		JBrowse link
G ABHD13 abhydrolase domain containing 13 decreases expression EXP Irinotecan analog results in decreased expression of ABHD13 mRNA CTD PMID:18927307 NCBI chr13:108,218,392...108,234,243
Ensembl chr13:108,218,392...108,234,243 		JBrowse link
G ABI2 abl interactor 2 decreases expression EXP Irinotecan results in decreased expression of ABI2 mRNA CTD PMID:20185912 NCBI chr 2:203,328,394...203,432,169
Ensembl chr 2:203,328,280...203,447,728 		JBrowse link
G ACACA acetyl-CoA carboxylase alpha decreases expression EXP Irinotecan analog results in decreased expression of ACACA mRNA CTD PMID:18927307 NCBI chr17:37,084,992...37,406,836
Ensembl chr17:37,084,992...37,406,836 		JBrowse link
G ACAT1 acetyl-CoA acetyltransferase 1 increases response to substance EXP ACAT1 protein results in increased susceptibility to Irinotecan CTD PMID:16734730 NCBI chr11:108,116,705...108,147,603
Ensembl chr11:108,116,695...108,147,603 		JBrowse link
G ACHE acetylcholinesterase (Yt blood group) decreases activity ISO Irinotecan results in decreased activity of ACHE protein CTD PMID:11740913 NCBI chr 7:100,889,994...100,896,994
Ensembl chr 7:100,889,994...100,896,974 		JBrowse link
G ACTA2 actin alpha 2, smooth muscle multiple interactions
increases expression		 ISO Silymarin affects the reaction [Irinotecan results in increased expression of ACTA2 protein] CTD PMID:28454924 NCBI chr10:88,935,074...88,991,337
Ensembl chr10:88,934,822...88,991,339 		JBrowse link
G ADA adenosine deaminase affects expression ISO Irinotecan affects the expression of ADA mRNA CTD PMID:20097248 NCBI chr20:44,619,522...44,651,699
Ensembl chr20:44,584,896...44,652,252 		JBrowse link
G ADAM19 ADAM metallopeptidase domain 19 increases expression EXP Irinotecan analog results in increased expression of ADAM19 mRNA CTD PMID:18927307 NCBI chr 5:157,477,304...157,575,775
Ensembl chr 5:157,395,534...157,575,775 		JBrowse link
G ADAMTS1 ADAM metallopeptidase with thrombospondin type 1 motif 1 increases expression ISO Irinotecan results in increased expression of ADAMTS1 mRNA CTD PMID:20097248 NCBI chr21:26,835,755...26,845,409
Ensembl chr21:26,835,755...26,845,409 		JBrowse link
G ADD3 adducin 3 decreases expression EXP Irinotecan metabolite results in decreased expression of ADD3 mRNA; Irinotecan results in decreased expression of ADD3 mRNA CTD PMID:15956246 NCBI chr10:109,996,373...110,135,565
Ensembl chr10:109,996,368...110,135,565 		JBrowse link
G ADH1C alcohol dehydrogenase 1C (class I), gamma polypeptide affects expression ISO Irinotecan affects the expression of ADH1 mRNA CTD PMID:20097248 NCBI chr 4:99,336,497...99,352,746
Ensembl chr 4:99,336,497...99,352,746 		JBrowse link
G ADI1 acireductone dioxygenase 1 decreases expression EXP Irinotecan analog results in decreased expression of ADI1 mRNA CTD PMID:18927307 NCBI chr 2:3,497,366...3,519,531
Ensembl chr 2:3,497,366...3,519,531 		JBrowse link
G ADK adenosine kinase affects expression ISO Irinotecan affects the expression of ADK mRNA CTD PMID:20097248 NCBI chr10:74,151,221...74,709,290
Ensembl chr10:74,151,202...74,709,963 		JBrowse link
G AGPAT4 1-acylglycerol-3-phosphate O-acyltransferase 4 affects expression ISO Irinotecan affects the expression of AGPAT4 mRNA CTD PMID:20097248 NCBI chr 6:161,129,967...161,274,061
Ensembl chr 6:161,129,967...161,274,061 		JBrowse link
G AGT angiotensinogen decreases expression EXP Irinotecan analog results in decreased expression of AGT mRNA CTD PMID:18927307 NCBI chr 1:230,702,523...230,745,583
Ensembl chr 1:230,690,776...230,745,576 		JBrowse link
G AHCYL1 adenosylhomocysteinase like 1 affects expression ISO Irinotecan affects the expression of AHCYL1 mRNA CTD PMID:20097248 NCBI chr 1:109,984,765...110,023,742
Ensembl chr 1:109,984,765...110,023,742 		JBrowse link
G AK2 adenylate kinase 2 increases response to substance EXP AK2 protein results in increased susceptibility to Irinotecan CTD PMID:16734730 NCBI chr 1:33,007,940...33,036,883
Ensembl chr 1:33,007,986...33,080,996 		JBrowse link
G AKAP10 A-kinase anchoring protein 10 decreases expression EXP Irinotecan metabolite results in decreased expression of AKAP10 mRNA; Irinotecan results in decreased expression of AKAP10 mRNA CTD PMID:15956246 NCBI chr17:19,904,302...19,977,828
Ensembl chr17:19,904,302...19,978,343 		JBrowse link
G ALAS2 5'-aminolevulinate synthase 2 increases expression EXP Irinotecan metabolite results in increased expression of ALAS2 mRNA; Irinotecan results in increased expression of ALAS2 mRNA CTD PMID:15956246 NCBI chr  X:55,009,055...55,030,977
Ensembl chr  X:55,009,055...55,030,977 		JBrowse link
G ALB albumin decreases expression EXP Irinotecan analog results in decreased expression of ALB mRNA CTD PMID:18927307 NCBI chr 4:73,404,287...73,421,482
Ensembl chr 4:73,397,114...73,421,482 		JBrowse link
G ALDH18A1 aldehyde dehydrogenase 18 family member A1 decreases expression ISO Irinotecan results in decreased expression of ALDH18A1 mRNA CTD PMID:30012503 NCBI chr10:95,605,941...95,656,711
Ensembl chr10:95,605,941...95,656,711 		JBrowse link
G ALDH1A1 aldehyde dehydrogenase 1 family member A1 decreases expression EXP Irinotecan metabolite results in decreased expression of ALDH1A1 mRNA; Irinotecan results in decreased expression of ALDH1A1 mRNA CTD PMID:15956246 NCBI chr 9:72,900,671...72,953,053
Ensembl chr 9:72,900,671...73,080,442 		JBrowse link
G AMIGO2 adhesion molecule with Ig like domain 2 increases expression EXP Irinotecan analog results in increased expression of AMIGO2 mRNA CTD PMID:18927307 NCBI chr12:47,075,707...47,079,959
Ensembl chr12:47,075,707...47,079,959 		JBrowse link
G ANGPTL2 angiopoietin like 2 multiple interactions EXP ANGPTL2 mRNA results in increased susceptibility to [Leucovorin co-treated with Fluorouracil co-treated with Irinotecan] CTD PMID:17327601 NCBI chr 9:127,087,348...127,122,635
Ensembl chr 9:127,087,348...127,122,635 		JBrowse link
G ANKH ANKH inorganic pyrophosphate transport regulator affects expression ISO Irinotecan affects the expression of ANKH mRNA CTD PMID:20097248 NCBI chr 5:14,704,800...14,871,778
Ensembl chr 5:14,704,800...14,871,778 		JBrowse link
G ANKRD17 ankyrin repeat domain 17 decreases expression EXP Irinotecan analog results in decreased expression of ANKRD17 mRNA CTD PMID:18927307 NCBI chr 4:73,073,376...73,258,798
Ensembl chr 4:73,073,376...73,258,798 		JBrowse link
G ANKRD28 ankyrin repeat domain 28 decreases expression EXP Irinotecan analog results in decreased expression of ANKRD28 mRNA CTD PMID:18927307 NCBI chr 3:15,667,236...15,859,814
Ensembl chr 3:15,667,236...15,859,771 		JBrowse link
G ANXA13 annexin A13 decreases expression EXP Irinotecan analog results in decreased expression of ANXA13 mRNA CTD PMID:18927307 NCBI chr 8:123,680,794...123,737,393
Ensembl chr 8:123,680,794...123,737,402 		JBrowse link
G ANXA2 annexin A2 increases expression
multiple interactions		 EXP
ISO		 Irinotecan results in increased expression of ANXA2 mRNA
[PHY 906 co-treated with Irinotecan] affects the expression of ANXA2 mRNA		 CTD PMID:15152939 PMID:32812032 NCBI chr15:60,347,151...60,397,986
Ensembl chr15:60,347,134...60,402,883 		JBrowse link
G ANXA6 annexin A6 increases expression EXP Irinotecan metabolite results in increased expression of ANXA6 mRNA; Irinotecan results in increased expression of ANXA6 mRNA CTD PMID:15956246 NCBI chr 5:151,100,706...151,157,779
Ensembl chr 5:151,100,706...151,157,815 		JBrowse link
G AP2B1 adaptor related protein complex 2 subunit beta 1 decreases expression EXP Irinotecan analog results in decreased expression of AP2B1 mRNA CTD PMID:18927307 NCBI chr17:35,587,322...35,726,413
Ensembl chr17:35,578,046...35,726,413 		JBrowse link
G AP2S1 adaptor related protein complex 2 subunit sigma 1 multiple interactions EXP [Fluorouracil co-treated with Irinotecan] results in decreased expression of AP2S1 mRNA CTD PMID:16391804 NCBI chr19:46,838,167...46,850,846
Ensembl chr19:46,838,136...46,850,846 		JBrowse link
G APC APC regulator of WNT signaling pathway decreases expression EXP Irinotecan metabolite results in decreased expression of APC mRNA; Irinotecan results in decreased expression of APC mRNA CTD PMID:15956246 NCBI chr 5:112,707,498...112,846,239
Ensembl chr 5:112,707,518...112,846,239 		JBrowse link
G ARAF A-Raf proto-oncogene, serine/threonine kinase increases expression EXP Irinotecan metabolite results in increased expression of ARAF mRNA; Irinotecan results in increased expression of ARAF mRNA CTD PMID:15956246 NCBI chr  X:47,561,205...47,571,908
Ensembl chr  X:47,561,205...47,571,908 		JBrowse link
G AREG amphiregulin increases expression
multiple interactions		 EXP Irinotecan metabolite results in increased expression of AREG mRNA; Irinotecan results in increased expression of AREG mRNA
Gefitinib inhibits the reaction [Irinotecan metabolite results in increased expression of AREG mRNA]; Gefitinib inhibits the reaction [Irinotecan results in increased expression of AREG mRNA]		 CTD PMID:15723263 NCBI chr 4:74,445,136...74,455,005
Ensembl chr 4:74,445,136...74,455,005 		JBrowse link
G ARF1 ADP ribosylation factor 1 multiple interactions
decreases expression		 EXP ARF1 protein affects the susceptibility to [Fluorouracil co-treated with Irinotecan analog]
Irinotecan analog results in decreased expression of ARF1 mRNA		 CTD PMID:18927307 NCBI chr 1:228,082,708...228,099,212
Ensembl chr 1:228,082,708...228,099,212 		JBrowse link
G ARG2 arginase 2 affects expression ISO Irinotecan affects the expression of ARG2 mRNA CTD PMID:20097248 NCBI chr14:67,619,920...67,651,708
Ensembl chr14:67,619,920...67,651,708 		JBrowse link
G ARHGAP5 Rho GTPase activating protein 5 increases expression
decreases expression		 EXP Irinotecan metabolite results in increased expression of ARHGAP5 mRNA; Irinotecan results in increased expression of ARHGAP5 mRNA
Irinotecan metabolite results in decreased expression of ARHGAP5 mRNA; Irinotecan results in decreased expression of ARHGAP5 mRNA		 CTD PMID:15956246 NCBI chr14:32,077,304...32,159,728
Ensembl chr14:32,076,114...32,159,728 		JBrowse link
G ARHGEF12 Rho guanine nucleotide exchange factor 12 decreases expression EXP Irinotecan analog results in decreased expression of ARHGEF12 mRNA CTD PMID:18927307 NCBI chr11:120,336,413...120,489,937
Ensembl chr11:120,336,413...120,489,937 		JBrowse link
G ARHGEF39 Rho guanine nucleotide exchange factor 39 decreases expression EXP Irinotecan analog results in decreased expression of ARHGEF39 mRNA CTD PMID:18927307 NCBI chr 9:35,659,343...35,665,195
Ensembl chr 9:35,658,875...35,675,866 		JBrowse link
G ARID2 AT-rich interaction domain 2 decreases expression EXP Irinotecan analog results in decreased expression of ARID2 mRNA CTD PMID:18927307 NCBI chr12:45,729,706...45,908,037
Ensembl chr12:45,729,706...45,908,040 		JBrowse link
G ARID4A AT-rich interaction domain 4A decreases expression EXP Irinotecan metabolite results in decreased expression of ARID4A mRNA; Irinotecan results in decreased expression of ARID4A mRNA CTD PMID:15956246 NCBI chr14:58,298,555...58,373,876
Ensembl chr14:58,298,504...58,373,887 		JBrowse link
G ARL4C ADP ribosylation factor like GTPase 4C increases expression EXP Irinotecan analog results in increased expression of ARL4C mRNA CTD PMID:18927307 NCBI chr 2:234,493,041...234,497,081
Ensembl chr 2:234,493,041...234,497,081 		JBrowse link
G ARMC8 armadillo repeat containing 8 decreases expression EXP Irinotecan analog results in decreased expression of ARMC8 mRNA CTD PMID:18927307 NCBI chr 3:138,187,248...138,298,389
Ensembl chr 3:138,187,248...138,298,384 		JBrowse link
G ARSB arylsulfatase B decreases expression EXP Irinotecan analog results in decreased expression of ARSB mRNA CTD PMID:18927307 NCBI chr 5:78,777,209...78,985,958
Ensembl chr 5:78,777,209...78,986,087 		JBrowse link
G AS3MT arsenite methyltransferase affects expression ISO Irinotecan affects the expression of AS3MT mRNA CTD PMID:20097248 NCBI chr10:102,869,470...102,901,899
Ensembl chr10:102,869,470...102,901,899 		JBrowse link
G ASB2 ankyrin repeat and SOCS box containing 2 affects expression ISO Irinotecan affects the expression of ASB2 mRNA CTD PMID:20097248 NCBI chr14:93,934,166...93,976,570
Ensembl chr14:93,934,166...93,976,739 		JBrowse link
G ASS1 argininosuccinate synthase 1 multiple interactions EXP [Fluorouracil co-treated with Irinotecan] results in decreased expression of ASS1 mRNA CTD PMID:16391804 NCBI chr 9:130,444,707...130,501,274
Ensembl chr 9:130,444,961...130,501,274 		JBrowse link
G ATF3 activating transcription factor 3 increases expression EXP Irinotecan metabolite results in increased expression of ATF3 mRNA; Irinotecan results in increased expression of ATF3 mRNA CTD PMID:15956246 NCBI chr 1:212,565,407...212,620,777
Ensembl chr 1:212,565,334...212,620,777 		JBrowse link
G ATG10 autophagy related 10 decreases expression EXP Irinotecan metabolite results in decreased expression of ATG10 mRNA; Irinotecan results in decreased expression of ATG10 mRNA CTD PMID:15956246 NCBI chr 5:81,972,023...82,256,133
Ensembl chr 5:81,972,023...82,276,857 		JBrowse link
G ATL2 atlastin GTPase 2 increases expression EXP Irinotecan analog results in increased expression of ATL2 mRNA CTD PMID:18927307 NCBI chr 2:38,293,954...38,378,584
Ensembl chr 2:38,293,954...38,377,285 		JBrowse link
G ATM ATM serine/threonine kinase increases phosphorylation EXP Irinotecan results in increased phosphorylation of ATM protein CTD PMID:22898888 NCBI chr11:108,223,067...108,369,102
Ensembl chr11:108,222,804...108,369,102 		JBrowse link
G ATP2B1 ATPase plasma membrane Ca2+ transporting 1 affects expression ISO Irinotecan affects the expression of ATP2B1 mRNA CTD PMID:20097248 NCBI chr12:89,588,049...89,709,366
Ensembl chr12:89,588,049...89,709,366 		JBrowse link
G ATP2B4 ATPase plasma membrane Ca2+ transporting 4 decreases response to substance EXP ATP2B4 protein results in decreased susceptibility to Irinotecan CTD PMID:16734730 NCBI chr 1:203,626,832...203,744,081
Ensembl chr 1:203,626,832...203,744,081 		JBrowse link
G ATP5PO ATP synthase peripheral stalk subunit OSCP multiple interactions EXP ATP5PO mRNA results in increased susceptibility to [Leucovorin co-treated with Fluorouracil co-treated with Irinotecan] CTD PMID:17327601 NCBI chr21:33,903,453...33,915,804
Ensembl chr21:33,903,453...33,915,814 		JBrowse link
G ATP6V0B ATPase H+ transporting V0 subunit b increases response to substance EXP ATP6V0B protein results in increased susceptibility to Irinotecan CTD PMID:16734730 NCBI chr 1:43,974,960...43,978,295
Ensembl chr 1:43,974,487...43,978,295 		JBrowse link
G ATP7A ATPase copper transporting alpha increases export
decreases response to substance		 EXP ATP7A protein results in increased export of Irinotecan
ATP7A protein results in decreased susceptibility to Irinotecan		 CTD PMID:17510416 NCBI chr  X:77,910,693...78,050,395
Ensembl chr  X:77,910,690...78,050,395 		JBrowse link
G ATP8B1 ATPase phospholipid transporting 8B1 affects expression ISO Irinotecan affects the expression of ATP8B1 mRNA CTD PMID:20097248 NCBI chr18:57,646,426...57,803,315
Ensembl chr18:57,646,426...57,803,315 		JBrowse link
G ATRX ATRX chromatin remodeler decreases expression EXP Irinotecan analog results in decreased expression of ATRX mRNA CTD PMID:18927307 NCBI chr  X:77,504,880...77,786,216
Ensembl chr  X:77,504,880...77,786,233 		JBrowse link
G AURKB aurora kinase B decreases expression EXP Irinotecan metabolite results in decreased expression of AURKB mRNA; Irinotecan results in decreased expression of AURKB mRNA CTD PMID:15956246 NCBI chr17:8,204,731...8,210,575
Ensembl chr17:8,204,733...8,210,600 		JBrowse link
G B2M beta-2-microglobulin increases expression ISO Irinotecan results in increased expression of B2M mRNA CTD PMID:20097248 NCBI chr15:44,711,517...44,718,145
Ensembl chr15:44,711,358...44,718,851 		JBrowse link
G BAMBI BMP and activin membrane bound inhibitor increases expression EXP Irinotecan analog results in increased expression of BAMBI mRNA CTD PMID:18927307 NCBI chr10:28,677,521...28,682,932
Ensembl chr10:28,677,510...28,682,932 		JBrowse link
G BAX BCL2 associated X, apoptosis regulator multiple interactions EXP [Fluorouracil co-treated with Irinotecan co-treated with Vorinostat] results in increased expression of BAX protein CTD PMID:15754201 NCBI chr19:48,954,875...48,961,798
Ensembl chr19:48,954,815...48,961,798 		JBrowse link
G BCL2 BCL2 apoptosis regulator multiple interactions
affects response to substance		 EXP [Fluorouracil co-treated with Irinotecan co-treated with Vorinostat] results in decreased expression of BCL2 protein; [Fluorouracil co-treated with Irinotecan] results in decreased expression of BCL2 mRNA; [Fluorouracil co-treated with Irinotecan] results in decreased expression of BCL2 protein
BCL2 protein affects the susceptibility to Irinotecan		 CTD PMID:15754201 PMID:16391804 PMID:18949393 NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128 		JBrowse link
G BCL2L1 BCL2 like 1 multiple interactions
decreases expression		 EXP Irinotecan promotes the reaction [AS602868 results in decreased expression of BCL2L1 mRNA]
Irinotecan results in decreased expression of BCL2L1 mRNA		 CTD PMID:16432164 PMID:18182997 NCBI chr20:31,664,452...31,723,963
Ensembl chr20:31,664,452...31,723,989 		JBrowse link
G BCL7A BAF chromatin remodeling complex subunit BCL7A increases expression EXP Irinotecan metabolite results in increased expression of BCL7A mRNA; Irinotecan results in increased expression of BCL7A mRNA CTD PMID:15956246 NCBI chr12:122,021,884...122,062,044
Ensembl chr12:122,019,422...122,062,044 		JBrowse link
G BCL9 BCL9 transcription coactivator increases expression EXP Irinotecan metabolite results in increased expression of BCL9 mRNA; Irinotecan results in increased expression of BCL9 mRNA CTD PMID:15956246 NCBI chr 1:147,541,501...147,626,216
Ensembl chr 1:147,541,501...147,626,216 		JBrowse link
G BCR BCR activator of RhoGEF and GTPase decreases expression EXP Irinotecan analog results in decreased expression of BCR mRNA CTD PMID:18927307 NCBI chr22:23,180,509...23,318,037
Ensembl chr22:23,179,704...23,318,037 		JBrowse link
G BID BH3 interacting domain death agonist decreases expression
multiple interactions		 EXP Irinotecan results in decreased expression of BID protein
[Fluorouracil co-treated with Irinotecan co-treated with Vorinostat] results in increased cleavage of BID protein		 CTD PMID:15754201 NCBI chr22:17,734,138...17,774,665
Ensembl chr22:17,734,138...17,774,770 		JBrowse link
G BIRC3 baculoviral IAP repeat containing 3 affects expression ISO Irinotecan affects the expression of BIRC3 mRNA CTD PMID:20097248 NCBI chr11:102,317,484...102,339,403
Ensembl chr11:102,317,484...102,339,403 		JBrowse link
G BIRC5 baculoviral IAP repeat containing 5 multiple interactions
decreases expression		 EXP [Irinotecan co-treated with Bortezomib] results in decreased expression of BIRC5 protein; Irinotecan promotes the reaction [AS602868 results in decreased expression of BIRC5 mRNA]
Irinotecan metabolite results in decreased expression of BIRC5 mRNA; Irinotecan results in decreased expression of BIRC5 mRNA		 CTD PMID:15956246 PMID:16373703 PMID:18182997 NCBI chr17:78,214,253...78,225,635
Ensembl chr17:78,214,186...78,225,636 		JBrowse link
G BMP8A bone morphogenetic protein 8a increases expression EXP Irinotecan metabolite results in increased expression of BMP8A mRNA; Irinotecan results in increased expression of BMP8A mRNA CTD PMID:15956246 NCBI chr 1:39,491,636...39,529,869
Ensembl chr 1:39,491,636...39,529,869 		JBrowse link
G BOD1L1 biorientation of chromosomes in cell division 1 like 1 decreases expression EXP Irinotecan analog results in decreased expression of BOD1L1 mRNA CTD PMID:18927307 NCBI chr 4:13,568,738...13,627,725
Ensembl chr 4:13,568,738...13,627,725 		JBrowse link
G BOLL boule homolog, RNA binding protein multiple interactions EXP BOLL mRNA results in increased susceptibility to [Leucovorin co-treated with Fluorouracil co-treated with Irinotecan] CTD PMID:17327601 NCBI chr 2:197,726,890...197,786,206
Ensembl chr 2:197,726,879...197,786,762 		JBrowse link
G BTBD3 BTB domain containing 3 decreases expression EXP Irinotecan analog results in decreased expression of BTBD3 mRNA CTD PMID:18927307 NCBI chr20:11,890,817...11,926,595
Ensembl chr20:11,890,723...11,926,609 		JBrowse link
G BUB1 BUB1 mitotic checkpoint serine/threonine kinase decreases expression
affects expression		 EXP
ISO		 Irinotecan metabolite results in decreased expression of BUB1 mRNA; Irinotecan results in decreased expression of BUB1 mRNA
Irinotecan affects the expression of BUB1 mRNA		 CTD PMID:15956246 PMID:20097248 NCBI chr 2:110,637,528...110,678,063
Ensembl chr 2:110,637,528...110,678,063 		JBrowse link
G C16orf87 chromosome 16 open reading frame 87 decreases expression EXP Irinotecan analog results in decreased expression of C16ORF87 mRNA CTD PMID:18927307 NCBI chr16:46,796,603...46,831,180
Ensembl chr16:46,796,603...46,831,180 		JBrowse link
G C1orf43 chromosome 1 open reading frame 43 decreases expression EXP Irinotecan analog results in decreased expression of C1ORF43 mRNA CTD PMID:18927307 NCBI chr 1:154,206,720...154,220,590
Ensembl chr 1:154,206,696...154,220,637 		JBrowse link
G C1QC complement C1q C chain multiple interactions ISO [PHY 906 co-treated with Irinotecan] affects the expression of C1QC mRNA CTD PMID:32812032 NCBI chr 1:22,643,633...22,648,108
Ensembl chr 1:22,643,014...22,648,110 		JBrowse link
G C2 complement C2 affects expression ISO Irinotecan affects the expression of C2 mRNA CTD PMID:20097248 NCBI chr 6:31,897,783...31,945,672
Ensembl chr 6:31,897,785...31,945,673 		JBrowse link
G C3AR1 complement C3a receptor 1 multiple interactions ISO [PHY 906 co-treated with Irinotecan] affects the expression of C3AR1 mRNA CTD PMID:32812032 NCBI chr12:8,056,844...8,066,359
Ensembl chr12:8,056,844...8,066,359 		JBrowse link
G C7 complement C7 increases expression ISO Irinotecan results in increased expression of C7 mRNA CTD PMID:20097248 NCBI chr 5:40,909,497...40,984,643
Ensembl chr 5:40,909,492...41,020,216 		JBrowse link
G CABIN1 calcineurin binding protein 1 decreases expression EXP Irinotecan analog results in decreased expression of CABIN1 mRNA CTD PMID:18927307 NCBI chr22:24,011,304...24,178,628
Ensembl chr22:24,011,192...24,178,628 		JBrowse link
G CACNA1I calcium voltage-gated channel subunit alpha1 I decreases expression EXP Irinotecan analog results in decreased expression of CACNA1I mRNA CTD PMID:18927307 NCBI chr22:39,570,753...39,689,735
Ensembl chr22:39,570,753...39,689,735 		JBrowse link
G CASP1 caspase 1 multiple interactions
increases cleavage
affects expression		 ISO
EXP		 [Irinotecan co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein; EVP 4593 inhibits the reaction [Irinotecan results in increased cleavage of CASP1 protein]; pyrazolanthrone inhibits the reaction [Irinotecan results in increased cleavage of CASP1 protein]
Irinotecan affects the expression of CASP1 mRNA		 CTD PMID:20097248 PMID:26431797 NCBI chr11:105,025,443...105,036,686
Ensembl chr11:105,025,397...105,035,250 		JBrowse link
G CASP3 caspase 3 multiple interactions
increases expression
increases activity		 EXP [Irinotecan co-treated with alvocidib] results in increased activity of CASP3 protein; [Irinotecan co-treated with rucaparib] results in increased expression of CASP3 protein; Irinotecan promotes the reaction [AS602868 results in increased cleavage of and results in increased activity of CASP3 protein]; RNF34 protein inhibits the reaction [Irinotecan results in increased activity of CASP3 protein]; Ursodeoxycholic Acid promotes the reaction [Irinotecan results in increased activity of CASP3 protein]
Irinotecan results in increased expression of CASP3 protein		 CTD PMID:11751522 PMID:16080519 PMID:16432164 PMID:18182997 PMID:22898888 More... NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062 		JBrowse link
G CASP4 caspase 4 decreases expression EXP Irinotecan metabolite results in decreased expression of CASP4 mRNA; Irinotecan results in decreased expression of CASP4 mRNA CTD PMID:15956246 NCBI chr11:104,942,866...104,968,574
Ensembl chr11:104,942,866...104,969,366 		JBrowse link
G CASP8 caspase 8 increases activity
multiple interactions		 EXP Irinotecan results in increased activity of CASP8 protein
Irinotecan promotes the reaction [AS602868 results in increased cleavage of and results in increased activity of CASP8 protein]; Irinotecan results in increased cleavage of and results in increased activity of CASP8 protein; Ursodeoxycholic Acid promotes the reaction [Irinotecan results in increased activity of CASP8 protein]		 CTD PMID:16432164 PMID:18182997 NCBI chr 2:201,233,463...201,287,711
Ensembl chr 2:201,233,443...201,361,836 		JBrowse link
G CASP9 caspase 9 multiple interactions
increases activity		 EXP benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone inhibits the reaction [Irinotecan results in increased activity of CASP9 protein]; benzyloxycarbonyl-leucyl-glutamyl-histidyl-aspartic acid fluoromethyl ketone inhibits the reaction [Irinotecan results in increased activity of CASP9 protein]; Irinotecan promotes the reaction [AS602868 results in increased cleavage of and results in increased activity of CASP9 protein]; Irinotecan results in increased cleavage of and results in increased activity of CASP9 protein CTD PMID:18182997 PMID:22898888 NCBI chr 1:15,491,401...15,524,912
Ensembl chr 1:15,490,832...15,526,534 		JBrowse link
G CBLC Cbl proto-oncogene C affects expression ISO Irinotecan affects the expression of CBLC mRNA CTD PMID:20097248 NCBI chr19:44,777,869...44,800,652
Ensembl chr19:44,777,869...44,800,652 		JBrowse link
G CCK cholecystokinin affects expression ISO Irinotecan affects the expression of CCK mRNA CTD PMID:20097248 NCBI chr 3:42,257,826...42,266,185
Ensembl chr 3:42,257,825...42,266,185 		JBrowse link
G CCN1 cellular communication network factor 1 decreases response to substance EXP CCN1 protein results in decreased susceptibility to Irinotecan CTD PMID:16734730 NCBI chr 1:85,580,761...85,583,950
Ensembl chr 1:85,580,761...85,584,589 		JBrowse link
G CCN2 cellular communication network factor 2 increases expression EXP Irinotecan results in increased expression of CCN2 mRNA CTD PMID:20185912 NCBI chr 6:131,948,176...131,951,372
Ensembl chr 6:131,948,176...131,951,372 		JBrowse link
G CCNA2 cyclin A2 decreases expression EXP Irinotecan metabolite results in decreased expression of CCNA2 mRNA; Irinotecan results in decreased expression of CCNA2 mRNA CTD PMID:15956246 NCBI chr 4:121,816,444...121,823,883
Ensembl chr 4:121,816,444...121,823,883 		JBrowse link
G CCNB1 cyclin B1 decreases expression ISO Irinotecan results in decreased expression of CCNB1 mRNA CTD PMID:20097248 NCBI chr 5:69,167,150...69,178,245
Ensembl chr 5:69,167,135...69,178,245 		JBrowse link
G CCNB1IP1 cyclin B1 interacting protein 1 increases response to substance EXP CCNB1IP1 protein results in increased susceptibility to Irinotecan CTD PMID:16734730 NCBI chr14:20,311,370...20,333,279
Ensembl chr14:20,311,368...20,333,312 		JBrowse link
G CCNB2 cyclin B2 increases response to substance
decreases expression		 EXP
ISO		 CCNB2 protein results in increased susceptibility to Irinotecan
Irinotecan results in decreased expression of CCNB2 mRNA
Irinotecan metabolite results in decreased expression of CCNB2 mRNA; Irinotecan results in decreased expression of CCNB2 mRNA		 CTD PMID:15956246 PMID:16734730 PMID:20097248 NCBI chr15:59,105,146...59,125,045
Ensembl chr15:59,105,126...59,125,045 		JBrowse link
G CCNF cyclin F decreases expression EXP Irinotecan metabolite results in decreased expression of CCNF mRNA; Irinotecan results in decreased expression of CCNF mRNA CTD PMID:15956246 NCBI chr16:2,429,447...2,458,854
Ensembl chr16:2,429,394...2,458,854 		JBrowse link
G CCNG2 cyclin G2 increases expression EXP Irinotecan analog results in increased expression of CCNG2 mRNA CTD PMID:18927307 NCBI chr 4:77,157,207...77,170,060
Ensembl chr 4:77,157,207...77,433,388 		JBrowse link
G CCR1 C-C motif chemokine receptor 1 increases expression EXP Irinotecan metabolite results in increased expression of CCR1 mRNA; Irinotecan results in increased expression of CCR1 mRNA CTD PMID:15956246 NCBI chr 3:46,201,711...46,208,313
Ensembl chr 3:46,201,711...46,208,313 		JBrowse link
G CCR6 C-C motif chemokine receptor 6 decreases expression EXP Irinotecan metabolite results in decreased expression of CCR6 mRNA; Irinotecan results in decreased expression of CCR6 mRNA CTD PMID:15956246 NCBI chr 6:167,111,795...167,139,141
Ensembl chr 6:167,111,807...167,139,141 		JBrowse link
G CCT6A chaperonin containing TCP1 subunit 6A decreases expression EXP Irinotecan analog results in decreased expression of CCT6A mRNA CTD PMID:18927307 NCBI chr 7:56,051,765...56,063,989
Ensembl chr 7:56,051,685...56,063,989 		JBrowse link
G CD163 CD163 molecule increases expression ISO Irinotecan results in increased expression of CD163 mRNA CTD PMID:20097248 NCBI chr12:7,470,811...7,503,777
Ensembl chr12:7,470,811...7,503,893 		JBrowse link
G CD36 CD36 molecule (CD36 blood group) affects expression ISO Irinotecan affects the expression of CD36 mRNA CTD PMID:20097248 NCBI chr 7:80,602,207...80,679,274
Ensembl chr 7:80,369,575...80,679,277 		JBrowse link
G CD47 CD47 molecule increases expression EXP Irinotecan analog results in increased expression of CD47 mRNA CTD PMID:18927307 NCBI chr 3:108,043,091...108,091,031
Ensembl chr 3:108,043,091...108,091,862 		JBrowse link
G CD70 CD70 molecule increases expression EXP Irinotecan metabolite results in increased expression of CD70 mRNA; Irinotecan results in increased expression of CD70 mRNA CTD PMID:15956246 NCBI chr19:6,581,648...6,591,150
Ensembl chr19:6,583,183...6,604,103 		JBrowse link
G CD80 CD80 molecule increases expression EXP Irinotecan metabolite results in increased expression of CD80 mRNA; Irinotecan results in increased expression of CD80 mRNA CTD PMID:15956246 NCBI chr 3:119,524,293...119,559,614
Ensembl chr 3:119,524,293...119,559,614 		JBrowse link
G CDC20 cell division cycle 20 increases response to substance
affects expression		 EXP
ISO		 CDC20 protein results in increased susceptibility to Irinotecan
Irinotecan affects the expression of CDC20 mRNA		 CTD PMID:16734730 PMID:20097248 NCBI chr 1:43,358,981...43,363,203
Ensembl chr 1:43,358,981...43,363,203 		JBrowse link
G CDC25B cell division cycle 25B decreases expression EXP Irinotecan metabolite results in decreased expression of CDC25B mRNA; Irinotecan results in decreased expression of CDC25B mRNA CTD PMID:15956246 NCBI chr20:3,786,951...3,806,115
Ensembl chr20:3,786,772...3,806,121 		JBrowse link
G CDC42BPA CDC42 binding protein kinase alpha decreases expression EXP Irinotecan analog results in decreased expression of CDC42BPA mRNA CTD PMID:18927307 NCBI chr 1:226,989,858...227,318,492
Ensembl chr 1:226,989,865...227,318,492 		JBrowse link
G CDCA3 cell division cycle associated 3 decreases expression ISO Irinotecan results in decreased expression of CDCA3 mRNA CTD PMID:20097248 NCBI chr12:6,844,798...6,851,286
Ensembl chr12:6,844,793...6,851,292 		JBrowse link
G CDH4 cadherin 4 decreases expression EXP Irinotecan analog results in decreased expression of CDH4 mRNA CTD PMID:18927307 NCBI chr20:61,252,261...61,940,617
Ensembl chr20:61,252,261...61,940,617 		JBrowse link
G CDK1 cyclin dependent kinase 1 decreases expression ISO
EXP		 Irinotecan results in decreased expression of CDK1 mRNA
Irinotecan metabolite results in decreased expression of CDK1 mRNA; Irinotecan results in decreased expression of CDK1 mRNA		 CTD PMID:15956246 PMID:20097248 NCBI chr10:60,778,331...60,794,852
Ensembl chr10:60,778,331...60,794,852 		JBrowse link
G CDK13 cyclin dependent kinase 13 decreases expression EXP Irinotecan metabolite results in decreased expression of CDK13 mRNA; Irinotecan results in decreased expression of CDK13 mRNA CTD PMID:15956246 NCBI chr 7:39,950,256...40,099,580
Ensembl chr 7:39,950,121...40,099,580 		JBrowse link
G CDK5R2 cyclin dependent kinase 5 regulatory subunit 2 increases expression EXP Irinotecan metabolite results in increased expression of CDK5R2 mRNA; Irinotecan results in increased expression of CDK5R2 mRNA CTD PMID:15956246 NCBI chr 2:218,959,666...218,962,155
Ensembl chr 2:218,959,666...218,962,155 		JBrowse link
G CDK6 cyclin dependent kinase 6 affects expression EXP Irinotecan analog affects the expression of CDK6 mRNA CTD PMID:18927307 NCBI chr 7:92,604,921...92,836,573
Ensembl chr 7:92,604,921...92,836,573 		JBrowse link
G CDKN1A cyclin dependent kinase inhibitor 1A affects expression
increases expression
multiple interactions		 EXP Irinotecan affects the expression of CDKN1A protein
Irinotecan results in increased expression of CDKN1A mRNA; Irinotecan results in increased expression of CDKN1A protein
[Fluorouracil co-treated with Irinotecan co-treated with Vorinostat] results in increased expression of CDKN1A protein		 CTD PMID:15132777 PMID:15754201 PMID:22510560 PMID:22898888 NCBI chr 6:36,676,463...36,687,332
Ensembl chr 6:36,676,460...36,687,337 		JBrowse link
G CDKN2A cyclin dependent kinase inhibitor 2A increases response to substance
decreases expression
affects expression		 EXP CDKN2A results in increased susceptibility to Irinotecan
Irinotecan results in decreased expression of CDKN2A mRNA
Irinotecan affects the expression of CDKN2A protein		 CTD PMID:16432164 PMID:22898888 NCBI chr 9:21,967,752...21,995,324
Ensembl chr 9:21,967,752...21,995,301 		JBrowse link
G CDKN3 cyclin dependent kinase inhibitor 3 decreases expression EXP
ISO		 Irinotecan metabolite results in decreased expression of CDKN3 mRNA; Irinotecan results in decreased expression of CDKN3 mRNA CTD PMID:15956246 PMID:20097248 NCBI chr14:54,397,007...54,420,218
Ensembl chr14:54,396,849...54,420,218 		JBrowse link
G CDON cell adhesion associated, oncogene regulated decreases expression EXP Irinotecan analog results in decreased expression of CDON mRNA CTD PMID:18927307 NCBI chr11:125,956,821...126,063,352
Ensembl chr11:125,955,796...126,063,335 		JBrowse link
G CEBPD CCAAT enhancer binding protein delta increases expression ISO Irinotecan results in increased expression of CEBPD mRNA CTD PMID:20097248 NCBI chr 8:47,736,913...47,738,164
Ensembl chr 8:47,736,913...47,738,164 		JBrowse link
G CEL carboxyl ester lipase increases response to substance EXP CEL protein results in increased susceptibility to Irinotecan CTD PMID:9766666 NCBI chr 9:133,061,981...133,071,861
Ensembl chr 9:133,061,981...133,071,861 		JBrowse link
G CELA3B chymotrypsin like elastase 3B affects expression ISO Irinotecan affects the expression of CELA3B mRNA CTD PMID:20097248 NCBI chr 1:21,977,022...21,998,642
Ensembl chr 1:21,977,022...21,998,642 		JBrowse link
G CENPE centromere protein E decreases expression EXP Irinotecan analog results in decreased expression of CENPE mRNA; Irinotecan metabolite results in decreased expression of CENPE mRNA; Irinotecan results in decreased expression of CENPE mRNA CTD PMID:15956246 PMID:18927307 NCBI chr 4:103,105,811...103,198,343
Ensembl chr 4:103,105,349...103,198,445 		JBrowse link
G CENPF centromere protein F decreases expression EXP Irinotecan metabolite results in decreased expression of CENPF mRNA; Irinotecan results in decreased expression of CENPF mRNA CTD PMID:15956246 NCBI chr 1:214,603,195...214,664,571
Ensembl chr 1:214,603,185...214,664,574 		JBrowse link
G CEP192 centrosomal protein 192 decreases expression EXP Irinotecan analog results in decreased expression of CEP192 mRNA CTD PMID:18927307 NCBI chr18:12,991,362...13,125,036
Ensembl chr18:12,991,362...13,125,052 		JBrowse link
G CEP290 centrosomal protein 290 decreases expression EXP Irinotecan analog results in decreased expression of CEP290 mRNA CTD PMID:18927307 NCBI chr12:88,049,016...88,142,088
Ensembl chr12:88,049,016...88,142,099 		JBrowse link
G CEP295 centrosomal protein 295 decreases expression EXP Irinotecan analog results in decreased expression of CEP295 mRNA CTD PMID:18927307 NCBI chr11:93,661,682...93,730,358
Ensembl chr11:93,661,682...93,730,358 		JBrowse link
G CES1 carboxylesterase 1 increases hydrolysis
increases response to substance		 EXP CES1 protein results in increased hydrolysis of Irinotecan
CES1 mRNA results in increased susceptibility to Irinotecan		 CTD PMID:15100172 PMID:15239142 NCBI chr16:55,802,851...55,833,096
Ensembl chr16:55,802,851...55,833,337 		JBrowse link
G CES2 carboxylesterase 2 affects response to substance
increases hydrolysis
increases chemical synthesis
increases expression
increases metabolic processing
increases response to substance
multiple interactions		 EXP CES2 protein affects the susceptibility to Irinotecan
CES2 protein results in increased hydrolysis of Irinotecan
CES2 protein results in increased chemical synthesis of Irinotecan
Irinotecan results in increased expression of CES2 mRNA
CES2 protein results in increased metabolism of Irinotecan
CES2 protein results in increased susceptibility to Irinotecan
CES2 mRNA results in increased chemical synthesis of and results in increased abundance of Irinotecan; CES2 mRNA results in increased metabolism of and results in increased activity of Irinotecan; CES2 protein affects the metabolism of and results in increased activity of Irinotecan; CES2 protein results in increased hydrolysis of and results in increased activity of Irinotecan; CES2 protein results in increased metabolism of and results in increased activity of Irinotecan		 CTD PMID:10728672 PMID:11716702 PMID:12171891 PMID:12171903 PMID:14581373 More... NCBI chr16:66,934,471...66,945,096
Ensembl chr16:66,934,444...66,945,096 		JBrowse link
G CES3 carboxylesterase 3 increases hydrolysis EXP CES3 protein results in increased hydrolysis of Irinotecan CTD PMID:15100172 NCBI chr16:66,961,266...66,975,149
Ensembl chr16:66,961,245...66,975,149 		JBrowse link
G CFLAR CASP8 and FADD like apoptosis regulator multiple interactions
affects response to substance
decreases expression		 EXP CFLAR protein alternative form inhibits the reaction [Irinotecan results in increased activity of TNFSF10 protein]
CFLAR protein affects the susceptibility to Irinotecan
Irinotecan results in decreased expression of CFLAR protein		 CTD PMID:16373718 NCBI chr 2:201,116,164...201,176,687
Ensembl chr 2:201,116,154...201,176,687 		JBrowse link
G CFTR CF transmembrane conductance regulator affects expression ISO Irinotecan affects the expression of CFTR mRNA CTD PMID:20097248 NCBI chr 7:117,480,025...117,668,665
Ensembl chr 7:117,287,120...117,715,971 		JBrowse link
G CHD1 chromodomain helicase DNA binding protein 1 decreases expression EXP Irinotecan metabolite results in decreased expression of CHD1 mRNA; Irinotecan results in decreased expression of CHD1 mRNA CTD PMID:15956246 NCBI chr 5:98,853,985...98,929,007
Ensembl chr 5:98,853,985...98,929,007 		JBrowse link
G CHEK1 checkpoint kinase 1 multiple interactions
increases phosphorylation		 EXP Irinotecan results in increased phosphorylation of and results in increased activity of CHEK1 protein; SAR 020106 inhibits the reaction [Irinotecan results in increased phosphorylation of CHEK1 protein] CTD PMID:22111927 PMID:22510560 PMID:22898888 NCBI chr11:125,625,136...125,681,124
Ensembl chr11:125,625,163...125,676,255 		JBrowse link
G CHEK2 checkpoint kinase 2 increases phosphorylation EXP Irinotecan results in increased phosphorylation of CHEK2 protein CTD PMID:22898888 NCBI chr22:28,687,743...28,741,834
Ensembl chr22:28,687,743...28,742,422 		JBrowse link
G CKS2 CDC28 protein kinase regulatory subunit 2 decreases expression ISO Irinotecan results in decreased expression of CKS2 mRNA CTD PMID:20097248 NCBI chr 9:89,311,195...89,316,703
Ensembl chr 9:89,311,195...89,316,703 		JBrowse link
G CLDN2 claudin 2 affects expression ISO Irinotecan affects the expression of CLDN2 mRNA CTD PMID:20097248 NCBI chr  X:106,900,164...106,930,861
Ensembl chr  X:106,900,164...106,930,861 		JBrowse link
G CLEC10A C-type lectin domain containing 10A increases expression ISO Irinotecan results in increased expression of CLEC10A mRNA CTD PMID:20097248 NCBI chr17:7,074,537...7,080,251
Ensembl chr17:7,074,537...7,080,307 		JBrowse link
G CLGN calmegin increases expression EXP Irinotecan analog results in increased expression of CLGN mRNA CTD PMID:18927307 NCBI chr 4:140,388,453...140,427,648
Ensembl chr 4:140,388,453...140,427,661 		JBrowse link
G CLPS colipase affects expression ISO Irinotecan affects the expression of CLPS mRNA CTD PMID:20097248 NCBI chr 6:35,794,982...35,797,323
Ensembl chr 6:35,794,982...35,797,344 		JBrowse link
G CLTC clathrin heavy chain decreases expression
multiple interactions		 EXP Irinotecan analog results in decreased expression of CLTC mRNA
CLTC protein affects the susceptibility to [Fluorouracil co-treated with Irinotecan analog]		 CTD PMID:18927307 NCBI chr17:59,619,895...59,696,956
Ensembl chr17:59,619,680...59,696,956 		JBrowse link
G CNNM2 cyclin and CBS domain divalent metal cation transport mediator 2 increases expression EXP Irinotecan analog results in increased expression of CNNM2 mRNA CTD PMID:18927307 NCBI chr10:102,918,294...103,090,222
Ensembl chr10:102,918,294...103,090,222 		JBrowse link
G COA1 cytochrome c oxidase assembly factor 1 decreases expression EXP Irinotecan analog results in decreased expression of COA1 mRNA CTD PMID:18927307 NCBI chr 7:43,608,457...43,729,523
Ensembl chr 7:43,608,456...43,729,717 		JBrowse link
G COL13A1 collagen type XIII alpha 1 chain increases expression EXP Irinotecan analog results in increased expression of COL13A1 mRNA CTD PMID:18927307 NCBI chr10:69,801,906...69,959,144
Ensembl chr10:69,801,880...69,964,275 		JBrowse link
G COL4A4 collagen type IV alpha 4 chain decreases expression EXP Irinotecan analog results in decreased expression of COL4A4 mRNA CTD PMID:18927307 NCBI chr 2:226,967,360...227,164,488
Ensembl chr 2:227,002,714...227,164,453 		JBrowse link
G COL6A1 collagen type VI alpha 1 chain increases expression EXP Irinotecan metabolite results in increased expression of COL6A1 mRNA; Irinotecan results in increased expression of COL6A1 mRNA CTD PMID:15956246 NCBI chr21:45,981,770...46,005,048
Ensembl chr21:45,981,770...46,005,050 		JBrowse link
G COL7A1 collagen type VII alpha 1 chain decreases response to substance EXP COL7A1 protein results in decreased susceptibility to Irinotecan CTD PMID:16734730 NCBI chr 3:48,564,073...48,595,329
Ensembl chr 3:48,564,073...48,595,329 		JBrowse link
G COMMD6 COMM domain containing 6 increases expression EXP Irinotecan metabolite results in increased expression of COMMD6 mRNA; Irinotecan results in increased expression of COMMD6 mRNA CTD PMID:15956246 NCBI chr13:75,525,214...75,549,439
Ensembl chr13:75,525,214...75,549,439 		JBrowse link
G COPA COPI coat complex subunit alpha increases expression EXP Irinotecan analog results in increased expression of COPA mRNA CTD PMID:18927307 NCBI chr 1:160,288,594...160,343,250
Ensembl chr 1:160,288,594...160,343,566 		JBrowse link
G COQ9 coenzyme Q9 decreases expression EXP Irinotecan results in decreased expression of COQ9 mRNA CTD PMID:20185912 NCBI chr16:57,447,479...57,461,270
Ensembl chr16:57,447,425...57,461,270 		JBrowse link
G CPE carboxypeptidase E increases expression EXP Irinotecan analog results in increased expression of CPE mRNA CTD PMID:18927307 NCBI chr 4:165,379,008...165,498,547
Ensembl chr 4:165,361,194...165,498,547 		JBrowse link
G CREBBP CREB binding protein decreases expression EXP Irinotecan analog results in decreased expression of CREBBP mRNA; Irinotecan metabolite results in decreased expression of CREBBP mRNA; Irinotecan results in decreased expression of CREBBP mRNA CTD PMID:15956246 PMID:18927307 NCBI chr16:3,725,054...3,880,713
Ensembl chr16:3,725,054...3,880,713 		JBrowse link
G CRIM1 cysteine rich transmembrane BMP regulator 1 decreases expression EXP Irinotecan analog results in decreased expression of CRIM1 mRNA CTD PMID:18927307 NCBI chr 2:36,355,778...36,551,135
Ensembl chr 2:36,355,778...36,551,135 		JBrowse link
G CSH2 chorionic somatomammotropin hormone 2 decreases expression EXP Irinotecan analog results in decreased expression of CSH2 mRNA CTD PMID:18927307 NCBI chr17:63,872,012...63,873,729
Ensembl chr17:63,872,012...63,873,766 		JBrowse link
G CTBP2 C-terminal binding protein 2 decreases expression
multiple interactions		 EXP Irinotecan analog results in decreased expression of CTBP2 mRNA
[Fluorouracil co-treated with Irinotecan] results in decreased expression of CTBP2 mRNA; CTBP2 protein affects the susceptibility to [Fluorouracil co-treated with Irinotecan analog]		 CTD PMID:16391804 PMID:18927307 NCBI chr10:124,984,317...125,162,463
Ensembl chr10:124,984,317...125,161,170 		JBrowse link
G CTH cystathionine gamma-lyase increases expression EXP Irinotecan analog results in increased expression of CTH mRNA CTD PMID:18927307 NCBI chr 1:70,411,268...70,439,851
Ensembl chr 1:70,411,218...70,439,851 		JBrowse link
G CUL4A cullin 4A decreases expression EXP Irinotecan analog results in decreased expression of CUL4A mRNA CTD PMID:18927307 NCBI chr13:113,208,193...113,267,108
Ensembl chr13:113,208,193...113,267,108 		JBrowse link
G CXCL1 C-X-C motif chemokine ligand 1 increases expression
multiple interactions		 ISO Irinotecan results in increased expression of CXCL1 protein
2-(1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-7H-purin-7-yl)-N-(4-isopropylphenyl)acetamide inhibits the reaction [carvacrol inhibits the reaction [Irinotecan results in increased expression of CXCL1 protein]]; carvacrol inhibits the reaction [Irinotecan results in increased expression of CXCL1 protein]		 CTD PMID:27838229 NCBI chr 4:73,869,393...73,871,308
Ensembl chr 4:73,869,393...73,871,308 		JBrowse link
G CXCL11 C-X-C motif chemokine ligand 11 affects expression ISO Irinotecan affects the expression of CXCL11 mRNA CTD PMID:20097248 NCBI chr 4:76,033,682...76,036,070
Ensembl chr 4:76,033,682...76,041,415 		JBrowse link
G CXCL12 C-X-C motif chemokine ligand 12 decreases expression EXP Irinotecan analog results in decreased expression of CXCL12 mRNA CTD PMID:18927307 NCBI chr10:44,370,165...44,385,097
Ensembl chr10:44,370,165...44,386,493 		JBrowse link
G CXCL8 C-X-C motif chemokine ligand 8 multiple interactions
increases expression		 EXP Gefitinib inhibits the reaction [Irinotecan metabolite results in increased expression of CXCL8 mRNA]; Gefitinib inhibits the reaction [Irinotecan results in increased expression of CXCL8 mRNA]
Irinotecan metabolite results in increased expression of CXCL8 mRNA; Irinotecan results in increased expression of CXCL8 mRNA		 CTD PMID:15723263 NCBI chr 4:73,740,569...73,743,716
Ensembl chr 4:73,740,519...73,743,716 		JBrowse link
G CYP27A1 cytochrome P450 family 27 subfamily A member 1 affects expression ISO Irinotecan affects the expression of CYP27A1 mRNA CTD PMID:20097248 NCBI chr 2:218,782,147...218,815,293
Ensembl chr 2:218,781,749...218,815,293 		JBrowse link
G CYP2A6 cytochrome P450 family 2 subfamily A member 6 decreases activity EXP Irinotecan metabolite results in decreased activity of CYP2A6 protein CTD PMID:11901092 NCBI chr19:40,843,541...40,850,447
Ensembl chr19:40,843,541...40,850,447 		JBrowse link
G CYP2C9 cytochrome P450 family 2 subfamily C member 9 decreases activity EXP Irinotecan metabolite results in decreased activity of CYP2C9 protein CTD PMID:11901092 NCBI chr10:94,938,658...94,990,091
Ensembl chr10:94,938,658...94,990,091 		JBrowse link
G CYP3A4 cytochrome P450 family 3 subfamily A member 4 affects metabolic processing
decreases activity
increases oxidation
increases response to substance		 EXP CYP3A4 protein affects the metabolism of Irinotecan
Irinotecan metabolite results in decreased activity of CYP3A4 protein; Irinotecan results in decreased activity of CYP3A4 protein
CYP3A4 protein results in increased oxidation of Irinotecan
CYP3A4 mRNA results in increased susceptibility to Irinotecan		 CTD PMID:11901092 PMID:15100172 PMID:15239142 PMID:15523087 PMID:15655543 NCBI chr 7:99,756,967...99,784,184
Ensembl chr 7:99,756,960...99,784,248 		JBrowse link
G CYP3A5 cytochrome P450 family 3 subfamily A member 5 multiple interactions EXP [selenomethylselenocysteine co-treated with Irinotecan] results in increased expression of CYP3A5 CTD PMID:15897249 NCBI chr 7:99,648,194...99,679,996
Ensembl chr 7:99,648,194...99,679,996 		JBrowse link
G CYP4B1 cytochrome P450 family 4 subfamily B member 1 affects expression ISO Irinotecan affects the expression of CYP4B1 mRNA CTD PMID:20097248 NCBI chr 1:46,799,046...46,819,413
Ensembl chr 1:46,757,838...46,819,413 		JBrowse link
G CYP4F12 cytochrome P450 family 4 subfamily F member 12 affects expression ISO Irinotecan affects the expression of CYP4F1 mRNA CTD PMID:20097248 NCBI chr19:15,673,087...15,697,174
Ensembl chr19:15,673,018...15,697,174 		JBrowse link
G DAGLB diacylglycerol lipase beta decreases expression EXP Irinotecan analog results in decreased expression of DAGLB mRNA CTD PMID:18927307 NCBI chr 7:6,409,129...6,447,954
Ensembl chr 7:6,409,126...6,484,190 		JBrowse link
G DBF4 DBF4-CDC7 kinase regulatory subunit increases response to substance EXP DBF4 protein results in increased susceptibility to Irinotecan CTD PMID:16734730 NCBI chr 7:87,876,493...87,909,553
Ensembl chr 7:87,876,216...87,909,553 		JBrowse link
G DCAF8 DDB1 and CUL4 associated factor 8 decreases expression EXP Irinotecan analog results in decreased expression of DCAF8 mRNA CTD PMID:18927307 NCBI chr 1:160,215,720...160,262,549
Ensembl chr 1:160,215,715...160,262,549 		JBrowse link
G DCLRE1A DNA cross-link repair 1A decreases expression EXP Irinotecan metabolite results in decreased expression of DCLRE1A mRNA; Irinotecan results in decreased expression of DCLRE1A mRNA CTD PMID:15956246 NCBI chr10:113,834,725...113,854,394
Ensembl chr10:113,834,725...113,854,383 		JBrowse link
G DCTN2 dynactin subunit 2 increases expression EXP Irinotecan analog results in increased expression of DCTN2 mRNA CTD PMID:18927307 NCBI chr12:57,530,051...57,547,192
Ensembl chr12:57,529,633...57,547,224 		JBrowse link
G DDB2 damage specific DNA binding protein 2 increases expression EXP Irinotecan metabolite results in increased expression of DDB2 mRNA; Irinotecan results in increased expression of DDB2 mRNA CTD PMID:15956246 NCBI chr11:47,214,454...47,239,217
Ensembl chr11:47,214,465...47,239,217 		JBrowse link
G DDHD1 DDHD domain containing 1 decreases expression EXP Irinotecan analog results in decreased expression of DDHD1 mRNA CTD PMID:18927307 NCBI chr14:53,036,755...53,153,323
Ensembl chr14:53,036,745...53,153,323 		JBrowse link
G DDIT3 DNA damage inducible transcript 3 increases expression ISO Irinotecan results in increased expression of DDIT3 mRNA CTD PMID:20097248 NCBI chr12:57,516,588...57,520,517
Ensembl chr12:57,516,588...57,521,737 		JBrowse link
G DDIT4 DNA damage inducible transcript 4 increases expression ISO Irinotecan results in increased expression of DDIT4 mRNA CTD PMID:20097248 NCBI chr10:72,273,924...72,276,036
Ensembl chr10:72,273,919...72,276,036 		JBrowse link
G DDX17 DEAD-box helicase 17 decreases expression EXP Irinotecan results in decreased expression of DDX17 mRNA CTD PMID:20185912 NCBI chr22:38,483,438...38,506,311
Ensembl chr22:38,483,438...38,507,660 		JBrowse link
G DDX3X DEAD-box helicase 3 X-linked affects expression ISO Irinotecan affects the expression of DDX3X mRNA CTD PMID:20097248 NCBI chr  X:41,333,308...41,364,472
Ensembl chr  X:41,333,348...41,364,472 		JBrowse link
G DDX5 DEAD-box helicase 5 multiple interactions ISO [PHY 906 co-treated with Irinotecan] affects the expression of DDX5 mRNA CTD PMID:32812032 NCBI chr17:64,498,254...64,506,866
Ensembl chr17:64,498,254...64,508,199 		JBrowse link
G DEDD death effector domain containing decreases expression EXP Irinotecan analog results in decreased expression of DEDD mRNA CTD PMID:18927307 NCBI chr 1:161,120,974...161,132,667
Ensembl chr 1:161,120,974...161,132,688 		JBrowse link
G DEFA1 defensin alpha 1 decreases expression EXP Irinotecan metabolite results in decreased expression of DEFA1 mRNA; Irinotecan results in decreased expression of DEFA1 mRNA CTD PMID:15956246 NCBI chr 8:6,977,649...6,980,092
Ensembl chr 8:6,977,649...6,980,092 		JBrowse link
G DENND4A DENN domain containing 4A decreases expression EXP Irinotecan metabolite results in decreased expression of DENND4A mRNA; Irinotecan results in decreased expression of DENND4A mRNA CTD PMID:15956246 NCBI chr15:65,659,123...65,792,293
Ensembl chr15:65,658,046...65,792,293 		JBrowse link
G DENR density regulated re-initiation and release factor decreases expression EXP Irinotecan analog results in decreased expression of DENR mRNA CTD PMID:18927307 NCBI chr12:122,752,824...122,771,064
Ensembl chr12:122,752,824...122,771,064 		JBrowse link
G DEPDC1B DEP domain containing 1B decreases expression EXP Irinotecan analog results in decreased expression of DEPDC1B mRNA CTD PMID:18927307 NCBI chr 5:60,596,912...60,700,166
Ensembl chr 5:60,596,912...60,700,190 		JBrowse link
G DESI2 desumoylating isopeptidase 2 decreases expression EXP Irinotecan analog results in decreased expression of DESI2 mRNA CTD PMID:18927307 NCBI chr 1:244,653,126...244,709,033
Ensembl chr 1:244,653,103...244,709,033 		JBrowse link
G DFFB DNA fragmentation factor subunit beta increases response to substance EXP DFFB protein results in increased susceptibility to Irinotecan CTD PMID:16734730 NCBI chr 1:3,857,476...3,885,429
Ensembl chr 1:3,857,267...3,885,429 		JBrowse link
G DGCR8 DGCR8 microprocessor complex subunit decreases expression EXP Irinotecan analog results in decreased expression of DGCR8 mRNA CTD PMID:18927307 NCBI chr22:20,080,241...20,111,872
Ensembl chr22:20,080,221...20,111,877 		JBrowse link
G DHFR2 dihydrofolate reductase 2 decreases expression EXP Irinotecan analog results in decreased expression of DHFR2 mRNA CTD PMID:18927307 NCBI chr 3:94,057,922...94,063,320
Ensembl chr 3:94,047,836...94,063,389 		JBrowse link
G DIP2A disco interacting protein 2 homolog A decreases expression EXP Irinotecan analog results in decreased expression of DIP2A mRNA CTD PMID:18927307 NCBI chr21:46,458,891...46,583,871
Ensembl chr21:46,458,891...46,570,015 		JBrowse link
G DLC1 DLC1 Rho GTPase activating protein decreases expression EXP Irinotecan analog results in decreased expression of DLC1 mRNA CTD PMID:18927307 NCBI chr 8:13,083,361...13,604,620
Ensembl chr 8:13,083,361...13,604,610 		JBrowse link
G DLD dihydrolipoamide dehydrogenase affects expression ISO Irinotecan affects the expression of DLD mRNA CTD PMID:20097248 NCBI chr 7:107,891,107...107,921,198
Ensembl chr 7:107,891,162...107,931,730 		JBrowse link
G DLG1 discs large MAGUK scaffold protein 1 decreases expression
multiple interactions		 EXP Irinotecan analog results in decreased expression of DLG1 mRNA
DLG1 protein affects the susceptibility to [Fluorouracil co-treated with Irinotecan analog]		 CTD PMID:18927307 NCBI chr 3:197,042,560...197,299,321
Ensembl chr 3:197,042,560...197,299,330 		JBrowse link
G DLX4 distal-less homeobox 4 increases expression EXP Irinotecan analog results in increased expression of DLX4 mRNA CTD PMID:18927307 NCBI chr17:49,968,572...49,974,959
Ensembl chr17:49,968,588...49,974,959 		JBrowse link
G DMAC2L distal membrane arm assembly component 2 like decreases expression EXP Irinotecan analog results in decreased expression of DMAC2L mRNA CTD PMID:18927307 NCBI chr14:50,311,516...50,327,957
Ensembl chr14:50,312,324...50,335,558 		JBrowse link
G DMWD DM1 locus, WD repeat containing increases expression EXP Irinotecan metabolite results in increased expression of DMWD mRNA; Irinotecan results in increased expression of DMWD mRNA CTD PMID:15956246 NCBI chr19:45,782,947...45,792,845
Ensembl chr19:45,782,947...45,792,845 		JBrowse link
G DOK6 docking protein 6 decreases expression EXP Irinotecan results in decreased expression of DOK6 mRNA CTD PMID:20185912 NCBI chr18:69,400,888...69,849,087
Ensembl chr18:69,400,888...69,849,087 		JBrowse link
G DPH2 diphthamide biosynthesis 2 decreases expression EXP Irinotecan analog results in decreased expression of DPH2 mRNA CTD PMID:18927307 NCBI chr 1:43,970,010...43,973,369
Ensembl chr 1:43,970,000...43,973,369 		JBrowse link
G DPH6 diphthamine biosynthesis 6 decreases expression EXP Irinotecan analog results in decreased expression of DPH6 mRNA CTD PMID:18927307 NCBI chr15:35,144,977...35,546,165
Ensembl chr15:35,217,345...35,546,193 		JBrowse link
G DPYD dihydropyrimidine dehydrogenase decreases response to substance
decreases expression		 EXP DPYD protein results in decreased susceptibility to Irinotecan
Irinotecan metabolite results in decreased expression of DPYD mRNA; Irinotecan results in decreased expression of DPYD mRNA		 CTD PMID:15956246 PMID:16734730 NCBI chr 1:97,077,743...97,921,059
Ensembl chr 1:97,077,743...97,995,000 		JBrowse link
G DRD5 dopamine receptor D5 multiple interactions EXP DRD5 mRNA results in increased susceptibility to [Leucovorin co-treated with Fluorouracil co-treated with Irinotecan] CTD PMID:17327601 NCBI chr 4:9,781,634...9,784,009
Ensembl chr 4:9,781,634...9,784,009 		JBrowse link
G DRG1 developmentally regulated GTP binding protein 1 multiple interactions EXP [selenomethylselenocysteine co-treated with Irinotecan] results in decreased expression of DRG1 CTD PMID:15897249 NCBI chr22:31,399,604...31,434,452
Ensembl chr22:31,399,604...31,528,740 		JBrowse link
G DST dystonin decreases expression EXP Irinotecan analog results in decreased expression of DST mRNA CTD PMID:18927307 NCBI chr 6:56,457,996...56,954,830
Ensembl chr 6:56,457,987...56,954,830 		JBrowse link
G DUOX2 dual oxidase 2 affects expression ISO Irinotecan affects the expression of DUOX2 mRNA CTD PMID:20097248 NCBI chr15:45,092,650...45,114,172
Ensembl chr15:45,092,650...45,114,172 		JBrowse link
G DUSP1 dual specificity phosphatase 1 increases expression ISO Irinotecan results in increased expression of DUSP1 mRNA CTD PMID:20097248 NCBI chr 5:172,768,096...172,771,195
Ensembl chr 5:172,768,096...172,771,195 		JBrowse link
G DUSP2 dual specificity phosphatase 2 increases expression EXP Irinotecan metabolite results in increased expression of DUSP2 mRNA; Irinotecan results in increased expression of DUSP2 mRNA CTD PMID:15956246 NCBI chr 2:96,143,169...96,145,440
Ensembl chr 2:96,143,169...96,145,440 		JBrowse link
G DUSP6 dual specificity phosphatase 6 affects expression ISO Irinotecan affects the expression of DUSP6 mRNA CTD PMID:20097248 NCBI chr12:89,347,235...89,352,501
Ensembl chr12:89,347,235...89,352,501 		JBrowse link
G DYRK1A dual specificity tyrosine phosphorylation regulated kinase 1A decreases expression EXP Irinotecan metabolite results in decreased expression of DYRK1A mRNA; Irinotecan results in decreased expression of DYRK1A mRNA CTD PMID:15956246 NCBI chr21:37,365,573...37,526,358
Ensembl chr21:37,365,573...37,526,358 		JBrowse link
G DYRK2 dual specificity tyrosine phosphorylation regulated kinase 2 decreases expression
affects expression		 EXP
ISO		 Irinotecan metabolite results in decreased expression of DYRK2 mRNA; Irinotecan results in decreased expression of DYRK2 mRNA
Irinotecan affects the expression of DYRK2 mRNA		 CTD PMID:15956246 PMID:20097248 NCBI chr12:67,648,745...67,665,406
Ensembl chr12:67,648,338...67,665,406 		JBrowse link
G EGFR epidermal growth factor receptor multiple interactions EXP bisindolylmaleimide I inhibits the reaction [Irinotecan metabolite results in increased phosphorylation of EGFR protein]; bisindolylmaleimide I inhibits the reaction [Irinotecan results in increased phosphorylation of EGFR protein]; Gefitinib inhibits the reaction [Irinotecan metabolite results in increased phosphorylation of and results in increased activity of EGFR protein]; Gefitinib inhibits the reaction [Irinotecan results in increased phosphorylation of and results in increased activity of EGFR protein]; Go 6976 inhibits the reaction [Irinotecan metabolite results in increased phosphorylation of EGFR protein]; Go 6976 inhibits the reaction [Irinotecan results in increased phosphorylation of EGFR protein]; Irinotecan metabolite results in increased phosphorylation of and results in increased activity of EGFR protein; Irinotecan results in increased phosphorylation of and results in increased activity of EGFR protein; rottlerin inhibits the reaction [Irinotecan metabolite results in increased phosphorylation of EGFR protein]; rottlerin inhibits the reaction [Irinotecan results in increased phosphorylation of EGFR protein] CTD PMID:15723263 NCBI chr 7:55,019,017...55,211,628
Ensembl chr 7:55,019,017...55,211,628 		JBrowse link
G EGR1 early growth response 1 increases expression ISO
EXP		 Irinotecan results in increased expression of EGR1 mRNA
Irinotecan metabolite results in increased expression of EGR1 mRNA; Irinotecan results in increased expression of EGR1 mRNA		 CTD PMID:15956246 PMID:16280599 PMID:20097248 NCBI chr 5:138,465,479...138,469,303
Ensembl chr 5:138,465,479...138,469,303 		JBrowse link
G EIF2AK4 eukaryotic translation initiation factor 2 alpha kinase 4 affects expression EXP Irinotecan analog affects the expression of EIF2AK4 mRNA CTD PMID:18927307 NCBI chr15:39,934,115...40,035,591
Ensembl chr15:39,934,115...40,035,591 		JBrowse link
G EIF4E eukaryotic translation initiation factor 4E multiple interactions ISO [PHY 906 co-treated with Irinotecan] affects the expression of EIF4E mRNA CTD PMID:32812032 NCBI chr 4:98,879,276...98,929,133
Ensembl chr 4:98,879,276...98,929,133 		JBrowse link
G EML2 EMAP like 2 multiple interactions EXP EML2 mRNA results in increased susceptibility to [Leucovorin co-treated with Fluorouracil co-treated with Irinotecan] CTD PMID:17327601 NCBI chr19:45,609,400...45,645,629
Ensembl chr19:45,606,994...45,645,602 		JBrowse link
G EML4 EMAP like 4 affects expression ISO Irinotecan affects the expression of EML4 mRNA CTD PMID:20097248 NCBI chr 2:42,169,353...42,332,548
Ensembl chr 2:42,169,353...42,332,548 		JBrowse link
G ENO1 enolase 1 decreases expression EXP Irinotecan analog results in decreased expression of ENO1 mRNA CTD PMID:18927307 NCBI chr 1:8,861,000...8,878,686
Ensembl chr 1:8,861,000...8,879,190 		JBrowse link
G EP300 E1A binding protein p300 decreases expression EXP Irinotecan metabolite results in decreased expression of EP300 mRNA; Irinotecan results in decreased expression of EP300 mRNA CTD PMID:15956246 NCBI chr22:41,092,592...41,180,077
Ensembl chr22:41,092,510...41,180,077 		JBrowse link
G EPPK1 epiplakin 1 increases expression EXP Irinotecan analog results in increased expression of EPPK1 mRNA CTD PMID:18927307 NCBI chr 8:143,857,324...143,879,194
Ensembl chr 8:143,857,324...143,878,467 		JBrowse link
G ERBB2 erb-b2 receptor tyrosine kinase 2 affects expression ISO Irinotecan affects the expression of ERBB2 mRNA CTD PMID:20097248 NCBI chr17:39,688,094...39,728,658
Ensembl chr17:39,687,914...39,730,426 		JBrowse link
G ERBB4 erb-b2 receptor tyrosine kinase 4 increases expression EXP Irinotecan metabolite results in increased expression of ERBB4 mRNA; Irinotecan results in increased expression of ERBB4 mRNA CTD PMID:15956246 NCBI chr 2:211,375,717...212,538,802
Ensembl chr 2:211,375,717...212,538,841 		JBrowse link
G ERC1 ELKS/RAB6-interacting/CAST family member 1 decreases expression EXP Irinotecan analog results in decreased expression of ERC1 mRNA CTD PMID:18927307 NCBI chr12:989,959...1,495,933
Ensembl chr12:990,509...1,495,933 		JBrowse link
G ERCC1 ERCC excision repair 1, endonuclease non-catalytic subunit decreases expression EXP Irinotecan results in decreased expression of ERCC1 protein CTD PMID:11593056 NCBI chr19:45,407,334...45,451,547
Ensembl chr19:45,407,334...45,478,828 		JBrowse link
G EREG epiregulin decreases expression EXP Irinotecan analog results in decreased expression of EREG mRNA CTD PMID:18927307 NCBI chr 4:74,365,145...74,388,749
Ensembl chr 4:74,365,145...74,388,749 		JBrowse link
G ETS2 ETS proto-oncogene 2, transcription factor increases expression EXP Irinotecan metabolite results in increased expression of ETS2 mRNA; Irinotecan results in increased expression of ETS2 mRNA CTD PMID:15956246 NCBI chr21:38,805,183...38,824,955
Ensembl chr21:38,805,183...38,824,955 		JBrowse link
G ETV6 ETS variant transcription factor 6 decreases expression EXP Irinotecan metabolite results in decreased expression of ETV6 mRNA; Irinotecan results in decreased expression of ETV6 mRNA CTD PMID:15956246 NCBI chr12:11,649,674...11,895,377
Ensembl chr12:11,649,674...11,895,377 		JBrowse link
G EXOC4 exocyst complex component 4 decreases expression EXP Irinotecan analog results in decreased expression of EXOC4 mRNA CTD PMID:18927307 NCBI chr 7:133,253,078...134,100,951
Ensembl chr 7:133,253,073...134,066,589 		JBrowse link
G F8 coagulation factor VIII multiple interactions EXP F8 mRNA results in increased susceptibility to [Leucovorin co-treated with Fluorouracil co-treated with Irinotecan] CTD PMID:17327601 NCBI chr  X:154,835,792...155,022,723
Ensembl chr  X:154,835,788...155,026,940 		JBrowse link
G FABP1 fatty acid binding protein 1 affects expression ISO Irinotecan affects the expression of FABP1 mRNA CTD PMID:20097248 NCBI chr 2:88,122,982...88,128,062
Ensembl chr 2:88,122,982...88,128,062 		JBrowse link
G FABP6 fatty acid binding protein 6 increases expression EXP Irinotecan analog results in increased expression of FABP6 mRNA CTD PMID:18927307 NCBI chr 5:160,187,381...160,238,722
Ensembl chr 5:160,187,367...160,238,735 		JBrowse link
G FAM219A family with sequence similarity 219 member A decreases expression EXP Irinotecan analog results in decreased expression of FAM219A mRNA CTD PMID:18927307 NCBI chr 9:34,398,184...34,458,570
Ensembl chr 9:34,398,184...34,458,570 		JBrowse link
G FAM3C FAM3 metabolism regulating signaling molecule C decreases expression EXP Irinotecan analog results in decreased expression of FAM3C mRNA CTD PMID:18927307 NCBI chr 7:121,348,878...121,396,396
Ensembl chr 7:121,348,878...121,396,364 		JBrowse link
G FANCG FA complementation group G increases expression EXP Irinotecan metabolite results in increased expression of FANCG mRNA; Irinotecan results in increased expression of FANCG mRNA CTD PMID:15956246 NCBI chr 9:35,073,839...35,079,942
Ensembl chr 9:35,073,835...35,080,004 		JBrowse link
G FARSB phenylalanyl-tRNA synthetase subunit beta decreases expression EXP Irinotecan analog results in decreased expression of FARSB mRNA CTD PMID:18927307 NCBI chr 2:222,566,899...222,656,092
Ensembl chr 2:222,566,899...222,656,092 		JBrowse link
G FAS Fas cell surface death receptor increases expression
multiple interactions		 EXP Irinotecan results in increased expression of FAS mRNA
Irinotecan results in increased expression of and results in increased localization of FAS protein; STAT1 protein promotes the reaction [Irinotecan results in increased localization of FAS protein]		 CTD PMID:16204068 NCBI chr10:88,964,050...89,017,059
Ensembl chr10:88,953,813...89,029,605 		JBrowse link
G FASLG Fas ligand increases expression
multiple interactions		 ISO
EXP		 Irinotecan results in increased expression of FASL protein
[selenomethylselenocysteine co-treated with Irinotecan] results in increased expression of FASLG		 CTD PMID:15897249 PMID:21475811 NCBI chr 1:172,659,103...172,666,876
Ensembl chr 1:172,659,103...172,666,876 		JBrowse link
G FBXW5 F-box and WD repeat domain containing 5 increases expression EXP Irinotecan results in increased expression of FBXW5 mRNA CTD PMID:20185912 NCBI chr 9:136,940,435...136,944,738
Ensembl chr 9:136,940,435...136,944,738 		JBrowse link
G FCF1 FCF1 rRNA-processing protein affects expression EXP Irinotecan analog affects the expression of FCF1 mRNA CTD PMID:18927307 NCBI chr14:74,713,144...74,738,620
Ensembl chr14:74,713,144...74,738,620 		JBrowse link
G FCGR2B Fc gamma receptor IIb increases expression ISO Irinotecan results in increased expression of FCGR2B mRNA CTD PMID:20097248 NCBI chr 1:161,647,243...161,678,654
Ensembl chr 1:161,663,143...161,678,654 		JBrowse link
G FGF2 fibroblast growth factor 2 increases expression EXP Irinotecan metabolite results in increased expression of FGF2 mRNA; Irinotecan results in increased expression of FGF2 mRNA CTD PMID:15956246 NCBI chr 4:122,826,682...122,898,236
Ensembl chr 4:122,826,682...122,898,236 		JBrowse link
G FGF9 fibroblast growth factor 9 decreases expression EXP Irinotecan analog results in decreased expression of FGF9 mRNA CTD PMID:18927307 NCBI chr13:21,671,073...21,704,498
Ensembl chr13:21,671,073...21,704,498 		JBrowse link
G FGL2 fibrinogen like 2 increases expression ISO Irinotecan results in increased expression of FGL2 mRNA CTD PMID:20097248 NCBI chr 7:77,193,369...77,199,819
Ensembl chr 7:77,193,369...77,199,848 		JBrowse link
G FH fumarate hydratase affects expression ISO Irinotecan affects the expression of FH mRNA CTD PMID:20097248 NCBI chr 1:241,497,603...241,519,755
Ensembl chr 1:241,497,511...241,519,799 		JBrowse link
G FKBP5 FKBP prolyl isomerase 5 increases expression ISO Irinotecan results in increased expression of FKBP5 mRNA CTD PMID:20097248 NCBI chr 6:35,573,590...35,728,583
Ensembl chr 6:35,573,585...35,728,583 		JBrowse link
G FMO5 flavin containing dimethylaniline monoxygenase 5 affects expression ISO Irinotecan affects the expression of FMO5 mRNA CTD PMID:20097248 NCBI chr 1:147,184,305...147,227,284
Ensembl chr 1:147,175,351...147,243,050 		JBrowse link
G FN1 fibronectin 1 increases expression EXP Irinotecan analog results in increased expression of FN1 mRNA; Irinotecan metabolite results in increased expression of FN1 mRNA; Irinotecan results in increased expression of FN1 mRNA CTD PMID:15956246 PMID:18927307 NCBI chr 2:215,360,865...215,436,068
Ensembl chr 2:215,360,440...215,436,073 		JBrowse link
G FOS Fos proto-oncogene, AP-1 transcription factor subunit increases expression
decreases expression		 EXP Irinotecan metabolite results in increased expression of FOS mRNA; Irinotecan results in increased expression of FOS mRNA
Irinotecan results in decreased expression of FOS mRNA		 CTD PMID:15956246 PMID:16432164 NCBI chr14:75,278,828...75,282,230
Ensembl chr14:75,278,826...75,282,230 		JBrowse link
G FOSB FosB proto-oncogene, AP-1 transcription factor subunit increases expression EXP Irinotecan metabolite results in increased expression of FOSB mRNA; Irinotecan results in increased expression of FOSB mRNA CTD PMID:15956246 NCBI chr19:45,467,996...45,475,179
Ensembl chr19:45,467,995...45,475,179 		JBrowse link
G FOXA1 forkhead box A1 affects expression ISO Irinotecan affects the expression of FOXA1 mRNA CTD PMID:20097248 NCBI chr14:37,589,552...37,595,249
Ensembl chr14:37,589,552...37,596,059 		JBrowse link
G FRK fyn related Src family tyrosine kinase affects expression ISO Irinotecan affects the expression of FRK mRNA CTD PMID:20097248 NCBI chr 6:115,931,149...116,100,725
Ensembl chr 6:115,931,149...116,060,891 		JBrowse link
G FRMD5 FERM domain containing 5 decreases expression EXP Irinotecan analog results in decreased expression of FRMD5 mRNA CTD PMID:18927307 NCBI chr15:43,870,764...44,199,473
Ensembl chr15:43,870,761...44,195,271 		JBrowse link
G FTO FTO alpha-ketoglutarate dependent dioxygenase decreases expression EXP Irinotecan analog results in decreased expression of FTO mRNA CTD PMID:18927307 NCBI chr16:53,703,963...54,121,941
Ensembl chr16:53,701,692...54,158,512 		JBrowse link
G FXYD3 FXYD domain containing ion transport regulator 3 increases expression EXP Irinotecan results in increased expression of FXYD3 mRNA CTD PMID:15152939 NCBI chr19:35,115,823...35,124,324
Ensembl chr19:35,115,823...35,124,324 		JBrowse link
G FYB1 FYN binding protein 1 decreases expression EXP Irinotecan analog results in decreased expression of FYB1 mRNA CTD PMID:18927307 NCBI chr 5:39,105,252...39,274,528
Ensembl chr 5:39,105,252...39,274,528 		JBrowse link
G G0S2 G0/G1 switch 2 increases expression ISO Irinotecan results in increased expression of G0S2 mRNA CTD PMID:20097248 NCBI chr 1:209,675,412...209,676,390
Ensembl chr 1:209,675,412...209,676,390 		JBrowse link
G G2E3 G2/M-phase specific E3 ubiquitin protein ligase decreases expression EXP Irinotecan analog results in decreased expression of G2E3 mRNA CTD PMID:18927307 NCBI chr14:30,559,158...30,620,064
Ensembl chr14:30,559,158...30,620,064 		JBrowse link
G GADD45A growth arrest and DNA damage inducible alpha increases expression ISO Irinotecan results in increased expression of GADD45A mRNA CTD PMID:20097248 NCBI chr 1:67,685,201...67,688,334
Ensembl chr 1:67,685,201...67,688,334 		JBrowse link
G GADD45G growth arrest and DNA damage inducible gamma increases expression ISO Irinotecan results in increased expression of GADD45G mRNA CTD PMID:20097248 NCBI chr 9:89,605,012...89,606,555
Ensembl chr 9:89,605,012...89,606,555 		JBrowse link
G GAMT guanidinoacetate N-methyltransferase affects expression ISO Irinotecan affects the expression of GAMT mRNA CTD PMID:20097248 NCBI chr19:1,397,026...1,401,542
Ensembl chr19:1,397,026...1,401,570 		JBrowse link
G GATA3 GATA binding protein 3 decreases expression EXP Irinotecan metabolite results in decreased expression of GATA3 mRNA; Irinotecan results in decreased expression of GATA3 mRNA CTD PMID:15956246 NCBI chr10:8,045,333...8,075,198
Ensembl chr10:8,045,378...8,075,198 		JBrowse link
G GATA4 GATA binding protein 4 affects expression ISO Irinotecan affects the expression of GATA4 mRNA CTD PMID:20097248 NCBI chr 8:11,676,935...11,760,002
Ensembl chr 8:11,676,959...11,760,002 		JBrowse link
G GCG glucagon affects expression ISO Irinotecan affects the expression of GCG mRNA CTD PMID:20097248 NCBI chr 2:162,142,882...162,152,247
Ensembl chr 2:162,142,882...162,152,404 		JBrowse link
G GDF15 growth differentiation factor 15 increases expression EXP Irinotecan metabolite results in increased expression of GDF15 mRNA; Irinotecan results in increased expression of GDF15 mRNA CTD PMID:15956246 NCBI chr19:18,386,158...18,389,176
Ensembl chr19:18,374,731...18,389,176 		JBrowse link
G GEM GTP binding protein overexpressed in skeletal muscle increases expression ISO Irinotecan results in increased expression of GEM mRNA CTD PMID:20097248 NCBI chr 8:94,249,253...94,262,319
Ensembl chr 8:94,249,253...94,262,350 		JBrowse link
G GGT1 gamma-glutamyltransferase 1 decreases expression EXP Irinotecan analog results in decreased expression of GGT1 mRNA CTD PMID:18927307 NCBI chr22:24,583,750...24,628,996
Ensembl chr22:24,594,811...24,629,005 		JBrowse link
G GJA1 gap junction protein alpha 1 increases expression
affects expression		 ISO
EXP		 Irinotecan results in increased expression of GJA1 mRNA
Irinotecan analog affects the expression of GJA1 mRNA		 CTD PMID:18927307 PMID:20097248 NCBI chr 6:121,435,646...121,449,727
Ensembl chr 6:121,435,595...121,449,727 		JBrowse link
G GK glycerol kinase decreases expression EXP Irinotecan analog results in decreased expression of GK mRNA CTD PMID:18927307 NCBI chr  X:30,653,423...30,731,462
Ensembl chr  X:30,653,359...30,731,462 		JBrowse link
G GKN1 gastrokine 1 affects expression ISO Irinotecan affects the expression of GKN1 mRNA CTD PMID:20097248 NCBI chr 2:68,974,636...68,980,976
Ensembl chr 2:68,974,573...68,980,980 		JBrowse link
G GLRX3 glutaredoxin 3 affects expression EXP Irinotecan analog affects the expression of GLRX3 mRNA CTD PMID:18927307 NCBI chr10:130,136,391...130,180,377
Ensembl chr10:130,136,391...130,184,521 		JBrowse link
G GNA13 G protein subunit alpha 13 increases expression EXP Irinotecan analog results in increased expression of GNA13 mRNA CTD PMID:18927307 NCBI chr17:65,009,289...65,056,740
Ensembl chr17:65,009,289...65,056,740 		JBrowse link
G GNG11 G protein subunit gamma 11 multiple interactions ISO [PHY 906 co-treated with Irinotecan] affects the expression of GNG11 mRNA CTD PMID:32812032 NCBI chr 7:93,921,735...93,928,610
Ensembl chr 7:93,921,735...93,928,610 		JBrowse link
G GOLGA8A golgin A8 family member A multiple interactions EXP GOLGA8A mRNA results in increased susceptibility to [Leucovorin co-treated with Fluorouracil co-treated with Irinotecan] CTD PMID:17327601 NCBI chr15:34,379,068...34,437,808
Ensembl chr15:34,378,935...34,437,808 		JBrowse link
G GPATCH2L G-patch domain containing 2 like decreases expression EXP Irinotecan analog results in decreased expression of GPATCH2L mRNA CTD PMID:18927307 NCBI chr14:76,151,922...76,235,555
Ensembl chr14:76,151,916...76,254,342 		JBrowse link
G GPATCH4 G-patch domain containing 4 (gene/pseudogene) decreases expression EXP Irinotecan analog results in decreased expression of GPATCH4 mRNA CTD PMID:18927307 NCBI chr 1:156,594,301...156,601,479
Ensembl chr 1:156,594,301...156,601,496 		JBrowse link
G GPHN gephyrin decreases expression ISO Irinotecan results in decreased expression of GPHN mRNA CTD PMID:20097248 NCBI chr14:66,508,147...67,735,355
Ensembl chr14:66,507,407...67,181,803 		JBrowse link
G GPR183 G protein-coupled receptor 183 increases expression EXP Irinotecan metabolite results in increased expression of GPR183 mRNA; Irinotecan results in increased expression of GPR183 mRNA CTD PMID:15956246 NCBI chr13:99,294,539...99,307,399
Ensembl chr13:99,294,539...99,307,399 		JBrowse link
G GPX3 glutathione peroxidase 3 increases expression EXP Irinotecan metabolite results in increased expression of GPX3 mRNA; Irinotecan results in increased expression of GPX3 mRNA CTD PMID:15956246 NCBI chr 5:151,020,591...151,028,988
Ensembl chr 5:151,020,591...151,028,988 		JBrowse link
G GREM1 gremlin 1, DAN family BMP antagonist increases expression ISO Irinotecan results in increased expression of GREM1 mRNA CTD PMID:20097248 NCBI chr15:32,718,004...32,745,106
Ensembl chr15:32,718,004...32,745,106 		JBrowse link
G GSTA4 glutathione S-transferase alpha 4 affects expression ISO Irinotecan affects the expression of GSTA4 mRNA CTD PMID:20097248 NCBI chr 6:52,977,953...52,995,284
Ensembl chr 6:52,977,948...52,995,304 		JBrowse link
G GZMB granzyme B affects expression ISO Irinotecan affects the expression of GZMB mRNA CTD PMID:20097248 NCBI chr14:24,630,954...24,634,190
Ensembl chr14:24,630,954...24,634,267 		JBrowse link
G H2AC6 H2A clustered histone 6 decreases expression EXP Irinotecan metabolite results in decreased expression of H2AC6 mRNA; Irinotecan results in decreased expression of H2AC6 mRNA CTD PMID:15956246 NCBI chr 6:26,124,172...26,124,690
Ensembl chr 6:26,124,145...26,139,116 		JBrowse link
G H2AX H2A.X variant histone increases expression
multiple interactions		 EXP Irinotecan metabolite results in increased expression of H2AX mRNA; Irinotecan results in increased expression of H2AX mRNA; Irinotecan results in increased expression of H2AX protein
[Irinotecan co-treated with rucaparib] results in increased expression of H2AX protein		 CTD PMID:15956246 PMID:30612311 NCBI chr11:119,093,874...119,095,465
Ensembl chr11:119,093,874...119,095,465 		JBrowse link
G H4C3 H4 clustered histone 3 decreases expression EXP Irinotecan analog results in decreased expression of H4C3 mRNA CTD PMID:18927307 NCBI chr 6:26,103,933...26,104,337
Ensembl chr 6:26,103,933...26,104,337 		JBrowse link
G HBEGF heparin binding EGF like growth factor multiple interactions
increases expression		 EXP Gefitinib inhibits the reaction [Irinotecan metabolite results in increased expression of HBEGF mRNA]; Gefitinib inhibits the reaction [Irinotecan results in increased expression of HBEGF mRNA]
Irinotecan metabolite results in increased expression of HBEGF mRNA; Irinotecan results in increased expression of HBEGF mRNA		 CTD PMID:15723263 NCBI chr 5:140,332,843...140,346,603
Ensembl chr 5:140,332,843...140,346,603 		JBrowse link
G HBG1 hemoglobin subunit gamma 1 decreases expression EXP Irinotecan analog results in decreased expression of HBG1 mRNA CTD PMID:18927307 NCBI chr11:5,248,269...5,249,857
Ensembl chr11:5,248,269...5,249,857 		JBrowse link
G HCAR3 hydroxycarboxylic acid receptor 3 increases expression EXP Irinotecan metabolite results in increased expression of HCAR3 mRNA; Irinotecan results in increased expression of HCAR3 mRNA CTD PMID:15956246 NCBI chr12:122,714,756...122,716,811
Ensembl chr12:122,714,756...122,716,811 		JBrowse link
G HCFC1 host cell factor C1 decreases expression EXP Irinotecan analog results in decreased expression of HCFC1 mRNA CTD PMID:18927307 NCBI chr  X:153,947,557...153,971,818
Ensembl chr  X:153,947,557...153,971,818 		JBrowse link
G HECTD2 HECT domain E3 ubiquitin protein ligase 2 decreases expression EXP Irinotecan analog results in decreased expression of HECTD2 mRNA CTD PMID:18927307 NCBI chr10:91,409,235...91,514,820
Ensembl chr10:91,409,280...91,514,829 		JBrowse link
G HELLS helicase, lymphoid specific decreases expression EXP Irinotecan analog results in decreased expression of HELLS mRNA CTD PMID:18927307 NCBI chr10:94,545,788...94,613,905
Ensembl chr10:94,545,329...94,613,905 		JBrowse link
G HES1 hes family bHLH transcription factor 1 increases activity EXP Irinotecan results in increased activity of HES1 protein CTD PMID:19147571 NCBI chr 3:194,136,148...194,138,732
Ensembl chr 3:194,136,148...194,138,732 		JBrowse link
G HGFAC HGF activator affects expression ISO Irinotecan affects the expression of HGFAC mRNA CTD PMID:20097248 NCBI chr 4:3,441,005...3,449,486
Ensembl chr 4:3,441,968...3,449,486 		JBrowse link
G HK2 hexokinase 2 affects expression ISO Irinotecan affects the expression of HK2 mRNA CTD PMID:20097248 NCBI chr 2:74,834,127...74,893,359
Ensembl chr 2:74,834,127...74,893,359 		JBrowse link
G HLA-B major histocompatibility complex, class I, B decreases expression EXP Irinotecan analog results in decreased expression of HLA-B mRNA CTD PMID:18927307 NCBI chr 6:31,353,875...31,357,179
Ensembl chr 6:31,353,872...31,367,067 		JBrowse link
G HLA-DRB1 major histocompatibility complex, class II, DR beta 1 increases expression EXP Irinotecan analog results in increased expression of HLA-DRB1 mRNA CTD PMID:18927307 NCBI chr 6:32,578,775...32,589,848
Ensembl chr 6:32,577,902...32,589,848 		JBrowse link
G HLA-DRB4 major histocompatibility complex, class II, DR beta 4 increases expression EXP Irinotecan analog results in increased expression of HLA-DRB4 mRNA CTD PMID:18927307
G HMMR hyaluronan mediated motility receptor decreases expression EXP Irinotecan metabolite results in decreased expression of HMMR mRNA; Irinotecan results in decreased expression of HMMR mRNA CTD PMID:15956246 NCBI chr 5:163,460,632...163,491,941
Ensembl chr 5:163,460,203...163,491,941 		JBrowse link
G HMOX1 heme oxygenase 1 multiple interactions
increases expression		 EXP Luteolin promotes the reaction [Irinotecan results in increased expression of HMOX1 mRNA] CTD PMID:34699766 NCBI chr22:35,381,096...35,394,207
Ensembl chr22:35,380,361...35,394,214 		JBrowse link
G HMX1 H6 family homeobox 1 increases expression EXP Irinotecan results in increased expression of HMX1 mRNA CTD PMID:20185912 NCBI chr 4:8,846,076...8,871,839
Ensembl chr 4:8,846,076...8,871,839 		JBrowse link
G HNRNPA1 heterogeneous nuclear ribonucleoprotein A1 decreases expression EXP Irinotecan analog results in decreased expression of HNRNPA1 mRNA CTD PMID:18927307 NCBI chr12:54,280,726...54,287,087
Ensembl chr12:54,280,193...54,287,088 		JBrowse link
G HNRNPA3 heterogeneous nuclear ribonucleoprotein A3 multiple interactions ISO [PHY 906 co-treated with Irinotecan] affects the expression of HNRNPA3 mRNA CTD PMID:32812032 NCBI chr 2:177,212,794...177,223,959
Ensembl chr 2:177,212,694...177,223,959 		JBrowse link
G HNRNPD heterogeneous nuclear ribonucleoprotein D decreases expression EXP Irinotecan analog results in decreased expression of HNRNPD mRNA CTD PMID:18927307 NCBI chr 4:82,352,498...82,373,991
Ensembl chr 4:82,352,498...82,374,503 		JBrowse link
G HNRNPDL heterogeneous nuclear ribonucleoprotein D like decreases expression EXP Irinotecan analog results in decreased expression of HNRNPDL mRNA CTD PMID:18927307 NCBI chr 4:82,422,564...82,430,462
Ensembl chr 4:82,422,565...82,430,462 		JBrowse link
G HRG histidine rich glycoprotein increases expression EXP Irinotecan metabolite results in increased expression of HRG mRNA; Irinotecan results in increased expression of HRG mRNA CTD PMID:15956246 NCBI chr 3:186,666,014...186,678,234
Ensembl chr 3:186,660,216...186,678,234 		JBrowse link
G HS3ST3B1 heparan sulfate-glucosamine 3-sulfotransferase 3B1 increases expression EXP Irinotecan analog results in increased expression of HS3ST3B1 mRNA CTD PMID:18927307 NCBI chr17:14,301,081...14,349,404
Ensembl chr17:14,301,081...14,349,404 		JBrowse link
G HSPA4L heat shock protein family A (Hsp70) member 4 like decreases expression EXP Irinotecan metabolite results in decreased expression of HSPA4L mRNA; Irinotecan results in decreased expression of HSPA4L mRNA CTD PMID:15956246 NCBI chr 4:127,781,796...127,840,733
Ensembl chr 4:127,781,821...127,840,733 		JBrowse link
G HTATIP2 HIV-1 Tat interactive protein 2 multiple interactions EXP [Fluorouracil co-treated with Irinotecan] results in increased expression of HTATIP2 mRNA CTD PMID:16391804 NCBI chr11:20,363,714...20,383,782
Ensembl chr11:20,363,685...20,383,782 		JBrowse link
G HYPK huntingtin interacting protein K affects expression EXP Irinotecan analog affects the expression of HYPK mRNA CTD PMID:18927307 NCBI chr15:43,800,421...43,804,427
Ensembl chr15:43,796,142...43,804,427 		JBrowse link
G IBTK inhibitor of Bruton tyrosine kinase decreases expression EXP Irinotecan results in decreased expression of IBTK mRNA CTD PMID:20185912 NCBI chr 6:82,169,987...82,247,744
Ensembl chr 6:82,169,986...82,247,754 		JBrowse link
G ID2 inhibitor of DNA binding 2 decreases expression EXP Irinotecan metabolite results in decreased expression of ID2 mRNA; Irinotecan results in decreased expression of ID2 mRNA CTD PMID:15956246 NCBI chr 2:8,682,056...8,684,461
Ensembl chr 2:8,678,845...8,684,461 		JBrowse link
G IER3 immediate early response 3 increases expression EXP Irinotecan results in increased expression of IER3 mRNA CTD PMID:20185912 NCBI chr 6:30,743,199...30,744,547
Ensembl chr 6:30,743,199...30,744,548 		JBrowse link
G IFI27L2 interferon alpha inducible protein 27 like 2 multiple interactions EXP [Fluorouracil co-treated with Irinotecan] results in increased expression of IFI27L2 mRNA CTD PMID:16391804 NCBI chr14:94,127,781...94,129,604
Ensembl chr14:94,127,779...94,130,253 		JBrowse link
G IFI6 interferon alpha inducible protein 6 increases expression EXP Irinotecan analog results in increased expression of IFI6 mRNA CTD PMID:18927307 NCBI chr 1:27,666,064...27,672,192
Ensembl chr 1:27,666,064...27,672,212 		JBrowse link
G IFITM1 interferon induced transmembrane protein 1 increases expression EXP
ISO		 Irinotecan analog results in increased expression of IFITM1 mRNA
Irinotecan results in increased expression of IFITM1 mRNA		 CTD PMID:18927307 PMID:20097248 NCBI chr11:314,040...315,272
Ensembl chr11:310,041...315,272 		JBrowse link
G IFITM3 interferon induced transmembrane protein 3 increases expression ISO Irinotecan results in increased expression of IFITM3 mRNA CTD PMID:20097248 NCBI chr11:319,676...320,860
Ensembl chr11:319,676...329,475 		JBrowse link
G IFNG interferon gamma increases expression
multiple interactions		 ISO Irinotecan results in increased expression of IFNG protein
Ciprofloxacin inhibits the reaction [Irinotecan promotes the reaction [Mitogens results in increased expression of IFNG protein]]; Irinotecan inhibits the reaction [Lipopolysaccharides results in increased expression of IFNG protein]; Irinotecan inhibits the reaction [Mitogens results in increased expression of IFNG protein]; Irinotecan promotes the reaction [Mitogens results in increased expression of IFNG protein]; Thalidomide inhibits the reaction [Irinotecan results in increased expression of IFNG protein]; Thalidomide promotes the reaction [Irinotecan results in increased expression of IFNG protein]		 CTD PMID:16815871 PMID:19401694 NCBI chr12:68,154,768...68,159,740
Ensembl chr12:68,154,768...68,159,740 		JBrowse link
G IGF1 insulin like growth factor 1 increases expression EXP Irinotecan metabolite results in increased expression of IGF1 mRNA; Irinotecan results in increased expression of IGF1 mRNA CTD PMID:15956246 NCBI chr12:102,395,874...102,481,839
Ensembl chr12:102,395,874...102,481,744 		JBrowse link
G IGFBP5 insulin like growth factor binding protein 5 increases expression ISO Irinotecan results in increased expression of IGFBP5 mRNA CTD PMID:20097248 NCBI chr 2:216,672,105...216,695,549
Ensembl chr 2:216,672,105...216,695,549 		JBrowse link
G IGHG1 immunoglobulin heavy constant gamma 1 (G1m marker) decreases expression EXP Irinotecan analog results in decreased expression of IGHG1 mRNA CTD PMID:18927307 NCBI chr14:105,741,473...105,743,070
Ensembl chr14:105,736,343...105,743,071 		JBrowse link
G IL10 interleukin 10 decreases secretion
multiple interactions		 ISO Irinotecan results in decreased secretion of IL10 protein
Ciprofloxacin inhibits the reaction [Irinotecan inhibits the reaction [Mitogens results in increased expression of IL10 protein]]; Irinotecan inhibits the reaction [Mitogens results in increased expression of IL10 protein]
Deoxycholic Acid promotes the reaction [Irinotecan results in decreased secretion of IL10 protein]; Taurodeoxycholic Acid promotes the reaction [Irinotecan results in decreased secretion of IL10 protein]		 CTD PMID:19401694 PMID:26706406 NCBI chr 1:206,767,602...206,772,494
Ensembl chr 1:206,767,602...206,774,541 		JBrowse link
G IL13RA1 interleukin 13 receptor subunit alpha 1 affects expression ISO Irinotecan affects the expression of IL13RA1 mRNA CTD PMID:20097248 NCBI chr  X:118,727,606...118,805,228
Ensembl chr  X:118,727,133...118,794,535 		JBrowse link
G IL15 interleukin 15 affects expression ISO Irinotecan affects the expression of IL15 mRNA CTD PMID:20097248 NCBI chr 4:141,636,583...141,733,987
Ensembl chr 4:141,636,583...141,733,987 		JBrowse link
G IL17A interleukin 17A increases expression ISO Irinotecan results in increased expression of IL17A mRNA; Irinotecan results in increased expression of IL17A protein CTD PMID:26431797 NCBI chr 6:52,186,375...52,190,638
Ensembl chr 6:52,186,375...52,190,638 		JBrowse link
G IL18 interleukin 18 multiple interactions
increases expression		 EXP
ISO		 [Fluorouracil co-treated with Irinotecan] results in decreased expression of IL18 mRNA; [Irinotecan co-treated with Lipopolysaccharides] results in increased expression of and results in increased secretion of IL18 protein; [Irinotecan co-treated with Lipopolysaccharides] results in increased expression of IL18 mRNA; EVP 4593 inhibits the reaction [[Lipopolysaccharides co-treated with Irinotecan] results in increased expression of and results in increased secretion of IL18 protein]; pyrazolanthrone inhibits the reaction [[Lipopolysaccharides co-treated with Irinotecan] results in increased expression of and results in increased secretion of IL18 protein]
[Irinotecan co-treated with Lipopolysaccharides] results in increased expression of and results in increased secretion of IL18 protein; [Irinotecan co-treated with Lipopolysaccharides] results in increased expression of IL18 mRNA; EVP 4593 inhibits the reaction [Irinotecan results in increased expression of and results in increased secretion of IL18 protein]; pyrazolanthrone inhibits the reaction [Irinotecan results in increased expression of and results in increased secretion of IL18 protein]
Irinotecan results in increased expression of IL18 mRNA; Irinotecan results in increased expression of IL18 protein		 CTD PMID:16391804 PMID:26431797 NCBI chr11:112,143,260...112,164,094
Ensembl chr11:112,143,253...112,164,096 		JBrowse link
G IL1B interleukin 1 beta affects expression
increases secretion
increases expression
multiple interactions		 ISO
EXP		 Irinotecan affects the expression of IL1B protein
Irinotecan affects the expression of IL1B mRNA
Irinotecan results in increased secretion of IL1B protein
Irinotecan metabolite results in increased expression of IL1B mRNA; Irinotecan results in increased expression of IL1B mRNA
[Irinotecan co-treated with Lipopolysaccharides] results in increased expression of and results in increased secretion of IL1B protein; [Irinotecan co-treated with Lipopolysaccharides] results in increased expression of IL1B mRNA; EVP 4593 inhibits the reaction [[Lipopolysaccharides co-treated with Irinotecan] results in increased expression of and results in increased secretion of IL1B protein]; Luteolin inhibits the reaction [Irinotecan results in increased expression of IL1B mRNA]; Luteolin inhibits the reaction [Irinotecan results in increased secretion of IL1B protein]; pyrazolanthrone inhibits the reaction [[Lipopolysaccharides co-treated with Irinotecan] results in increased expression of and results in increased secretion of IL1B protein]
2-(1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-7H-purin-7-yl)-N-(4-isopropylphenyl)acetamide inhibits the reaction [carvacrol inhibits the reaction [Irinotecan results in increased expression of IL1B protein]]; [Irinotecan co-treated with Lipopolysaccharides] results in increased expression of and results in increased secretion of IL1B protein; [Irinotecan co-treated with Lipopolysaccharides] results in increased expression of IL1B mRNA; carvacrol inhibits the reaction [Irinotecan results in increased expression of IL1B protein]; Irinotecan results in increased expression of and results in increased cleavage of and results in increased secretion of IL1B protein; MYD88 protein affects the reaction [Irinotecan affects the expression of IL1B mRNA]; Silymarin inhibits the reaction [Irinotecan results in increased expression of IL1B protein]; TLR2 protein affects the reaction [Irinotecan affects the expression of IL1B mRNA]; TLR4 protein affects the reaction [Irinotecan affects the expression of IL1B mRNA]
Irinotecan results in increased expression of IL1B mRNA; Irinotecan results in increased expression of IL1B protein
Ciprofloxacin inhibits the reaction [Irinotecan inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]]; Irinotecan inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]; Thalidomide inhibits the reaction [Irinotecan results in increased expression of IL1B protein]; Thalidomide promotes the reaction [Irinotecan results in increased expression of IL1B protein]		 CTD PMID:15956246 PMID:16815871 PMID:18535404 PMID:19401694 PMID:26431797 More... NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816 		JBrowse link
G IL2 interleukin 2 decreases expression
multiple interactions		 ISO Irinotecan results in decreased expression of IL2 protein
Ciprofloxacin inhibits the reaction [Irinotecan promotes the reaction [Mitogens results in increased expression of IL2 protein]]; Irinotecan inhibits the reaction [Mitogens results in increased expression of IL2 protein]; Irinotecan promotes the reaction [Mitogens results in increased expression of IL2 protein]; Thalidomide inhibits the reaction [Irinotecan results in decreased expression of IL2 protein]; Thalidomide promotes the reaction [Irinotecan results in decreased expression of IL2 protein]		 CTD PMID:16815871 PMID:19401694 NCBI chr 4:122,451,470...122,456,725
Ensembl chr 4:122,451,470...122,456,725 		JBrowse link
G IL33 interleukin 33 increases secretion
increases expression
multiple interactions		 EXP Irinotecan results in increased secretion of IL33 protein
Irinotecan results in increased expression of IL33 mRNA
Luteolin inhibits the reaction [Irinotecan results in increased expression of IL33 mRNA]; Luteolin inhibits the reaction [Irinotecan results in increased secretion of IL33 protein]; Rosiglitazone inhibits the reaction [Irinotecan results in increased expression of IL33 mRNA]; Rosiglitazone inhibits the reaction [Irinotecan results in increased secretion of IL33 protein]		 CTD PMID:34699766 NCBI chr 9:6,215,149...6,257,983
Ensembl chr 9:6,215,786...6,257,983 		JBrowse link
G IL6 interleukin 6 decreases response to substance
increases expression
multiple interactions		 EXP
ISO		 IL6 protein results in decreased susceptibility to Irinotecan
Irinotecan results in increased expression of IL6 protein
MYD88 protein affects the reaction [Irinotecan results in increased expression of IL6 mRNA]; Silymarin inhibits the reaction [Irinotecan results in increased expression of IL6 protein]; TLR2 protein affects the reaction [Irinotecan results in increased expression of IL6 mRNA]; TLR4 protein affects the reaction [Irinotecan results in increased expression of IL6 mRNA]
Ciprofloxacin inhibits the reaction [Irinotecan inhibits the reaction [Mitogens results in increased expression of IL6 protein]]; Ciprofloxacin inhibits the reaction [Irinotecan promotes the reaction [Mitogens results in increased expression of IL6 protein]]; Irinotecan inhibits the reaction [Mitogens results in increased expression of IL6 protein]; Irinotecan promotes the reaction [Mitogens results in increased expression of IL6 protein]; Thalidomide inhibits the reaction [Irinotecan results in increased expression of IL6 protein]
Irinotecan results in increased expression of IL6 mRNA; Irinotecan results in increased expression of IL6 protein		 CTD PMID:16815871 PMID:17537833 PMID:18535404 PMID:19401694 PMID:26431797 More... NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002 		JBrowse link
G IMMP2L inner mitochondrial membrane peptidase subunit 2 decreases expression EXP Irinotecan analog results in decreased expression of IMMP2L mRNA CTD PMID:18927307 NCBI chr 7:110,662,644...111,562,492
Ensembl chr 7:110,662,644...111,562,517 		JBrowse link
G IMMT inner membrane mitochondrial protein affects expression EXP Irinotecan analog affects the expression of IMMT mRNA CTD PMID:18927307 NCBI chr 2:86,143,936...86,195,462
Ensembl chr 2:86,143,932...86,195,472 		JBrowse link
G ING3 inhibitor of growth family member 3 decreases expression EXP Irinotecan analog results in decreased expression of ING3 mRNA CTD PMID:18927307 NCBI chr 7:120,950,777...120,977,216
Ensembl chr 7:120,950,763...120,977,216 		JBrowse link
G INSIG1 insulin induced gene 1 decreases expression EXP Irinotecan analog results in decreased expression of INSIG1 mRNA CTD PMID:18927307 NCBI chr 7:155,297,878...155,310,235
Ensembl chr 7:155,297,776...155,310,235 		JBrowse link
G ITGA2 integrin subunit alpha 2 increases expression EXP Irinotecan analog results in increased expression of ITGA2 mRNA CTD PMID:18927307 NCBI chr 5:52,989,352...53,094,779
Ensembl chr 5:52,989,340...53,094,779 		JBrowse link
G ITGAE integrin subunit alpha E increases response to substance EXP ITGAE protein results in increased susceptibility to Irinotecan CTD PMID:16734730 NCBI chr17:3,714,628...3,801,188
Ensembl chr17:3,714,628...3,801,188 		JBrowse link
G ITGAV integrin subunit alpha V decreases expression EXP Irinotecan metabolite results in decreased expression of ITGAV mRNA; Irinotecan results in decreased expression of ITGAV mRNA CTD PMID:15956246 NCBI chr 2:186,590,056...186,680,901
Ensembl chr 2:186,590,010...186,680,901 		JBrowse link
G ITGAX integrin subunit alpha X increases expression EXP Irinotecan metabolite results in increased expression of ITGAX mRNA; Irinotecan results in increased expression of ITGAX mRNA CTD PMID:15956246 NCBI chr16:31,355,176...31,382,999
Ensembl chr16:31,355,134...31,382,999 		JBrowse link
G ITGB3BP integrin subunit beta 3 binding protein decreases expression EXP Irinotecan metabolite results in decreased expression of ITGB3BP mRNA; Irinotecan results in decreased expression of ITGB3BP mRNA CTD PMID:15956246 NCBI chr 1:63,440,770...63,529,187
Ensembl chr 1:63,440,770...63,593,721 		JBrowse link
G JCHAIN joining chain of multimeric IgA and IgM affects expression ISO Irinotecan affects the expression of JCHAIN mRNA CTD PMID:20097248 NCBI chr 4:70,655,541...70,666,508
Ensembl chr 4:70,655,541...70,681,817 		JBrowse link
G JPT1 Jupiter microtubule associated homolog 1 decreases expression EXP Irinotecan analog results in decreased expression of JPT1 mRNA CTD PMID:18927307 NCBI chr17:75,135,243...75,154,512
Ensembl chr17:75,135,248...75,168,281 		JBrowse link
G JUN Jun proto-oncogene, AP-1 transcription factor subunit increases expression ISO
EXP		 Irinotecan results in increased expression of JUN mRNA
Irinotecan metabolite results in increased expression of JUN mRNA; Irinotecan results in increased expression of JUN mRNA		 CTD PMID:15956246 PMID:20097248 NCBI chr 1:58,780,791...58,784,047
Ensembl chr 1:58,776,845...58,784,048 		JBrowse link
G KANSL1 KAT8 regulatory NSL complex subunit 1 multiple interactions EXP KANSL1 protein affects the susceptibility to [Fluorouracil co-treated with Irinotecan analog] CTD PMID:18927307 NCBI chr17:46,029,916...46,225,367
Ensembl chr17:46,029,916...46,225,389 		JBrowse link
G KAT2B lysine acetyltransferase 2B increases expression EXP Irinotecan analog results in increased expression of KAT2B mRNA CTD PMID:18927307 NCBI chr 3:20,040,446...20,154,404
Ensembl chr 3:20,040,446...20,154,404 		JBrowse link
G KCNJ8 potassium inwardly rectifying channel subfamily J member 8 increases expression ISO Irinotecan results in increased expression of KCNJ8 mRNA CTD PMID:20097248 NCBI chr12:21,764,955...21,774,706
Ensembl chr12:21,764,955...21,775,600 		JBrowse link
G KHDRBS1 KH RNA binding domain containing, signal transduction associated 1 decreases expression EXP Irinotecan analog results in decreased expression of KHDRBS1 mRNA CTD PMID:18927307 NCBI chr 1:32,013,868...32,060,850
Ensembl chr 1:32,013,868...32,060,850 		JBrowse link
G KIAA0040 KIAA0040 increases expression EXP Irinotecan analog results in increased expression of KIAA0040 mRNA CTD PMID:18927307 NCBI chr 1:175,156,986...175,192,987
Ensembl chr 1:175,156,986...175,192,999 		JBrowse link
G KIF14 kinesin family member 14 decreases expression EXP Irinotecan analog results in decreased expression of KIF14 mRNA CTD PMID:18927307 NCBI chr 1:200,551,497...200,620,751
Ensembl chr 1:200,551,497...200,620,751 		JBrowse link
G KLF4 KLF transcription factor 4 increases expression EXP Irinotecan analog results in increased expression of KLF4 mRNA CTD PMID:18927307 NCBI chr 9:107,484,852...107,489,769
Ensembl chr 9:107,484,852...107,490,482 		JBrowse link
G KLF9 KLF transcription factor 9 increases expression EXP Irinotecan metabolite results in increased expression of KLF9 mRNA; Irinotecan results in increased expression of KLF9 mRNA CTD PMID:15956246 NCBI chr 9:70,384,604...70,414,657
Ensembl chr 9:70,384,604...70,414,657 		JBrowse link
G KLHL24 kelch like family member 24 increases expression EXP Irinotecan analog results in increased expression of KLHL24 mRNA CTD PMID:18927307 NCBI chr 3:183,635,623...183,684,519
Ensembl chr 3:183,635,610...183,684,519 		JBrowse link
G KNG1 kininogen 1 multiple interactions EXP [Fluorouracil co-treated with Irinotecan] results in decreased expression of KNG1 mRNA CTD PMID:16391804 NCBI chr 3:186,717,359...186,744,410
Ensembl chr 3:186,717,348...186,744,410 		JBrowse link
G KNSTRN kinetochore localized astrin (SPAG5) binding protein decreases expression ISO Irinotecan results in decreased expression of KNSTRN mRNA CTD PMID:20097248 NCBI chr15:40,382,721...40,394,288
Ensembl chr15:40,382,721...40,394,288 		JBrowse link
G KRIT1 KRIT1 ankyrin repeat containing decreases expression EXP Irinotecan analog results in decreased expression of KRIT1 mRNA CTD PMID:18927307 NCBI chr 7:92,198,969...92,246,100
Ensembl chr 7:92,197,498...92,246,166 		JBrowse link
G KRT18 keratin 18 multiple interactions EXP [Fluorouracil co-treated with Irinotecan co-treated with Vorinostat] results in increased cleavage of KRT18 protein CTD PMID:15754201 NCBI chr12:52,948,855...52,952,906
Ensembl chr12:52,948,871...52,952,906 		JBrowse link
G KRT5 keratin 5 decreases expression EXP Irinotecan metabolite results in decreased expression of KRT5 mRNA; Irinotecan results in decreased expression of KRT5 mRNA CTD PMID:15956246 NCBI chr12:52,514,575...52,520,394
Ensembl chr12:52,514,575...52,520,530 		JBrowse link
G LBH LBH regulator of WNT signaling pathway decreases expression EXP Irinotecan analog results in decreased expression of LBH mRNA CTD PMID:18927307 NCBI chr 2:30,231,534...30,260,028
Ensembl chr 2:30,231,534...30,323,730 		JBrowse link
G LGALS8 galectin 8 multiple interactions EXP LGALS8 mRNA results in increased susceptibility to [Leucovorin co-treated with Fluorouracil co-treated with Irinotecan] CTD PMID:17327601 NCBI chr 1:236,518,214...236,552,981
Ensembl chr 1:236,518,000...236,552,981 		JBrowse link
G LINC00597 long intergenic non-protein coding RNA 597 decreases expression EXP Irinotecan analog results in decreased expression of LINC00597 mRNA CTD PMID:18927307 NCBI chr15:77,223,893...77,225,404 JBrowse link
G LMF1 lipase maturation factor 1 multiple interactions EXP [Fluorouracil co-treated with Irinotecan] results in increased expression of LMF1 mRNA CTD PMID:16391804 NCBI chr16:853,634...981,613
Ensembl chr16:853,634...981,318 		JBrowse link
G LMO7 LIM domain 7 affects expression ISO Irinotecan affects the expression of LMO7 mRNA CTD PMID:20097248 NCBI chr13:75,620,434...75,859,870
Ensembl chr13:75,620,434...75,859,870 		JBrowse link
G LOXL3 lysyl oxidase like 3 decreases expression EXP Irinotecan analog results in decreased expression of LOXL3 mRNA CTD PMID:18927307 NCBI chr 2:74,532,258...74,555,702
Ensembl chr 2:74,532,258...74,555,690 		JBrowse link
G LPCAT1 lysophosphatidylcholine acyltransferase 1 decreases expression EXP Irinotecan analog results in decreased expression of LPCAT1 mRNA CTD PMID:18927307 NCBI chr 5:1,461,427...1,523,960
Ensembl chr 5:1,456,480...1,523,962 		JBrowse link
G LRCH3 leucine rich repeats and calponin homology domain containing 3 decreases expression EXP Irinotecan analog results in decreased expression of LRCH3 mRNA CTD PMID:18927307 NCBI chr 3:197,791,226...197,888,436
Ensembl chr 3:197,791,226...197,888,436 		JBrowse link
G LSM7 LSM7 homolog, U6 small nuclear RNA and mRNA degradation associated increases response to substance EXP LSM7 protein results in increased susceptibility to Irinotecan CTD PMID:16734730 NCBI chr19:2,321,521...2,328,586
Ensembl chr19:2,321,520...2,328,611 		JBrowse link
G LTF lactotransferrin decreases expression EXP Irinotecan metabolite results in decreased expression of LTF mRNA; Irinotecan results in decreased expression of LTF mRNA CTD PMID:15956246 NCBI chr 3:46,435,645...46,485,234
Ensembl chr 3:46,435,645...46,485,234 		JBrowse link
G LTV1 LTV1 ribosome biogenesis factor decreases expression EXP Irinotecan analog results in decreased expression of LTV1 mRNA CTD PMID:18927307 NCBI chr 6:143,843,338...143,863,812
Ensembl chr 6:143,843,338...143,863,812 		JBrowse link
G LYZ lysozyme multiple interactions ISO [PHY 906 co-treated with Irinotecan] affects the expression of LYZ2 mRNA CTD PMID:32812032 NCBI chr12:69,348,381...69,354,234
Ensembl chr12:69,348,381...69,354,234 		JBrowse link
G MAD2L1 mitotic arrest deficient 2 like 1 decreases expression EXP Irinotecan metabolite results in decreased expression of MAD2L1 mRNA; Irinotecan results in decreased expression of MAD2L1 mRNA CTD PMID:15956246 NCBI chr 4:120,055,623...120,066,848
Ensembl chr 4:120,055,623...120,066,858 		JBrowse link
G MAF MAF bZIP transcription factor affects expression ISO Irinotecan affects the expression of MAF mRNA CTD PMID:20097248 NCBI chr16:79,202,622...79,600,737
Ensembl chr16:79,585,843...79,600,737 		JBrowse link
G MAGI1 membrane associated guanylate kinase, WW and PDZ domain containing 1 decreases expression ISO Irinotecan results in decreased expression of MAGI1 mRNA CTD PMID:20097248 NCBI chr 3:65,353,526...66,038,918
Ensembl chr 3:65,353,525...66,038,918 		JBrowse link
G MAL mal, T cell differentiation protein increases expression EXP Irinotecan metabolite results in increased expression of MAL mRNA; Irinotecan results in increased expression of MAL mRNA CTD PMID:15956246 NCBI chr 2:95,025,708...95,053,992
Ensembl chr 2:95,025,677...95,053,992 		JBrowse link
G MALAT1 metastasis associated lung adenocarcinoma transcript 1 decreases expression
multiple interactions		 EXP Irinotecan analog results in decreased expression of MALAT1 mRNA
MALAT1 protein affects the susceptibility to [Fluorouracil co-treated with Irinotecan analog]		 CTD PMID:18927307 NCBI chr11:65,497,738...65,506,516
Ensembl chr11:65,497,640...65,508,073 		JBrowse link
G MALL mal, T cell differentiation protein like increases expression EXP Irinotecan metabolite results in increased expression of MALL mRNA; Irinotecan results in increased expression of MALL mRNA CTD PMID:15956246 NCBI chr 2:110,083,870...110,118,139
Ensembl chr 2:110,083,870...110,116,022 		JBrowse link
G MAP3K5 mitogen-activated protein kinase kinase kinase 5 decreases expression EXP Irinotecan metabolite results in decreased expression of MAP3K5 mRNA; Irinotecan results in decreased expression of MAP3K5 mRNA CTD PMID:15956246 NCBI chr 6:136,557,046...136,793,091
Ensembl chr 6:136,557,046...136,793,097 		JBrowse link
G MAP3K6 mitogen-activated protein kinase kinase kinase 6 increases expression ISO Irinotecan results in increased expression of MAP3K6 mRNA CTD PMID:20097248 NCBI chr 1:27,355,184...27,366,961
Ensembl chr 1:27,355,184...27,366,961 		JBrowse link
G MAP4K3 mitogen-activated protein kinase kinase kinase kinase 3 decreases expression EXP Irinotecan analog results in decreased expression of MAP4K3 mRNA CTD PMID:18927307 NCBI chr 2:39,249,266...39,437,285
Ensembl chr 2:39,249,266...39,437,301 		JBrowse link
G MAPK1 mitogen-activated protein kinase 1 multiple interactions
increases expression		 EXP
ISO		 Irinotecan results in increased phosphorylation of and results in increased activity of MAPK1 protein
Irinotecan results in increased expression of MAPK1 mRNA		 CTD PMID:16432164 PMID:20097248 NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,759,657...21,867,680 		JBrowse link
G MAPK13 mitogen-activated protein kinase 13 affects expression ISO Irinotecan affects the expression of MAPK13 mRNA CTD PMID:20097248 NCBI chr 6:36,130,513...36,144,521
Ensembl chr 6:36,127,809...36,144,524 		JBrowse link
G MAPK3 mitogen-activated protein kinase 3 multiple interactions EXP Irinotecan results in increased phosphorylation of and results in increased activity of MAPK3 protein CTD PMID:16432164 NCBI chr16:30,114,105...30,123,220
Ensembl chr16:30,114,105...30,123,506 		JBrowse link
G MARCHF6 membrane associated ring-CH-type finger 6 increases expression EXP Irinotecan analog results in increased expression of MARCHF6 mRNA CTD PMID:18927307 NCBI chr 5:10,353,695...10,440,388
Ensembl chr 5:10,353,695...10,440,388 		JBrowse link
G MATN2 matrilin 2 increases expression EXP Irinotecan analog results in increased expression of MATN2 mRNA CTD PMID:18927307 NCBI chr 8:97,869,064...98,036,724
Ensembl chr 8:97,868,840...98,036,724 		JBrowse link
G MATR3 matrin 3 decreases expression EXP Irinotecan analog results in decreased expression of MATR3 mRNA CTD PMID:18927307 NCBI chr 5:139,274,101...139,331,677
Ensembl chr 5:139,273,752...139,331,671
Ensembl chr 5:139,273,752...139,331,671 		JBrowse link
G MBNL1 muscleblind like splicing regulator 1 decreases expression EXP Irinotecan analog results in decreased expression of MBNL1 mRNA CTD PMID:18927307 NCBI chr 3:152,243,632...152,465,780
Ensembl chr 3:152,243,828...152,465,780 		JBrowse link
G MBP myelin basic protein decreases expression EXP Irinotecan analog results in decreased expression of MBP mRNA CTD PMID:18927307 NCBI chr18:76,978,833...77,133,708
Ensembl chr18:76,978,827...77,133,683 		JBrowse link
G MCCC2 methylcrotonyl-CoA carboxylase subunit 2 multiple interactions
decreases expression		 EXP MCCC2 protein affects the susceptibility to [Fluorouracil co-treated with Irinotecan analog]
Irinotecan analog results in decreased expression of MCCC2 mRNA		 CTD PMID:18927307 NCBI chr 5:71,587,340...71,658,706
Ensembl chr 5:71,579,531...71,658,706 		JBrowse link
G MCF2L MCF.2 cell line derived transforming sequence like decreases expression EXP Irinotecan metabolite results in decreased expression of MCF2L mRNA; Irinotecan results in decreased expression of MCF2L mRNA CTD PMID:15956246 NCBI chr13:112,894,335...113,099,742
Ensembl chr13:112,894,378...113,099,742 		JBrowse link
G MCL1 MCL1 apoptosis regulator, BCL2 family member decreases response to substance EXP MCL1 protein results in decreased susceptibility to Irinotecan CTD PMID:21507240 NCBI chr 1:150,574,558...150,579,610
Ensembl chr 1:150,560,895...150,579,738 		JBrowse link
G MCM4 minichromosome maintenance complex component 4 decreases expression EXP Irinotecan metabolite results in decreased expression of MCM4 mRNA; Irinotecan results in decreased expression of MCM4 mRNA CTD PMID:15956246 NCBI chr 8:47,960,941...47,978,160
Ensembl chr 8:47,960,185...47,978,160 		JBrowse link
G MDM2 MDM2 proto-oncogene increases expression EXP Irinotecan metabolite results in increased expression of MDM2 mRNA; Irinotecan results in increased expression of MDM2 mRNA CTD PMID:15956246 NCBI chr12:68,808,172...68,850,686
Ensembl chr12:68,808,177...68,845,544 		JBrowse link
G MDN1 midasin AAA ATPase 1 affects expression EXP Irinotecan analog affects the expression of MDN1 mRNA CTD PMID:18927307 NCBI chr 6:89,642,498...89,819,794
Ensembl chr 6:89,642,498...89,819,794 		JBrowse link
G MED13 mediator complex subunit 13 decreases expression EXP Irinotecan analog results in decreased expression of MED13 mRNA CTD PMID:18927307 NCBI chr17:61,942,605...62,065,278
Ensembl chr17:61,942,605...62,065,278 		JBrowse link
G MEF2B myocyte enhancer factor 2B increases expression EXP Irinotecan metabolite results in increased expression of MEF2B mRNA; Irinotecan results in increased expression of MEF2B mRNA CTD PMID:15956246 NCBI chr19:19,145,567...19,170,263
Ensembl chr19:19,145,567...19,192,131 		JBrowse link
G MGMT O-6-methylguanine-DNA methyltransferase increases response to substance
decreases expression		 EXP MGMT mRNA results in increased susceptibility to Irinotecan
Irinotecan metabolite results in decreased expression of MGMT mRNA		 CTD PMID:15239142 PMID:18492797 NCBI chr10:129,467,241...129,770,983
Ensembl chr10:129,467,190...129,770,983 		JBrowse link
G MINPP1 multiple inositol-polyphosphate phosphatase 1 affects expression ISO Irinotecan affects the expression of MINPP1 mRNA CTD PMID:20097248 NCBI chr10:87,504,893...87,553,461
Ensembl chr10:87,504,875...87,553,461 		JBrowse link
G MIP major intrinsic protein of lens fiber decreases expression EXP Irinotecan analog results in decreased expression of MIP mRNA CTD PMID:18927307 NCBI chr12:56,449,502...56,456,553
Ensembl chr12:56,449,502...56,469,166 		JBrowse link
G MIR128-1 microRNA 128-1 increases expression EXP Irinotecan results in increased expression of MIR128-1 mRNA CTD PMID:22898888 NCBI chr 2:135,665,397...135,665,478
Ensembl chr 2:135,665,397...135,665,478 		JBrowse link
G MIR17HG miR-17-92a-1 cluster host gene decreases expression EXP Irinotecan analog results in decreased expression of MIR17HG mRNA CTD PMID:18927307 NCBI chr13:91,347,820...91,354,575
Ensembl chr13:91,347,686...91,397,592 		JBrowse link
G MIR34A microRNA 34a increases expression EXP Irinotecan results in increased expression of MIR34A mRNA CTD PMID:22898888 NCBI chr 1:9,151,668...9,151,777
Ensembl chr 1:9,151,668...9,151,777 		JBrowse link
G MIR449A microRNA 449a increases expression EXP Irinotecan results in increased expression of MIR449A mRNA CTD PMID:22898888 NCBI chr 5:55,170,532...55,170,622
Ensembl chr 5:55,170,532...55,170,622 		JBrowse link
G MKI67 marker of proliferation Ki-67 multiple interactions EXP [Irinotecan co-treated with rucaparib] results in decreased expression of MKI67 protein CTD PMID:30612311 NCBI chr10:128,096,659...128,126,423
Ensembl chr10:128,096,659...128,126,423 		JBrowse link
G MKX mohawk homeobox decreases expression EXP Irinotecan analog results in decreased expression of MKX mRNA CTD PMID:18927307 NCBI chr10:27,672,874...27,745,819
Ensembl chr10:27,672,874...27,746,060 		JBrowse link
G MLH1 mutL homolog 1 affects response to substance EXP MLH1 protein affects the susceptibility to Irinotecan CTD PMID:18949393 NCBI chr 3:36,993,466...37,050,846
Ensembl chr 3:36,993,226...37,050,896 		JBrowse link
G MLXIPL MLX interacting protein like affects expression ISO Irinotecan affects the expression of MLXIPL mRNA CTD PMID:20097248 NCBI chr 7:73,593,202...73,647,907
Ensembl chr 7:73,593,194...73,624,543 		JBrowse link
G MMP2 matrix metallopeptidase 2 multiple interactions EXP [Oleanolic Acid co-treated with Irinotecan] results in decreased secretion of and results in decreased activity of and results in decreased expression of MMP2 protein; [Ursolic Acid co-treated with Irinotecan] results in decreased secretion of and results in decreased activity of and results in decreased expression of MMP2 protein; [Ursolic Acid co-treated with Oleanolic Acid co-treated with Irinotecan] results in decreased secretion of and results in decreased activity of and results in decreased expression of MMP2 protein; Irinotecan results in decreased secretion of and results in decreased activity of and results in decreased expression of MMP2 protein CTD PMID:36191607 NCBI chr16:55,478,830...55,506,691
Ensembl chr16:55,389,700...55,506,691 		JBrowse link
G MMP9 matrix metallopeptidase 9 increases expression
multiple interactions		 EXP Irinotecan metabolite results in increased expression of MMP9 mRNA; Irinotecan results in increased expression of MMP9 mRNA
[Oleanolic Acid co-treated with Irinotecan] results in decreased secretion of and results in decreased activity of and results in decreased expression of MMP9 protein; [Ursolic Acid co-treated with Irinotecan] results in decreased secretion of and results in decreased activity of and results in decreased expression of MMP9 protein; [Ursolic Acid co-treated with Oleanolic Acid co-treated with Irinotecan] results in decreased secretion of and results in decreased expression of MMP9 protein; Irinotecan results in decreased secretion of and results in decreased activity of and affects the expression of MMP9 protein		 CTD PMID:15956246 PMID:36191607 NCBI chr20:46,008,908...46,016,561
Ensembl chr20:46,008,908...46,016,561 		JBrowse link
G MPO myeloperoxidase multiple interactions
decreases expression
increases activity		 ISO
EXP		 2-(1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-7H-purin-7-yl)-N-(4-isopropylphenyl)acetamide inhibits the reaction [carvacrol inhibits the reaction [Irinotecan results in increased activity of MPO protein]]; carvacrol inhibits the reaction [Irinotecan results in increased activity of MPO protein]
Irinotecan metabolite results in decreased expression of MPO mRNA; Irinotecan results in decreased expression of MPO mRNA		 CTD PMID:15956246 PMID:27838229 NCBI chr17:58,269,855...58,280,935
Ensembl chr17:58,269,855...58,280,935 		JBrowse link
G MPP7 MAGUK p55 scaffold protein 7 increases expression EXP Irinotecan analog results in increased expression of MPP7 mRNA CTD PMID:18927307 NCBI chr10:28,050,993...28,335,203
Ensembl chr10:28,050,993...28,334,486 		JBrowse link
G MPST mercaptopyruvate sulfurtransferase decreases expression EXP Irinotecan results in decreased expression of MPST mRNA CTD PMID:20185912 NCBI chr22:37,019,742...37,029,815
Ensembl chr22:37,019,635...37,029,821 		JBrowse link
G MRPS30 mitochondrial ribosomal protein S30 decreases expression EXP Irinotecan analog results in decreased expression of MRPS30 mRNA CTD PMID:18927307 NCBI chr 5:44,808,947...44,815,514
Ensembl chr 5:44,808,947...44,820,428 		JBrowse link
G MSH2 mutS homolog 2 decreases expression
affects response to substance		 EXP Irinotecan metabolite results in decreased expression of MSH2 mRNA; Irinotecan results in decreased expression of MSH2 mRNA
MSH2 protein affects the susceptibility to Irinotecan		 CTD PMID:15956246 PMID:18949393 NCBI chr 2:47,403,067...47,709,830
Ensembl chr 2:47,403,067...47,663,146 		JBrowse link
G MSR1 macrophage scavenger receptor 1 increases expression ISO Irinotecan results in increased expression of MSR1 mRNA CTD PMID:20097248 NCBI chr 8:16,107,881...16,192,651
Ensembl chr 8:16,107,878...16,567,490 		JBrowse link
G MT-ATP6 mitochondrially encoded ATP synthase membrane subunit 6 multiple interactions EXP [Fluorouracil co-treated with Irinotecan] results in increased expression of ATP6 mRNA CTD PMID:16391804 NCBI chr MT:8,527...9,207
Ensembl chr MT:8,527...9,207 		JBrowse link
G MT1A metallothionein 1A increases expression ISO Irinotecan results in increased expression of MT1A mRNA CTD PMID:20097248 NCBI chr16:56,638,666...56,640,087
Ensembl chr16:56,638,666...56,640,087 		JBrowse link
G MTHFD1L methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1 like decreases expression EXP Irinotecan analog results in decreased expression of MTHFD1L mRNA CTD PMID:18927307 NCBI chr 6:150,865,702...151,101,887
Ensembl chr 6:150,865,679...151,101,887 		JBrowse link
G MTHFS methenyltetrahydrofolate synthetase decreases expression EXP Irinotecan metabolite results in decreased expression of MTHFS mRNA; Irinotecan results in decreased expression of MTHFS mRNA CTD PMID:15956246 NCBI chr15:79,843,547...79,897,285
Ensembl chr15:79,833,585...79,897,379 		JBrowse link
G MTMR4 myotubularin related protein 4 affects expression ISO Irinotecan affects the expression of MTMR4 mRNA CTD PMID:20097248 NCBI chr17:58,489,537...58,519,047
Ensembl chr17:58,489,529...58,517,905 		JBrowse link
G MX2 MX dynamin like GTPase 2 decreases expression EXP Irinotecan metabolite results in decreased expression of MX2 mRNA; Irinotecan results in decreased expression of MX2 mRNA CTD PMID:15956246 NCBI chr21:41,362,027...41,409,393
Ensembl chr21:41,361,999...41,409,393 		JBrowse link
G MYB MYB proto-oncogene, transcription factor increases response to substance EXP MYB protein results in increased susceptibility to Irinotecan CTD PMID:16734730 NCBI chr 6:135,181,308...135,219,172
Ensembl chr 6:135,181,308...135,219,173 		JBrowse link
G MYD88 MYD88 innate immune signal transduction adaptor multiple interactions
affects response to substance		 ISO MYD88 protein affects the reaction [Irinotecan affects the expression of IL1B mRNA]; MYD88 protein affects the reaction [Irinotecan affects the expression of NR1I2 mRNA]; MYD88 protein affects the reaction [Irinotecan affects the expression of NR1I3 mRNA]; MYD88 protein affects the reaction [Irinotecan affects the expression of TNF mRNA]; MYD88 protein affects the reaction [Irinotecan results in decreased expression of UGT1A1 mRNA]; MYD88 protein affects the reaction [Irinotecan results in increased expression of IL6 mRNA]
MYD88 protein affects the susceptibility to Irinotecan		 CTD PMID:35728726 NCBI chr 3:38,138,661...38,143,022
Ensembl chr 3:38,138,552...38,143,024 		JBrowse link
G MYH10 myosin heavy chain 10 decreases expression EXP Irinotecan analog results in decreased expression of MYH10 mRNA CTD PMID:18927307 NCBI chr17:8,474,212...8,630,725
Ensembl chr17:8,474,207...8,631,376 		JBrowse link
G MYSM1 Myb like, SWIRM and MPN domains 1 decreases expression EXP Irinotecan analog results in decreased expression of MYSM1 mRNA CTD PMID:18927307 NCBI chr 1:58,654,743...58,700,062
Ensembl chr 1:58,643,440...58,700,090 		JBrowse link
G N4BP1 NEDD4 binding protein 1 decreases expression EXP Irinotecan analog results in decreased expression of N4BP1 mRNA CTD PMID:18927307 NCBI chr16:48,538,726...48,610,180
Ensembl chr16:48,538,726...48,620,148 		JBrowse link
G NBPF1 NBPF member 1 decreases expression EXP Irinotecan analog results in decreased expression of NBPF1 mRNA CTD PMID:18927307 NCBI chr 1:16,562,423...16,613,564
Ensembl chr 1:16,562,319...16,613,562 		JBrowse link
G NCF1 neutrophil cytosolic factor 1 multiple interactions ISO [PHY 906 co-treated with Irinotecan] affects the expression of NCF1 mRNA CTD PMID:32812032 NCBI chr 7:74,774,011...74,789,315
Ensembl chr 7:74,774,011...74,789,315 		JBrowse link
G NCK1 NCK adaptor protein 1 decreases expression EXP Irinotecan metabolite results in decreased expression of NCK1 mRNA; Irinotecan results in decreased expression of NCK1 mRNA CTD PMID:15956246 NCBI chr 3:136,862,208...136,951,606
Ensembl chr 3:136,862,208...136,951,606 		JBrowse link
G NCOA1 nuclear receptor coactivator 1 increases expression EXP Irinotecan metabolite results in increased expression of NCOA1 mRNA; Irinotecan results in increased expression of NCOA1 mRNA CTD PMID:15956246 NCBI chr 2:24,491,254...24,770,702
Ensembl chr 2:24,491,254...24,770,702 		JBrowse link
G NCOR1 nuclear receptor corepressor 1 multiple interactions
decreases expression		 EXP NCOR1 protein affects the susceptibility to [Fluorouracil co-treated with Irinotecan analog]
Irinotecan analog results in decreased expression of NCOR1 mRNA		 CTD PMID:18927307 NCBI chr17:16,029,157...16,215,534
Ensembl chr17:16,029,065...16,218,185 		JBrowse link
G NCSTN nicastrin affects response to substance EXP NCSTN protein affects the susceptibility to Irinotecan CTD PMID:19147571 NCBI chr 1:160,343,383...160,358,949
Ensembl chr 1:160,343,294...160,358,952 		JBrowse link
G NDRG1 N-myc downstream regulated 1 decreases response to substance EXP NDRG1 protein results in decreased susceptibility to Irinotecan CTD PMID:15867226 NCBI chr 8:133,237,175...133,297,252
Ensembl chr 8:133,237,175...133,302,022 		JBrowse link
G NEK2 NIMA related kinase 2 decreases expression EXP Irinotecan metabolite results in decreased expression of NEK2 mRNA; Irinotecan results in decreased expression of NEK2 mRNA CTD PMID:15956246 NCBI chr 1:211,658,256...211,675,621
Ensembl chr 1:211,658,657...211,675,630 		JBrowse link
G NFE2L2 NFE2 like bZIP transcription factor 2 increases expression
multiple interactions		 EXP Irinotecan results in increased expression of NFE2L2 mRNA
Luteolin inhibits the reaction [Irinotecan results in increased expression of NFE2L2 mRNA]; PPARG protein affects the reaction [Rosiglitazone inhibits the reaction [Irinotecan results in increased expression of NFE2L2 mRNA]]; Rosiglitazone inhibits the reaction [Irinotecan results in increased expression of NFE2L2 mRNA]		 CTD PMID:34699766 NCBI chr 2:177,230,303...177,264,727
Ensembl chr 2:177,218,667...177,392,756 		JBrowse link
G NFKB1 nuclear factor kappa B subunit 1 increases activity
increases expression
multiple interactions		 EXP
ISO		 Irinotecan results in increased activity of NFKB1 protein
Irinotecan results in increased expression of NFKB1 mRNA
carvacrol inhibits the reaction [Irinotecan results in increased expression of NFKB1 protein]; Silymarin inhibits the reaction [Irinotecan results in increased expression of NFKB1 protein]		 CTD PMID:18182997 PMID:20097248 PMID:27838229 PMID:28454924 NCBI chr 4:102,501,359...102,617,302
Ensembl chr 4:102,501,330...102,617,302 		JBrowse link
G NFKBIA NFKB inhibitor alpha increases expression
multiple interactions
increases response to substance		 ISO
EXP		 Irinotecan results in increased expression of NFKBIA mRNA
AS602868 inhibits the reaction [Irinotecan results in increased phosphorylation of and results in decreased expression of NFKBIA protein]; Irinotecan results in increased phosphorylation of and results in decreased expression of NFKBIA protein
NFKBIA gene mutant form results in increased susceptibility to Irinotecan		 CTD PMID:12675310 PMID:18182997 PMID:20097248 NCBI chr14:35,401,513...35,404,749
Ensembl chr14:35,401,079...35,404,749 		JBrowse link
G NHERF2 NHERF family PDZ scaffold protein 2 increases expression EXP Irinotecan metabolite results in increased expression of NHERF2 mRNA; Irinotecan results in increased expression of NHERF2 mRNA CTD PMID:15956246 NCBI chr16:2,026,902...2,039,026
Ensembl chr16:2,025,356...2,039,026 		JBrowse link
G NID1 nidogen 1 increases expression EXP Irinotecan metabolite results in increased expression of NID1 mRNA; Irinotecan results in increased expression of NID1 mRNA CTD PMID:15956246 NCBI chr 1:235,975,830...236,065,090
Ensembl chr 1:235,975,830...236,065,109 		JBrowse link
G NMU neuromedin U affects expression ISO Irinotecan affects the expression of NMU mRNA CTD PMID:20097248 NCBI chr 4:55,595,231...55,636,793
Ensembl chr 4:55,595,229...55,636,698 		JBrowse link
G NOS2 nitric oxide synthase 2 multiple interactions
increases expression		 EXP Luteolin inhibits the reaction [Irinotecan results in increased expression of NOS2 mRNA]; Rosiglitazone inhibits the reaction [Irinotecan results in increased expression of NOS2 mRNA] CTD PMID:34699766 NCBI chr17:27,756,766...27,800,529
Ensembl chr17:27,756,766...27,800,529 		JBrowse link
G NQO1 NAD(P)H quinone dehydrogenase 1 decreases expression
multiple interactions
increases expression		 EXP Irinotecan analog results in decreased expression of NQO1 mRNA
Luteolin inhibits the reaction [Irinotecan results in increased expression of NQO1 mRNA]; PPARG protein affects the reaction [Luteolin inhibits the reaction [Irinotecan results in increased expression of NQO1 mRNA]]; PPARG protein affects the reaction [Rosiglitazone inhibits the reaction [Irinotecan results in increased expression of NQO1 mRNA]]; Rosiglitazone inhibits the reaction [Irinotecan results in increased expression of NQO1 mRNA]		 CTD PMID:18927307 PMID:34699766 NCBI chr16:69,709,401...69,726,560
Ensembl chr16:69,706,996...69,726,668 		JBrowse link
G NR1I2 nuclear receptor subfamily 1 group I member 2 multiple interactions
affects expression		 ISO MYD88 protein affects the reaction [Irinotecan affects the expression of NR1I2 mRNA]; TLR2 protein affects the reaction [Irinotecan affects the expression of NR1I2 mRNA]; TLR4 protein affects the reaction [Irinotecan affects the expression of NR1I2 mRNA] CTD PMID:35728726 NCBI chr 3:119,782,101...119,818,487
Ensembl chr 3:119,780,484...119,818,487 		JBrowse link
G NR1I3 nuclear receptor subfamily 1 group I member 3 affects expression
multiple interactions		 ISO Irinotecan affects the expression of NR1I3 mRNA
MYD88 protein affects the reaction [Irinotecan affects the expression of NR1I3 mRNA]; TLR2 protein affects the reaction [Irinotecan affects the expression of NR1I3 mRNA]; TLR4 protein affects the reaction [Irinotecan affects the expression of NR1I3 mRNA]		 CTD PMID:35728726 NCBI chr 1:161,229,669...161,238,203
Ensembl chr 1:161,229,666...161,238,244 		JBrowse link
G NR3C1 nuclear receptor subfamily 3 group C member 1 decreases response to substance EXP NR3C1 protein results in decreased susceptibility to Irinotecan CTD PMID:16734730 NCBI chr 5:143,277,931...143,435,512
Ensembl chr 5:143,277,931...143,435,512 		JBrowse link
G NR3C2 nuclear receptor subfamily 3 group C member 2 affects expression ISO Irinotecan affects the expression of NR3C2 mRNA CTD PMID:20097248 NCBI chr 4:148,078,764...148,445,508
Ensembl chr 4:148,078,762...148,444,698 		JBrowse link
G NRIP1 nuclear receptor interacting protein 1 multiple interactions EXP [Fluorouracil co-treated with Irinotecan] results in increased expression of NRIP1 mRNA CTD PMID:16391804 NCBI chr21:14,961,235...15,065,936
Ensembl chr21:14,961,235...15,065,936 		JBrowse link
G NSF N-ethylmaleimide sensitive factor, vesicle fusing ATPase decreases expression EXP Irinotecan analog results in decreased expression of NSF mRNA CTD PMID:18927307 NCBI chr17:46,590,669...46,757,464
Ensembl chr17:46,590,669...46,757,679 		JBrowse link
G NSMAF neutral sphingomyelinase activation associated factor decreases expression EXP Irinotecan results in decreased expression of NSMAF mRNA CTD PMID:20185912 NCBI chr 8:58,583,504...58,659,853
Ensembl chr 8:58,583,508...58,659,853 		JBrowse link
G NUP153 nucleoporin 153 decreases expression EXP Irinotecan analog results in decreased expression of NUP153 mRNA CTD PMID:18927307 NCBI chr 6:17,615,037...17,706,925
Ensembl chr 6:17,615,035...17,706,925 		JBrowse link
G NUSAP1 nucleolar and spindle associated protein 1 decreases expression EXP
ISO		 Irinotecan analog results in decreased expression of NUSAP1 mRNA
Irinotecan results in decreased expression of NUSAP1 mRNA		 CTD PMID:18927307 PMID:20097248 NCBI chr15:41,332,881...41,381,046
Ensembl chr15:41,320,794...41,381,050 		JBrowse link
G OAT ornithine aminotransferase decreases expression ISO Irinotecan results in decreased expression of OAT mRNA CTD PMID:30012503 NCBI chr10:124,397,303...124,418,923
Ensembl chr10:124,397,303...124,418,976 		JBrowse link
G OPHN1 oligophrenin 1 increases expression EXP Irinotecan analog results in increased expression of OPHN1 mRNA CTD PMID:18927307 NCBI chr  X:68,042,344...68,433,841
Ensembl chr  X:67,949,349...68,433,913 		JBrowse link
G ORC1 origin recognition complex subunit 1 increases response to substance EXP ORC1 protein results in increased susceptibility to Irinotecan CTD PMID:16734730 NCBI chr 1:52,372,829...52,409,503
Ensembl chr 1:52,372,829...52,404,423 		JBrowse link
G OSMR oncostatin M receptor increases expression
decreases response to substance		 EXP Irinotecan metabolite results in increased expression of OSMR mRNA; Irinotecan results in increased expression of OSMR mRNA
OSMR protein results in decreased susceptibility to Irinotecan		 CTD PMID:15956246 PMID:16734730 NCBI chr 5:38,846,012...38,945,579
Ensembl chr 5:38,845,858...38,945,596 		JBrowse link
G PAG1 phosphoprotein membrane anchor with glycosphingolipid microdomains 1 increases expression EXP Irinotecan analog results in increased expression of PAG1 mRNA CTD PMID:18927307 NCBI chr 8:80,967,810...81,112,068
Ensembl chr 8:80,967,810...81,112,068 		JBrowse link
G PAM peptidylglycine alpha-amidating monooxygenase decreases expression EXP Irinotecan analog results in decreased expression of PAM mRNA CTD PMID:18927307 NCBI chr 5:102,754,783...103,031,105
Ensembl chr 5:102,753,981...103,029,730 		JBrowse link
G PAN3 poly(A) specific ribonuclease subunit PAN3 decreases expression EXP Irinotecan analog results in decreased expression of PAN3 mRNA CTD PMID:18927307 NCBI chr13:28,138,193...28,295,335
Ensembl chr13:28,138,506...28,295,335 		JBrowse link
G PARP1 poly(ADP-ribose) polymerase 1 increases expression
multiple interactions		 EXP Irinotecan results in increased expression of PARP1 protein
rucaparib inhibits the reaction [Irinotecan results in increased expression of PARP1 protein]		 CTD PMID:30612311 NCBI chr 1:226,360,691...226,408,093
Ensembl chr 1:226,360,210...226,408,154 		JBrowse link
G PAWR pro-apoptotic WT1 regulator decreases expression EXP Irinotecan results in decreased expression of PAWR mRNA CTD PMID:20185912 NCBI chr12:79,584,879...79,690,964
Ensembl chr12:79,574,979...79,690,964 		JBrowse link
G PAX5 paired box 5 decreases expression EXP Irinotecan analog results in decreased expression of PAX5 mRNA CTD PMID:18927307 NCBI chr 9:36,833,269...37,034,268
Ensembl chr 9:36,833,269...37,034,268 		JBrowse link
G PAX7 paired box 7 decreases expression EXP Irinotecan analog results in decreased expression of PAX7 mRNA CTD PMID:18927307 NCBI chr 1:18,630,846...18,748,866
Ensembl chr 1:18,630,846...18,748,866 		JBrowse link
G PBXIP1 PBX homeobox interacting protein 1 decreases response to substance EXP PBXIP1 protein results in decreased susceptibility to Irinotecan CTD PMID:16734730 NCBI chr 1:154,944,080...154,956,099
Ensembl chr 1:154,944,076...154,956,123 		JBrowse link
G PCBD2 pterin-4 alpha-carbinolamine dehydratase 2 decreases expression EXP Irinotecan analog results in decreased expression of PCBD2 mRNA CTD PMID:18927307 NCBI chr 5:134,905,131...134,962,644
Ensembl chr 5:134,905,120...135,007,959 		JBrowse link
G PCDHGC3 protocadherin gamma subfamily C, 3 increases expression EXP Irinotecan metabolite results in increased expression of PCDHGC3 mRNA; Irinotecan results in increased expression of PCDHGC3 mRNA CTD PMID:15956246 NCBI chr 5:141,475,966...141,512,975
Ensembl chr 5:141,475,947...141,512,977 		JBrowse link
G PCK1 phosphoenolpyruvate carboxykinase 1 affects expression ISO Irinotecan affects the expression of PCK1 mRNA CTD PMID:20097248 NCBI chr20:57,561,110...57,568,121
Ensembl chr20:57,561,080...57,568,121 		JBrowse link
G PCLAF PCNA clamp associated factor multiple interactions EXP [Fluorouracil co-treated with Irinotecan] results in decreased expression of PCLAF mRNA CTD PMID:16391804 NCBI chr15:64,364,304...64,387,687
Ensembl chr15:64,364,304...64,387,687 		JBrowse link
G PCNA proliferating cell nuclear antigen multiple interactions ISO Irinotecan inhibits the reaction [nitrosobenzylmethylamine results in increased expression of PCNA protein] CTD PMID:15547733 NCBI chr20:5,114,953...5,126,622
Ensembl chr20:5,114,953...5,126,626 		JBrowse link
G PDE4B phosphodiesterase 4B affects expression
decreases expression		 ISO
EXP		 Irinotecan affects the expression of PDE4B mRNA
Irinotecan metabolite results in decreased expression of PDE4B mRNA; Irinotecan results in decreased expression of PDE4B mRNA		 CTD PMID:15956246 PMID:20097248 NCBI chr 1:65,792,510...66,374,579
Ensembl chr 1:65,792,514...66,374,579 		JBrowse link
G PDLIM5 PDZ and LIM domain 5 decreases expression EXP Irinotecan analog results in decreased expression of PDLIM5 mRNA CTD PMID:18927307 NCBI chr 4:94,451,942...94,668,223
Ensembl chr 4:94,451,857...94,668,227 		JBrowse link
G PFDN2 prefoldin subunit 2 multiple interactions ISO [PHY 906 co-treated with Irinotecan] affects the expression of PFDN2 mRNA CTD PMID:32812032 NCBI chr 1:161,100,561...161,118,037
Ensembl chr 1:161,100,556...161,118,055 		JBrowse link
G PGM2L1 phosphoglucomutase 2 like 1 increases expression EXP Irinotecan analog results in increased expression of PGM2L1 mRNA CTD PMID:18927307 NCBI chr11:74,330,316...74,398,433
Ensembl chr11:74,330,316...74,398,433 		JBrowse link
G PHLDA1 pleckstrin homology like domain family A member 1 decreases expression EXP Irinotecan analog results in decreased expression of PHLDA1 mRNA CTD PMID:18927307 NCBI chr12:76,025,447...76,031,776
Ensembl chr12:76,025,447...76,031,776 		JBrowse link
G PHLDA2 pleckstrin homology like domain family A member 2 increases expression EXP Irinotecan results in increased expression of PHLDA2 mRNA CTD PMID:20185912 NCBI chr11:2,928,273...2,929,420
Ensembl chr11:2,928,273...2,929,420 		JBrowse link
G PI4KAP2 phosphatidylinositol 4-kinase alpha pseudogene 2 decreases expression EXP Irinotecan metabolite results in decreased expression of PI4KAP2 mRNA; Irinotecan results in decreased expression of PI4KAP2 mRNA CTD PMID:15956246 NCBI chr22:21,472,998...21,517,491
Ensembl chr22:21,473,059...21,488,358 		JBrowse link
G PIGW phosphatidylinositol glycan anchor biosynthesis class W decreases expression EXP Irinotecan analog results in decreased expression of PIGW mRNA CTD PMID:18927307 NCBI chr17:36,534,987...36,539,303
Ensembl chr17:36,534,987...36,539,310 		JBrowse link
G PIP5K1B phosphatidylinositol-4-phosphate 5-kinase type 1 beta affects expression ISO Irinotecan affects the expression of PIP5K1B mRNA CTD PMID:20097248 NCBI chr 9:68,705,240...69,009,176
Ensembl chr 9:68,705,240...69,009,176 		JBrowse link
G PKDCC protein kinase domain containing, cytoplasmic decreases expression EXP Irinotecan results in decreased expression of PKDCC mRNA CTD PMID:20185912 NCBI chr 2:42,048,021...42,058,517
Ensembl chr 2:42,048,021...42,058,517 		JBrowse link
G PLA2G1B phospholipase A2 group IB affects expression ISO Irinotecan affects the expression of PLA2G1B mRNA CTD PMID:20097248 NCBI chr12:120,322,115...120,327,779
Ensembl chr12:120,322,115...120,327,779 		JBrowse link
G PLA2G2D phospholipase A2 group IID affects expression ISO Irinotecan affects the expression of PLA2G2D mRNA CTD PMID:20097248 NCBI chr 1:20,111,939...20,119,536
Ensembl chr 1:20,111,939...20,119,566 		JBrowse link
G PLAT plasminogen activator, tissue type increases expression
decreases expression		 ISO
EXP		 Irinotecan results in increased expression of PLAT mRNA
Irinotecan analog results in decreased expression of PLAT mRNA		 CTD PMID:18927307 PMID:20097248 NCBI chr 8:42,174,718...42,207,565
Ensembl chr 8:42,174,718...42,207,709 		JBrowse link
G PLAU plasminogen activator, urokinase multiple interactions
decreases secretion		 EXP [Oleanolic Acid co-treated with Irinotecan] results in decreased secretion of PLAU protein; [Ursolic Acid co-treated with Irinotecan] results in decreased secretion of PLAU protein; [Ursolic Acid co-treated with Oleanolic Acid co-treated with Irinotecan] results in decreased secretion of PLAU protein
Irinotecan results in decreased secretion of PLAU protein		 CTD PMID:36191607 NCBI chr10:73,909,164...73,917,494
Ensembl chr10:73,909,177...73,917,496 		JBrowse link
G PLAUR plasminogen activator, urokinase receptor multiple interactions EXP [Oleanolic Acid co-treated with Irinotecan] results in increased secretion of and results in decreased expression of PLAUR protein; [Ursolic Acid co-treated with Irinotecan] results in increased secretion of and results in decreased expression of PLAUR protein; [Ursolic Acid co-treated with Oleanolic Acid co-treated with Irinotecan] results in increased secretion of and results in decreased expression of PLAUR protein; Irinotecan results in increased secretion of and results in decreased expression of PLAUR protein CTD PMID:36191607 NCBI chr19:43,646,095...43,670,169
Ensembl chr19:43,646,095...43,670,547 		JBrowse link
G PLCB1 phospholipase C beta 1 decreases expression ISO Irinotecan results in decreased expression of PLCB1 mRNA CTD PMID:20097248 NCBI chr20:8,132,266...8,884,900
Ensembl chr20:8,077,251...8,968,360 		JBrowse link
G PLCXD2 phosphatidylinositol specific phospholipase C X domain containing 2 increases expression EXP Irinotecan analog results in increased expression of PLCXD2 mRNA CTD PMID:18927307 NCBI chr 3:111,674,676...111,727,007
Ensembl chr 3:111,674,676...111,846,447 		JBrowse link
G PLD1 phospholipase D1 affects expression ISO Irinotecan affects the expression of PLD1 mRNA CTD PMID:20097248 NCBI chr 3:171,600,404...171,810,483
Ensembl chr 3:171,600,404...171,810,950 		JBrowse link
G PLEKHA5 pleckstrin homology domain containing A5 decreases expression EXP Irinotecan analog results in decreased expression of PLEKHA5 mRNA CTD PMID:18927307 NCBI chr12:19,129,733...19,376,400
Ensembl chr12:19,129,669...19,376,400 		JBrowse link
G PLEKHH3 pleckstrin homology, MyTH4 and FERM domain containing H3 increases expression EXP Irinotecan metabolite results in increased expression of PLEKHH3 mRNA; Irinotecan results in increased expression of PLEKHH3 mRNA CTD PMID:15956246 NCBI chr17:42,667,914...42,676,994
Ensembl chr17:42,667,914...42,676,994 		JBrowse link
G PLK1 polo like kinase 1 decreases expression EXP Irinotecan metabolite results in decreased expression of PLK1 mRNA; Irinotecan results in decreased expression of PLK1 mRNA CTD PMID:15956246 NCBI chr16:23,678,889...23,690,367
Ensembl chr16:23,677,656...23,690,367 		JBrowse link
G PLK2 polo like kinase 2 increases expression EXP Irinotecan metabolite results in increased expression of PLK2 mRNA; Irinotecan results in increased expression of PLK2 mRNA CTD PMID:15956246 NCBI chr 5:58,453,982...58,460,086
Ensembl chr 5:58,453,982...58,460,139 		JBrowse link
G PLK3 polo like kinase 3 increases expression EXP Irinotecan metabolite results in increased expression of PLK3 mRNA; Irinotecan results in increased expression of PLK3 mRNA CTD PMID:15956246 NCBI chr 1:44,800,377...44,805,990
Ensembl chr 1:44,800,377...44,805,990 		JBrowse link
G PLPP1 phospholipid phosphatase 1 decreases response to substance EXP PLPP1 protein results in decreased susceptibility to Irinotecan CTD PMID:16734730 NCBI chr 5:55,424,854...55,534,964
Ensembl chr 5:55,424,854...55,534,969 		JBrowse link
G PLRG1 pleiotropic regulator 1 multiple interactions EXP [Fluorouracil co-treated with Irinotecan] results in increased expression of PLRG1 mRNA CTD PMID:16391804 NCBI chr 4:154,535,005...154,550,400
Ensembl chr 4:154,535,005...154,550,400 		JBrowse link
G PMAIP1 phorbol-12-myristate-13-acetate-induced protein 1 increases expression EXP Irinotecan metabolite results in increased expression of PMAIP1 mRNA; Irinotecan results in increased expression of PMAIP1 mRNA CTD PMID:15956246 NCBI chr18:59,899,996...59,904,305
Ensembl chr18:59,899,996...59,904,305 		JBrowse link
G PMP22 peripheral myelin protein 22 affects expression ISO Irinotecan affects the expression of PMP22 mRNA CTD PMID:20097248 NCBI chr17:15,229,779...15,265,326
Ensembl chr17:15,229,773...15,272,292 		JBrowse link
G PNRC1 proline rich nuclear receptor coactivator 1 increases expression EXP Irinotecan analog results in increased expression of PNRC1 mRNA CTD PMID:18927307 NCBI chr 6:89,080,751...89,085,160
Ensembl chr 6:89,080,751...89,085,160 		JBrowse link
G POGZ pogo transposable element derived with ZNF domain decreases expression EXP Irinotecan analog results in decreased expression of POGZ mRNA CTD PMID:18927307 NCBI chr 1:151,402,724...151,459,494
Ensembl chr 1:151,402,724...151,459,494 		JBrowse link
G POLA1 DNA polymerase alpha 1, catalytic subunit increases response to substance
affects expression		 EXP
ISO		 POLA1 protein results in increased susceptibility to Irinotecan
Irinotecan affects the expression of POLA1 mRNA		 CTD PMID:16734730 PMID:20097248 NCBI chr  X:24,693,918...24,996,986
Ensembl chr  X:24,693,873...24,996,986 		JBrowse link
G POLE2 DNA polymerase epsilon 2, accessory subunit increases response to substance EXP POLE2 protein results in increased susceptibility to Irinotecan CTD PMID:16734730 NCBI chr14:49,643,555...49,688,214
Ensembl chr14:49,643,555...49,688,422 		JBrowse link
G POLK DNA polymerase kappa decreases expression EXP Irinotecan analog results in decreased expression of POLK mRNA CTD PMID:18927307 NCBI chr 5:75,510,774...75,609,991
Ensembl chr 5:75,511,845...75,609,991 		JBrowse link
G POLR3G RNA polymerase III subunit G increases response to substance EXP POLR3G protein results in increased susceptibility to Irinotecan CTD PMID:16734730 NCBI chr 5:90,473,929...90,514,557
Ensembl chr 5:90,471,748...90,514,557 		JBrowse link
G PON3 paraoxonase 3 affects expression ISO Irinotecan affects the expression of PON3 mRNA CTD PMID:20097248 NCBI chr 7:95,359,872...95,396,375
Ensembl chr 7:95,359,872...95,396,375 		JBrowse link
G POR cytochrome p450 oxidoreductase increases response to substance EXP POR mRNA results in increased susceptibility to Irinotecan CTD PMID:15239142 NCBI chr 7:75,915,155...75,986,855
Ensembl chr 7:75,899,200...75,986,855 		JBrowse link
G PPARG peroxisome proliferator activated receptor gamma multiple interactions
decreases expression		 EXP Luteolin inhibits the reaction [Irinotecan results in decreased expression of PPARG mRNA]; PPARG protein affects the reaction [Luteolin inhibits the reaction [Irinotecan results in increased expression of NQO1 mRNA]]; PPARG protein affects the reaction [Luteolin inhibits the reaction [Irinotecan results in increased expression of TNF mRNA]]; PPARG protein affects the reaction [Rosiglitazone inhibits the reaction [Irinotecan results in increased expression of NFE2L2 mRNA]]; PPARG protein affects the reaction [Rosiglitazone inhibits the reaction [Irinotecan results in increased expression of NQO1 mRNA]]; PPARG protein affects the reaction [Rosiglitazone inhibits the reaction [Irinotecan results in increased expression of TNF mRNA]] CTD PMID:34699766 NCBI chr 3:12,287,368...12,434,344
Ensembl chr 3:12,287,368...12,434,356 		JBrowse link
G PPM1D protein phosphatase, Mg2+/Mn2+ dependent 1D increases expression EXP Irinotecan analog results in increased expression of PPM1D mRNA CTD PMID:18927307 NCBI chr17:60,600,193...60,666,280
Ensembl chr17:60,600,193...60,666,280 		JBrowse link
G PPP3CA protein phosphatase 3 catalytic subunit alpha multiple interactions
decreases expression		 EXP [Fluorouracil co-treated with Irinotecan] results in increased expression of PPP3CA mRNA; PPP3CA protein affects the susceptibility to [Fluorouracil co-treated with Irinotecan analog]
Irinotecan analog results in decreased expression of PPP3CA mRNA		 CTD PMID:16391804 PMID:18927307 NCBI chr 4:101,023,418...101,347,526
Ensembl chr 4:101,023,409...101,348,278 		JBrowse link
G PPP3CB protein phosphatase 3 catalytic subunit beta decreases expression EXP Irinotecan metabolite results in decreased expression of PPP3CB mRNA; Irinotecan results in decreased expression of PPP3CB mRNA CTD PMID:15956246 NCBI chr10:73,436,433...73,496,024
Ensembl chr10:73,436,433...73,496,024 		JBrowse link
G PPP4R3B protein phosphatase 4 regulatory subunit 3B decreases expression EXP Irinotecan analog results in decreased expression of PPP4R3B mRNA CTD PMID:18927307 NCBI chr 2:55,547,292...55,617,622
Ensembl chr 2:55,547,292...55,618,880 		JBrowse link
G PRAP1 proline rich acidic protein 1 affects expression ISO Irinotecan affects the expression of PRAP1 mRNA CTD PMID:20097248 NCBI chr10:133,347,373...133,352,683
Ensembl chr10:133,347,368...133,352,683 		JBrowse link
G PRKAA1 protein kinase AMP-activated catalytic subunit alpha 1 decreases expression EXP Irinotecan analog results in decreased expression of PRKAA1 mRNA CTD PMID:18927307 NCBI chr 5:40,759,389...40,798,374
Ensembl chr 5:40,759,389...40,798,374 		JBrowse link
G PRKCA protein kinase C alpha increases phosphorylation EXP Irinotecan metabolite results in increased phosphorylation of PRKCA protein; Irinotecan results in increased phosphorylation of PRKCA protein CTD PMID:15723263 NCBI chr17:66,302,613...66,810,743
Ensembl chr17:66,302,613...66,810,743 		JBrowse link
G PRKCB protein kinase C beta increases phosphorylation EXP Irinotecan metabolite results in increased phosphorylation of PRKCB protein; Irinotecan results in increased phosphorylation of PRKCB protein CTD PMID:15723263 NCBI chr16:23,835,983...24,220,611
Ensembl chr16:23,835,983...24,220,611 		JBrowse link
G PRKCD protein kinase C delta increases phosphorylation EXP Irinotecan metabolite results in increased phosphorylation of PRKCD protein; Irinotecan results in increased phosphorylation of PRKCD protein CTD PMID:15723263 NCBI chr 3:53,161,209...53,192,717
Ensembl chr 3:53,156,009...53,192,717 		JBrowse link
G PRKCI protein kinase C iota increases phosphorylation EXP Irinotecan metabolite results in increased phosphorylation of PRKCI protein; Irinotecan results in increased phosphorylation of PRKCI protein CTD PMID:15723263 NCBI chr 3:170,222,424...170,305,977
Ensembl chr 3:170,222,424...170,305,977 		JBrowse link
G PRKDC protein kinase, DNA-activated, catalytic subunit multiple interactions
increases phosphorylation		 EXP IC486241 inhibits the reaction [Irinotecan results in increased phosphorylation of PRKDC protein] CTD PMID:17441964 PMID:21221710 NCBI chr 8:47,773,111...47,960,136
Ensembl chr 8:47,773,111...47,960,178 		JBrowse link
G PRLR prolactin receptor affects expression ISO Irinotecan affects the expression of PRLR mRNA CTD PMID:20097248 NCBI chr 5:35,048,756...35,230,487
Ensembl chr 5:35,048,756...35,230,487 		JBrowse link
G PROM1 prominin 1 decreases expression EXP Irinotecan metabolite results in decreased expression of PROM1 mRNA; Irinotecan results in decreased expression of PROM1 mRNA CTD PMID:15956246 NCBI chr 4:15,968,228...16,084,023
Ensembl chr 4:15,963,076...16,084,378 		JBrowse link
G PRR13 proline rich 13 multiple interactions EXP [Fluorouracil co-treated with Irinotecan] results in increased expression of PRR13 mRNA CTD PMID:16391804 NCBI chr12:53,441,734...53,446,638
Ensembl chr12:53,441,678...53,446,645 		JBrowse link
G PRR15 proline rich 15 multiple interactions ISO [PHY 906 co-treated with Irinotecan] affects the expression of PRR15 mRNA CTD PMID:32812032 NCBI chr 7:29,563,835...29,567,295
Ensembl chr 7:29,563,835...29,567,293 		JBrowse link
G PRSS12 serine protease 12 multiple interactions ISO [PHY 906 co-treated with Irinotecan] affects the expression of PRSS12 mRNA CTD PMID:32812032 NCBI chr 4:118,280,038...118,353,003
Ensembl chr 4:118,280,038...118,353,003 		JBrowse link
G PSAT1 phosphoserine aminotransferase 1 increases response to substance EXP PSAT1 protein results in increased susceptibility to Irinotecan CTD PMID:16734730 NCBI chr 9:78,297,125...78,330,093
Ensembl chr 9:78,297,125...78,330,093 		JBrowse link
G PSG9 pregnancy specific beta-1-glycoprotein 9 multiple interactions EXP PSG9 mRNA results in increased susceptibility to [Leucovorin co-treated with Fluorouracil co-treated with Irinotecan] CTD PMID:17327601 NCBI chr19:43,253,282...43,269,530
Ensembl chr19:43,211,791...43,269,530 		JBrowse link
G PTCH1 patched 1 multiple interactions EXP [Fluorouracil co-treated with Irinotecan] results in increased expression of PTCH1 mRNA CTD PMID:16391804 NCBI chr 9:95,442,980...95,516,971
Ensembl chr 9:95,442,980...95,517,057 		JBrowse link
G PTGES prostaglandin E synthase increases expression EXP Irinotecan metabolite results in increased expression of PTGES mRNA; Irinotecan results in increased expression of PTGES mRNA CTD PMID:15956246 NCBI chr 9:129,738,349...129,753,042
Ensembl chr 9:129,738,331...129,753,042 		JBrowse link
G PTGS2 prostaglandin-endoperoxide synthase 2 multiple interactions
increases expression		 ISO carvacrol inhibits the reaction [Irinotecan results in increased expression of PTGS2 protein] CTD PMID:27838229 NCBI chr 1:186,671,791...186,680,423
Ensembl chr 1:186,671,791...186,680,922 		JBrowse link
G PTK2 protein tyrosine kinase 2 decreases expression EXP Irinotecan analog results in decreased expression of PTK2 mRNA CTD PMID:18927307 NCBI chr 8:140,657,900...141,002,079
Ensembl chr 8:140,657,900...141,002,216 		JBrowse link
G PTP4A1 protein tyrosine phosphatase 4A1 decreases expression EXP Irinotecan analog results in decreased expression of PTP4A1 mRNA CTD PMID:18927307 NCBI chr 6:63,516,440...63,583,588
Ensembl chr 6:63,521,746...63,583,588 		JBrowse link
G PTPN13 protein tyrosine phosphatase non-receptor type 13 decreases expression EXP Irinotecan metabolite results in decreased expression of PTPN13 mRNA; Irinotecan results in decreased expression of PTPN13 mRNA CTD PMID:15956246 NCBI chr 4:86,594,315...86,815,161
Ensembl chr 4:86,594,315...86,815,171 		JBrowse link
G PTPN22 protein tyrosine phosphatase non-receptor type 22 increases expression EXP Irinotecan metabolite results in increased expression of PTPN22 mRNA; Irinotecan results in increased expression of PTPN22 mRNA CTD PMID:15956246 NCBI chr 1:113,813,811...113,871,759
Ensembl chr 1:113,813,811...113,871,753 		JBrowse link
G PTPRD protein tyrosine phosphatase receptor type D increases expression EXP Irinotecan metabolite results in increased expression of PTPRD mRNA; Irinotecan results in increased expression of PTPRD mRNA CTD PMID:15956246 NCBI chr 9:8,314,246...10,613,002
Ensembl chr 9:8,314,246...10,613,002 		JBrowse link
G PTPRG protein tyrosine phosphatase receptor type G decreases expression EXP Irinotecan analog results in decreased expression of PTPRG mRNA CTD PMID:18927307 NCBI chr 3:61,561,571...62,297,609
Ensembl chr 3:61,561,569...62,297,609 		JBrowse link
G PTPRN protein tyrosine phosphatase receptor type N increases expression EXP Irinotecan metabolite results in increased expression of PTPRN mRNA; Irinotecan results in increased expression of PTPRN mRNA CTD PMID:15956246 NCBI chr 2:219,289,623...219,309,401
Ensembl chr 2:219,289,623...219,309,648 		JBrowse link
G PTTG1 PTTG1 regulator of sister chromatid separation, securin affects expression ISO Irinotecan affects the expression of PTTG1 mRNA CTD PMID:20097248 NCBI chr 5:160,421,855...160,428,744
Ensembl chr 5:160,421,855...160,428,739 		JBrowse link
G RAB27A RAB27A, member RAS oncogene family affects expression ISO Irinotecan affects the expression of RAB27A mRNA CTD PMID:20097248 NCBI chr15:55,202,966...55,289,813
Ensembl chr15:55,202,966...55,319,113 		JBrowse link
G RAB31 RAB31, member RAS oncogene family decreases response to substance EXP RAB31 protein results in decreased susceptibility to Irinotecan CTD PMID:16734730 NCBI chr18:9,708,301...9,862,551
Ensembl chr18:9,708,275...9,862,551 		JBrowse link
G RAC3 Rac family small GTPase 3 increases expression EXP Irinotecan metabolite results in increased expression of RAC3 mRNA; Irinotecan results in increased expression of RAC3 mRNA CTD PMID:15956246 NCBI chr17:82,031,678...82,034,204
Ensembl chr17:82,031,678...82,034,204 		JBrowse link
G RAD23B RAD23 homolog B, nucleotide excision repair protein decreases expression EXP Irinotecan metabolite results in decreased expression of RAD23B mRNA; Irinotecan results in decreased expression of RAD23B mRNA CTD PMID:15956246 NCBI chr 9:107,283,279...107,332,194
Ensembl chr 9:107,283,137...107,332,192 		JBrowse link
G RAD51 RAD51 recombinase increases expression
multiple interactions		 EXP Irinotecan results in increased expression of RAD51 protein
[Irinotecan co-treated with 2-(morpholin-4-yl)benzo(h)chromen-4-one] results in increased expression of RAD51 protein; [Irinotecan co-treated with IC486241] results in increased expression of RAD51 protein		 CTD PMID:21221710 NCBI chr15:40,694,733...40,732,340
Ensembl chr15:40,694,774...40,732,340 		JBrowse link
G RAMP1 receptor activity modifying protein 1 affects expression ISO Irinotecan affects the expression of RAMP1 mRNA CTD PMID:20097248 NCBI chr 2:237,858,880...237,912,106
Ensembl chr 2:237,858,893...237,912,106 		JBrowse link
G RARRES1 retinoic acid receptor responder 1 increases expression ISO Irinotecan results in increased expression of RARRES1 mRNA CTD PMID:20097248 NCBI chr 3:158,696,892...158,732,457
Ensembl chr 3:158,696,892...158,732,489 		JBrowse link
G RASA1 RAS p21 protein activator 1 decreases expression EXP Irinotecan analog results in decreased expression of RASA1 mRNA CTD PMID:18927307 NCBI chr 5:87,267,883...87,391,916
Ensembl chr 5:87,267,883...87,391,931 		JBrowse link
G RB1 RB transcriptional corepressor 1 affects expression EXP Irinotecan affects the expression of RB1 protein CTD PMID:15132777 NCBI chr13:48,303,751...48,481,890
Ensembl chr13:48,303,744...48,599,436 		JBrowse link
G RBBP5 RB binding protein 5, histone lysine methyltransferase complex subunit decreases expression
increases expression		 EXP Irinotecan metabolite results in decreased expression of RBBP5 mRNA; Irinotecan results in decreased expression of RBBP5 mRNA
Irinotecan metabolite results in increased expression of RBBP5 mRNA; Irinotecan results in increased expression of RBBP5 mRNA		 CTD PMID:15956246 NCBI chr 1:205,086,142...205,121,978
Ensembl chr 1:205,086,142...205,122,015 		JBrowse link
G RBL1 RB transcriptional corepressor like 1 decreases expression EXP Irinotecan metabolite results in decreased expression of RBL1 mRNA; Irinotecan results in decreased expression of RBL1 mRNA CTD PMID:15956246 NCBI chr20:36,996,349...37,095,997
Ensembl chr20:36,996,349...37,095,997 		JBrowse link
G RBM24 RNA binding motif protein 24 increases expression EXP Irinotecan analog results in increased expression of RBM24 mRNA CTD PMID:18927307 NCBI chr 6:17,281,361...17,293,871
Ensembl chr 6:17,281,361...17,293,871 		JBrowse link
G RBMS1 RNA binding motif single stranded interacting protein 1 decreases response to substance EXP RBMS1 protein results in decreased susceptibility to Irinotecan CTD PMID:16734730 NCBI chr 2:160,272,151...160,493,807
Ensembl chr 2:160,272,151...160,493,807 		JBrowse link
G RBP2 retinol binding protein 2 affects expression ISO Irinotecan affects the expression of RBP2 mRNA CTD PMID:20097248 NCBI chr 3:139,452,884...139,476,516
Ensembl chr 3:139,452,884...139,480,747 		JBrowse link
G RBPJ recombination signal binding protein for immunoglobulin kappa J region multiple interactions
decreases expression		 EXP [Fluorouracil co-treated with Irinotecan] results in decreased expression of RBPJ mRNA
Irinotecan analog results in decreased expression of RBPJ mRNA		 CTD PMID:16391804 PMID:18927307 NCBI chr 4:26,105,449...26,435,131
Ensembl chr 4:26,163,455...26,435,131 		JBrowse link
G RECK reversion inducing cysteine rich protein with kazal motifs increases expression EXP Irinotecan analog results in increased expression of RECK mRNA CTD PMID:18927307 NCBI chr 9:36,036,913...36,124,455
Ensembl chr 9:36,036,913...36,124,455 		JBrowse link
G REG1A regenerating family member 1 alpha affects expression ISO Irinotecan affects the expression of REG1A mRNA CTD PMID:20097248 NCBI chr 2:79,120,488...79,123,409
Ensembl chr 2:79,120,362...79,123,409 		JBrowse link
G REG3A regenerating family member 3 alpha affects expression ISO Irinotecan affects the expression of REG3B mRNA CTD PMID:20097248 NCBI chr 2:79,157,006...79,159,753
Ensembl chr 2:79,157,003...79,159,753 		JBrowse link
G REG3G regenerating family member 3 gamma affects expression ISO Irinotecan affects the expression of REG3G mRNA CTD PMID:20097248 NCBI chr 2:79,025,702...79,028,501
Ensembl chr 2:79,025,686...79,028,505 		JBrowse link
G RELA RELA proto-oncogene, NF-kB subunit decreases response to substance
increases activity
increases expression
multiple interactions		 EXP
ISO		 RELA protein results in decreased susceptibility to Irinotecan
Irinotecan results in increased activity of RELA protein
Irinotecan results in increased expression of RELA protein
[Irinotecan co-treated with Thalidomide co-treated with Celecoxib] results in increased expression of RELA protein; [Irinotecan co-treated with Thalidomide] results in increased expression of RELA protein		 CTD PMID:15161687 PMID:16685529 PMID:18182997 PMID:18535404 NCBI chr11:65,653,601...65,663,857
Ensembl chr11:65,653,599...65,663,090 		JBrowse link
G REPS1 RALBP1 associated Eps domain containing 1 multiple interactions
decreases expression		 EXP REPS1 protein affects the susceptibility to [Fluorouracil co-treated with Irinotecan analog]
Irinotecan analog results in decreased expression of REPS1 mRNA		 CTD PMID:18927307 NCBI chr 6:138,903,493...138,988,253
Ensembl chr 6:138,903,493...138,988,261 		JBrowse link
G RFC3 replication factor C subunit 3 decreases expression
increases response to substance		 EXP Irinotecan metabolite results in decreased expression of RFC3 mRNA; Irinotecan results in decreased expression of RFC3 mRNA
RFC3 protein results in increased susceptibility to Irinotecan		 CTD PMID:15956246 PMID:16734730 NCBI chr13:33,818,149...33,977,377
Ensembl chr13:33,818,069...33,966,558 		JBrowse link
G RGS1 regulator of G protein signaling 1 increases expression EXP Irinotecan metabolite results in increased expression of RGS1 mRNA; Irinotecan results in increased expression of RGS1 mRNA CTD PMID:15956246 NCBI chr 1:192,575,773...192,580,024
Ensembl chr 1:192,575,763...192,580,024 		JBrowse link
G RGS10 regulator of G protein signaling 10 multiple interactions ISO [PHY 906 co-treated with Irinotecan] affects the expression of RGS10 mRNA CTD PMID:32812032 NCBI chr10:119,499,817...119,542,719
Ensembl chr10:119,499,817...119,542,719 		JBrowse link
G RGS22 regulator of G protein signaling 22 decreases expression EXP Irinotecan analog results in decreased expression of RGS22 mRNA CTD PMID:18927307 NCBI chr 8:99,960,936...100,106,049
Ensembl chr 8:99,960,936...100,131,268 		JBrowse link
G RGS4 regulator of G protein signaling 4 increases expression ISO Irinotecan results in increased expression of RGS4 mRNA CTD PMID:20097248 NCBI chr 1:163,068,871...163,076,802
Ensembl chr 1:163,068,775...163,076,802 		JBrowse link
G RHOB ras homolog family member B increases expression EXP Irinotecan results in increased expression of RHOB mRNA CTD PMID:20185912 NCBI chr 2:20,447,074...20,449,440
Ensembl chr 2:20,447,074...20,449,440 		JBrowse link
G RHOU ras homolog family member U increases expression EXP Irinotecan analog results in increased expression of RHOU mRNA CTD PMID:18927307 NCBI chr 1:228,644,647...228,746,669
Ensembl chr 1:228,735,479...228,746,664 		JBrowse link
G RLIM ring finger protein, LIM domain interacting decreases expression EXP Irinotecan analog results in decreased expression of RLIM mRNA CTD PMID:18927307 NCBI chr  X:74,582,976...74,614,624
Ensembl chr  X:74,582,976...74,614,624 		JBrowse link
G RNF34 ring finger protein 34 multiple interactions
decreases response to substance		 EXP RNF34 protein inhibits the reaction [Irinotecan results in increased activity of CASP3 protein]
RNF34 protein results in decreased susceptibility to Irinotecan		 CTD PMID:16080519 NCBI chr12:121,400,118...121,424,348
Ensembl chr12:121,400,083...121,430,623 		JBrowse link
G RPL4 ribosomal protein L4 decreases expression EXP Irinotecan analog results in decreased expression of RPL4 mRNA CTD PMID:18927307 NCBI chr15:66,498,015...66,504,855
Ensembl chr15:66,498,015...66,524,532 		JBrowse link
G RPS6KB1 ribosomal protein S6 kinase B1 multiple interactions EXP [Irinotecan co-treated with rucaparib] results in decreased expression of RPS6KB1 protein CTD PMID:30612311 NCBI chr17:59,893,121...59,950,574
Ensembl chr17:59,893,046...59,950,574 		JBrowse link
G RTP4 receptor transporter protein 4 affects expression ISO Irinotecan affects the expression of RTP4 mRNA CTD PMID:20097248 NCBI chr 3:187,368,385...187,372,076
Ensembl chr 3:187,368,385...187,372,076 		JBrowse link
G RUNX1 RUNX family transcription factor 1 decreases expression EXP Irinotecan metabolite results in decreased expression of RUNX1 mRNA; Irinotecan results in decreased expression of RUNX1 mRNA CTD PMID:15956246 NCBI chr21:34,787,801...35,049,302
Ensembl chr21:34,787,801...36,004,667 		JBrowse link
G S100G S100 calcium binding protein G affects expression ISO Irinotecan affects the expression of S100G mRNA CTD PMID:20097248 NCBI chr  X:16,650,158...16,654,670
Ensembl chr  X:16,650,158...16,654,670 		JBrowse link
G SAMD9 sterile alpha motif domain containing 9 increases expression EXP Irinotecan analog results in increased expression of SAMD9 mRNA CTD PMID:18927307 NCBI chr 7:93,099,518...93,117,979
Ensembl chr 7:93,099,513...93,118,023 		JBrowse link
G SAMHD1 SAM and HD domain containing deoxynucleoside triphosphate triphosphohydrolase 1 affects expression EXP Irinotecan analog affects the expression of SAMHD1 mRNA CTD PMID:18927307 NCBI chr20:36,889,773...36,951,708
Ensembl chr20:36,890,229...36,951,893 		JBrowse link
G SAT1 spermidine/spermine N1-acetyltransferase 1 increases expression
decreases response to substance		 EXP Irinotecan results in increased expression of SAT1 mRNA
SAT1 mRNA results in decreased susceptibility to Irinotecan		 CTD PMID:15152939 NCBI chr  X:23,783,173...23,786,210
Ensembl chr  X:23,783,173...23,786,210 		JBrowse link
G SCAF4 SR-related CTD associated factor 4 decreases expression EXP Irinotecan analog results in decreased expression of SCAF4 mRNA CTD PMID:18927307 NCBI chr21:31,671,000...31,732,118
Ensembl chr21:31,671,000...31,732,118 		JBrowse link
G SCAI suppressor of cancer cell invasion decreases expression EXP Irinotecan analog results in decreased expression of SCAI mRNA CTD PMID:18927307 NCBI chr 9:124,942,608...125,143,528
Ensembl chr 9:124,942,608...125,143,528 		JBrowse link
G SCAMP3 secretory carrier membrane protein 3 multiple interactions EXP [Fluorouracil co-treated with Irinotecan] results in decreased expression of SCAMP3 mRNA CTD PMID:16391804 NCBI chr 1:155,255,981...155,262,360
Ensembl chr 1:155,255,979...155,262,433 		JBrowse link
G SCD stearoyl-CoA desaturase increases expression EXP Irinotecan analog results in increased expression of SCD4 mRNA CTD PMID:18927307 NCBI chr10:100,347,233...100,364,826
Ensembl chr10:100,347,233...100,364,826 		JBrowse link
G SCIN scinderin affects expression ISO Irinotecan affects the expression of SCIN mRNA CTD PMID:20097248 NCBI chr 7:12,570,720...12,660,182
Ensembl chr 7:12,570,577...12,660,182 		JBrowse link
G SDC4 syndecan 4 increases expression EXP Irinotecan metabolite results in increased expression of SDC4 mRNA; Irinotecan results in increased expression of SDC4 mRNA CTD PMID:15956246 NCBI chr20:45,325,288...45,348,424
Ensembl chr20:45,325,288...45,348,424 		JBrowse link
G SEC31A SEC31 homolog A, COPII coat complex component decreases expression EXP Irinotecan analog results in decreased expression of SEC31A mRNA CTD PMID:18927307 NCBI chr 4:82,818,509...82,900,569
Ensembl chr 4:82,818,509...82,901,166 		JBrowse link
G SEMA3C semaphorin 3C increases expression EXP Irinotecan analog results in increased expression of SEMA3C mRNA CTD PMID:18927307 NCBI chr 7:80,742,538...80,922,389
Ensembl chr 7:80,742,538...80,922,359 		JBrowse link
G SENP6 SUMO specific peptidase 6 decreases expression EXP Irinotecan analog results in decreased expression of SENP6 mRNA CTD PMID:18927307 NCBI chr 6:75,601,880...75,718,281
Ensembl chr 6:75,601,509...75,718,281 		JBrowse link
G SERPINB5 serpin family B member 5 multiple interactions EXP [Fluorouracil co-treated with Irinotecan] results in decreased expression of SERPINB5 mRNA CTD PMID:16391804 NCBI chr18:63,476,958...63,505,085
Ensembl chr18:63,476,958...63,505,085 		JBrowse link
G SERPINE2 serpin family E member 2 multiple interactions EXP SERPINE2 mRNA results in increased susceptibility to [Leucovorin co-treated with Fluorouracil co-treated with Irinotecan] CTD PMID:17327601 NCBI chr 2:223,975,045...224,039,286
Ensembl chr 2:223,975,045...224,039,318 		JBrowse link
G SERTAD1 SERTA domain containing 1 increases expression EXP Irinotecan results in increased expression of SERTAD1 mRNA CTD PMID:20185912 NCBI chr19:40,421,589...40,425,992
Ensembl chr19:40,421,589...40,425,992 		JBrowse link
G SESN2 sestrin 2 increases expression EXP Irinotecan metabolite results in increased expression of SESN2 mRNA; Irinotecan results in increased expression of SESN2 mRNA CTD PMID:15956246 NCBI chr 1:28,259,518...28,282,491
Ensembl chr 1:28,259,518...28,282,491 		JBrowse link
G SETD1B SET domain containing 1B, histone lysine methyltransferase decreases expression EXP Irinotecan analog results in decreased expression of SETD1B mRNA CTD PMID:18927307 NCBI chr12:121,790,155...121,832,656
Ensembl chr12:121,804,009...121,832,656 		JBrowse link
G SETD5 SET domain containing 5 decreases expression EXP Irinotecan analog results in decreased expression of SETD5 mRNA CTD PMID:18927307 NCBI chr 3:9,397,615...9,478,154
Ensembl chr 3:9,397,615...9,479,240 		JBrowse link
G SFN stratifin multiple interactions EXP [Irinotecan co-treated with Bortezomib] results in decreased expression of SFN protein CTD PMID:16373703 NCBI chr 1:26,863,149...26,864,456
Ensembl chr 1:26,863,149...26,864,456 		JBrowse link
G SGK1 serum/glucocorticoid regulated kinase 1 increases expression EXP Irinotecan analog results in increased expression of SGK1 mRNA; Irinotecan metabolite results in increased expression of SGK1 mRNA; Irinotecan results in increased expression of SGK1 mRNA CTD PMID:15956246 PMID:18927307 PMID:20185912 NCBI chr 6:134,169,256...134,318,112
Ensembl chr 6:134,169,248...134,318,112 		JBrowse link
G SGO2 shugoshin 2 decreases expression EXP Irinotecan analog results in decreased expression of SGO2 mRNA CTD PMID:18927307 NCBI chr 2:200,526,142...200,584,096
Ensembl chr 2:200,510,008...200,584,096 		JBrowse link
G SIGLEC1 sialic acid binding Ig like lectin 1 multiple interactions EXP [Fluorouracil co-treated with Irinotecan] results in increased expression of SIGLEC1 mRNA CTD PMID:16391804 NCBI chr20:3,686,970...3,712,600
Ensembl chr20:3,686,970...3,712,600 		JBrowse link
G SKP2 S-phase kinase associated protein 2 increases response to substance EXP SKP2 protein results in increased susceptibility to Irinotecan CTD PMID:16734730 NCBI chr 5:36,152,111...36,193,530
Ensembl chr 5:36,151,989...36,196,849 		JBrowse link
G SLC13A2 solute carrier family 13 member 2 affects expression ISO Irinotecan affects the expression of SLC13A2 mRNA CTD PMID:20097248 NCBI chr17:28,473,644...28,497,781
Ensembl chr17:28,473,293...28,497,781 		JBrowse link
G SLC16A4 solute carrier family 16 member 4 decreases expression EXP Irinotecan metabolite results in decreased expression of SLC16A4 mRNA; Irinotecan results in decreased expression of SLC16A4 mRNA CTD PMID:15956246 NCBI chr 1:110,362,857...110,391,026
Ensembl chr 1:110,362,851...110,391,082 		JBrowse link
G SLC19A1 solute carrier family 19 member 1 decreases expression EXP Irinotecan analog results in decreased expression of SLC19A1 mRNA CTD PMID:18927307 NCBI chr21:45,502,517...45,563,025
Ensembl chr21:45,493,572...45,573,365 		JBrowse link
G SLC25A21 solute carrier family 25 member 21 decreases expression EXP Irinotecan analog results in decreased expression of SLC25A21 mRNA CTD PMID:18927307 NCBI chr14:36,677,921...37,172,606
Ensembl chr14:36,677,921...37,172,606 		JBrowse link
G SLC25A36 solute carrier family 25 member 36 affects expression ISO Irinotecan affects the expression of SLC25A36 mRNA CTD PMID:20097248 NCBI chr 3:140,941,836...140,980,995
Ensembl chr 3:140,941,830...140,980,995 		JBrowse link
G SLC30A1 solute carrier family 30 member 1 decreases expression EXP Irinotecan analog results in decreased expression of SLC30A1 mRNA CTD PMID:18927307 NCBI chr 1:211,571,568...211,579,161
Ensembl chr 1:211,571,568...211,579,161 		JBrowse link
G SLC31A1 solute carrier family 31 member 1 affects expression ISO Irinotecan affects the expression of SLC31A1 mRNA CTD PMID:20097248 NCBI chr 9:113,221,544...113,264,492
Ensembl chr 9:113,221,544...113,264,492 		JBrowse link
G SLC39A4 solute carrier family 39 member 4 affects expression ISO Irinotecan affects the expression of SLC39A4 mRNA CTD PMID:20097248 NCBI chr 8:144,412,414...144,416,844
Ensembl chr 8:144,409,742...144,416,844 		JBrowse link
G SLC44A1 solute carrier family 44 member 1 affects expression ISO Irinotecan affects the expression of SLC44A1 mRNA CTD PMID:20097248 NCBI chr 9:105,244,651...105,438,504
Ensembl chr 9:105,244,622...105,439,171 		JBrowse link
G SLCO2B1 solute carrier organic anion transporter family member 2B1 multiple interactions EXP Irinotecan inhibits the reaction [SLCO2B1 protein results in increased uptake of Cascade Blue] CTD PMID:30863990 NCBI chr11:75,151,107...75,206,549
Ensembl chr11:75,100,563...75,206,549 		JBrowse link
G SLPI secretory leukocyte peptidase inhibitor affects expression ISO Irinotecan affects the expression of SLPI mRNA CTD PMID:20097248 NCBI chr20:45,252,239...45,254,564
Ensembl chr20:45,252,239...45,254,564 		JBrowse link
G SMAD3 SMAD family member 3 decreases expression EXP Irinotecan analog results in decreased expression of SMAD3 mRNA CTD PMID:18927307 NCBI chr15:67,065,602...67,195,169
Ensembl chr15:67,063,763...67,195,173 		JBrowse link
G SMCHD1 structural maintenance of chromosomes flexible hinge domain containing 1 decreases expression EXP Irinotecan analog results in decreased expression of SMCHD1 mRNA CTD PMID:18927307 NCBI chr18:2,655,726...2,805,017
Ensembl chr18:2,655,726...2,805,017 		JBrowse link
G SMU1 SMU1 DNA replication regulator and spliceosomal factor decreases expression EXP Irinotecan analog results in decreased expression of SMU1 mRNA CTD PMID:18927307 NCBI chr 9:33,041,765...33,076,674
Ensembl chr 9:33,041,765...33,076,674 		JBrowse link
G SMURF1 SMAD specific E3 ubiquitin protein ligase 1 affects expression EXP Irinotecan analog affects the expression of SMURF1 mRNA CTD PMID:18927307 NCBI chr 7:99,027,440...99,144,108
Ensembl chr 7:99,027,440...99,144,108 		JBrowse link
G SNRPA1 small nuclear ribonucleoprotein polypeptide A' decreases expression
multiple interactions		 EXP Irinotecan analog results in decreased expression of SNRPA1 mRNA
SNRPA1 protein affects the susceptibility to [Fluorouracil co-treated with Irinotecan analog]		 CTD PMID:18927307 NCBI chr15:101,281,510...101,295,248
Ensembl chr15:101,281,510...101,295,282 		JBrowse link
G SNRPF small nuclear ribonucleoprotein polypeptide F increases response to substance EXP SNRPF protein results in increased susceptibility to Irinotecan CTD PMID:16734730 NCBI chr12:95,858,952...95,866,140
Ensembl chr12:95,858,952...95,903,828 		JBrowse link
G SNX18 sorting nexin 18 decreases expression EXP Irinotecan metabolite results in decreased expression of SNX18 mRNA; Irinotecan results in decreased expression of SNX18 mRNA CTD PMID:15956246 NCBI chr 5:54,517,759...54,648,005
Ensembl chr 5:54,517,759...54,546,586 		JBrowse link
G SOD1 superoxide dismutase 1 multiple interactions
decreases expression
increases expression		 EXP Luteolin inhibits the reaction [Irinotecan results in decreased expression of SOD1 protein]; Luteolin inhibits the reaction [Irinotecan results in increased expression of SOD1 mRNA]; Rosiglitazone inhibits the reaction [Irinotecan results in increased expression of SOD1 mRNA] CTD PMID:34699766 NCBI chr21:31,659,693...31,668,931
Ensembl chr21:31,659,666...31,668,931 		JBrowse link
G SOD2 superoxide dismutase 2 multiple interactions EXP [Irinotecan co-treated with Fluorouracil] results in increased activity of SOD2 protein CTD PMID:15886469 NCBI chr 6:159,669,069...159,762,281
Ensembl chr 6:159,669,069...159,762,529 		JBrowse link
G SP1 Sp1 transcription factor decreases expression
multiple interactions
increases phosphorylation		 EXP Irinotecan analog results in decreased expression of SP1 mRNA
SP1 protein affects the susceptibility to [Fluorouracil co-treated with Irinotecan analog]
Irinotecan results in increased phosphorylation of SP1 protein		 CTD PMID:17441964 PMID:18927307 NCBI chr12:53,380,176...53,416,446
Ensembl chr12:53,380,176...53,416,446 		JBrowse link
G SPHK1 sphingosine kinase 1 affects expression ISO Irinotecan affects the expression of SPHK1 mRNA CTD PMID:20097248 NCBI chr17:76,383,204...76,387,855
Ensembl chr17:76,376,584...76,387,860 		JBrowse link
G SPIB Spi-B transcription factor increases expression EXP Irinotecan metabolite results in increased expression of SPIB mRNA; Irinotecan results in increased expression of SPIB mRNA CTD PMID:15956246 NCBI chr19:50,418,938...50,431,314
Ensembl chr19:50,418,938...50,431,314 		JBrowse link
G SRP19 signal recognition particle 19 multiple interactions EXP [Fluorouracil co-treated with Irinotecan] results in decreased expression of SRP19 mRNA CTD PMID:16391804 NCBI chr 5:112,861,287...112,898,371
Ensembl chr 5:112,861,188...112,898,371 		JBrowse link
G SRPX sushi repeat containing protein X-linked increases expression ISO Irinotecan results in increased expression of SRPX mRNA CTD PMID:20097248 NCBI chr  X:38,149,339...38,220,871
Ensembl chr  X:38,149,336...38,220,924 		JBrowse link
G STAT1 signal transducer and activator of transcription 1 multiple interactions
increases phosphorylation		 EXP STAT1 protein promotes the reaction [Irinotecan results in increased localization of FAS protein]; TP53 protein inhibits the reaction [Irinotecan results in increased phosphorylation of STAT1 protein] CTD PMID:16204068 NCBI chr 2:190,969,149...191,014,171
Ensembl chr 2:190,908,460...191,020,960 		JBrowse link
G STK25 serine/threonine kinase 25 affects expression ISO Irinotecan affects the expression of STK25 mRNA CTD PMID:20097248 NCBI chr 2:241,492,670...241,509,572
Ensembl chr 2:241,492,670...241,509,730 		JBrowse link
G STK38 serine/threonine kinase 38 increases expression EXP Irinotecan metabolite results in increased expression of STK38 mRNA; Irinotecan results in increased expression of STK38 mRNA CTD PMID:15956246 NCBI chr 6:36,493,892...36,547,479
Ensembl chr 6:36,493,892...36,547,479 		JBrowse link
G STK4 serine/threonine kinase 4 decreases expression
multiple interactions		 EXP Irinotecan analog results in decreased expression of STK4 mRNA; Irinotecan metabolite results in decreased expression of STK4 mRNA; Irinotecan results in decreased expression of STK4 mRNA
STK4 protein affects the susceptibility to [Fluorouracil co-treated with Irinotecan analog]		 CTD PMID:15956246 PMID:18927307 NCBI chr20:44,966,512...45,080,021
Ensembl chr20:44,966,494...45,080,021 		JBrowse link
G STX5 syntaxin 5 multiple interactions EXP [Fluorouracil co-treated with Irinotecan] results in increased expression of STX5 mRNA CTD PMID:16391804 NCBI chr11:62,806,860...62,832,051
Ensembl chr11:62,806,860...62,832,051 		JBrowse link
G SULT1A4 sulfotransferase family 1A member 4 increases expression EXP Irinotecan metabolite results in increased expression of SULT1A4 mRNA; Irinotecan results in increased expression of SULT1A4 mRNA CTD PMID:15956246 NCBI chr16:29,459,913...29,464,966
Ensembl chr16:29,459,913...29,464,966 		JBrowse link
G SYDE2 synapse defective Rho GTPase homolog 2 increases expression EXP Irinotecan analog results in increased expression of SYDE2 mRNA CTD PMID:18927307 NCBI chr 1:85,152,491...85,201,016
Ensembl chr 1:85,156,889...85,201,724 		JBrowse link
G SYT1 synaptotagmin 1 decreases expression EXP Irinotecan analog results in decreased expression of SYT1 mRNA CTD PMID:18927307 NCBI chr12:78,863,982...79,452,008
Ensembl chr12:78,863,993...79,452,008 		JBrowse link
G TAF2 TATA-box binding protein associated factor 2 decreases expression EXP Irinotecan metabolite results in decreased expression of TAF2 mRNA; Irinotecan results in decreased expression of TAF2 mRNA CTD PMID:15956246 NCBI chr 8:119,730,774...119,832,841
Ensembl chr 8:119,730,774...119,832,863 		JBrowse link
G TAF5L TATA-box binding protein associated factor 5 like multiple interactions EXP [Fluorouracil co-treated with Irinotecan] results in decreased expression of TAF5L mRNA CTD PMID:16391804 NCBI chr 1:229,593,134...229,626,122
Ensembl chr 1:229,593,134...229,626,122 		JBrowse link
G TARDBP TAR DNA binding protein multiple interactions ISO [PHY 906 co-treated with Irinotecan] affects the expression of TARDBP mRNA CTD PMID:32812032 NCBI chr 1:11,012,654...11,030,528
Ensembl chr 1:11,012,344...11,030,528 		JBrowse link
G TBCC tubulin folding cofactor C increases expression EXP Irinotecan metabolite results in increased expression of TBCC mRNA; Irinotecan results in increased expression of TBCC mRNA CTD PMID:15956246 PMID:20185912 NCBI chr 6:42,744,498...42,746,103
Ensembl chr 6:42,744,498...42,746,103 		JBrowse link
G TCF12 transcription factor 12 decreases expression EXP Irinotecan analog results in decreased expression of TCF12 mRNA CTD PMID:18927307 NCBI chr15:56,918,090...57,291,310
Ensembl chr15:56,918,623...57,299,281 		JBrowse link
G TCF7L2 transcription factor 7 like 2 decreases expression EXP Irinotecan analog results in decreased expression of TCF7L2 mRNA CTD PMID:18927307 NCBI chr10:112,950,247...113,167,678
Ensembl chr10:112,950,247...113,167,678 		JBrowse link
G TESK2 testis associated actin remodelling kinase 2 affects expression ISO Irinotecan affects the expression of TESK2 mRNA CTD PMID:20097248 NCBI chr 1:45,343,883...45,491,163
Ensembl chr 1:45,343,883...45,491,163 		JBrowse link
G TFCP2 transcription factor CP2 decreases expression EXP Irinotecan analog results in decreased expression of TFCP2 mRNA CTD PMID:18927307 NCBI chr12:51,093,656...51,173,135
Ensembl chr12:51,093,656...51,173,135 		JBrowse link
G TFF1 trefoil factor 1 affects expression ISO Irinotecan affects the expression of TFF1 mRNA CTD PMID:20097248 NCBI chr21:42,362,282...42,366,535
Ensembl chr21:42,362,282...42,366,535 		JBrowse link
G TFF3 trefoil factor 3 affects expression ISO Irinotecan affects the expression of TFF3 mRNA CTD PMID:20097248 NCBI chr21:42,311,667...42,315,409
Ensembl chr21:42,311,667...42,315,409 		JBrowse link
G TFPI tissue factor pathway inhibitor decreases expression EXP Irinotecan analog results in decreased expression of TFPI mRNA CTD PMID:18927307 NCBI chr 2:187,464,230...187,554,435
Ensembl chr 2:187,464,230...187,565,760 		JBrowse link
G TFRC transferrin receptor increases expression EXP Irinotecan analog results in increased expression of TFRC mRNA CTD PMID:18927307 NCBI chr 3:196,049,284...196,082,090
Ensembl chr 3:196,012,511...196,082,153 		JBrowse link
G TGFA transforming growth factor alpha multiple interactions
decreases response to substance
increases secretion		 EXP Gefitinib inhibits the reaction [Irinotecan metabolite results in increased secretion of TGFA protein]; Gefitinib inhibits the reaction [Irinotecan results in increased secretion of TGFA protein]; rottlerin inhibits the reaction [Irinotecan metabolite results in increased secretion of TGFA protein]; rottlerin inhibits the reaction [Irinotecan results in increased secretion of TGFA protein]
TGFA protein results in decreased susceptibility to Irinotecan
Irinotecan metabolite results in increased secretion of TGFA protein; Irinotecan results in increased secretion of TGFA protein		 CTD PMID:15723263 PMID:16734730 NCBI chr 2:70,447,284...70,553,826
Ensembl chr 2:70,447,284...70,554,193 		JBrowse link
G TGFBI transforming growth factor beta induced decreases expression EXP Irinotecan analog results in decreased expression of TGFBI mRNA CTD PMID:18927307 NCBI chr 5:136,028,988...136,063,818
Ensembl chr 5:136,028,988...136,063,818 		JBrowse link
G THBS1 thrombospondin 1 decreases response to substance EXP THBS1 protein results in decreased susceptibility to Irinotecan CTD PMID:16734730 NCBI chr15:39,581,079...39,599,466
Ensembl chr15:39,581,079...39,599,466 		JBrowse link
G THBS2 thrombospondin 2 increases expression ISO Irinotecan results in increased expression of THBS2 mRNA CTD PMID:20097248 NCBI chr 6:169,215,785...169,253,846
Ensembl chr 6:169,215,780...169,254,050 		JBrowse link
G THEM4 thioesterase superfamily member 4 decreases expression EXP Irinotecan analog results in decreased expression of THEM4 mRNA CTD PMID:18927307 NCBI chr 1:151,870,866...151,909,511
Ensembl chr 1:151,870,866...151,909,637 		JBrowse link
G THNSL1 threonine synthase like 1 decreases expression EXP Irinotecan analog results in decreased expression of THNSL1 mRNA CTD PMID:18927307 NCBI chr10:24,952,364...25,026,664
Ensembl chr10:25,016,612...25,026,664 		JBrowse link
G THRAP3 thyroid hormone receptor associated protein 3 decreases expression EXP Irinotecan analog results in decreased expression of THRAP3 mRNA CTD PMID:18927307 NCBI chr 1:36,207,637...36,305,357
Ensembl chr 1:36,224,432...36,305,357 		JBrowse link
G THY1 Thy-1 cell surface antigen increases expression EXP Irinotecan metabolite results in increased expression of THY1 mRNA; Irinotecan results in increased expression of THY1 mRNA CTD PMID:15956246 NCBI chr11:119,415,476...119,424,985
Ensembl chr11:119,415,476...119,424,985 		JBrowse link
G TLR2 toll like receptor 2 multiple interactions
affects response to substance		 ISO TLR2 protein affects the reaction [Irinotecan affects the expression of IL1B mRNA]; TLR2 protein affects the reaction [Irinotecan affects the expression of NR1I2 mRNA]; TLR2 protein affects the reaction [Irinotecan affects the expression of NR1I3 mRNA]; TLR2 protein affects the reaction [Irinotecan affects the expression of TNF mRNA]; TLR2 protein affects the reaction [Irinotecan results in decreased expression of UGT1A1 mRNA]; TLR2 protein affects the reaction [Irinotecan results in increased expression of IL6 mRNA]
TLR2 protein affects the susceptibility to Irinotecan		 CTD PMID:35728726 NCBI chr 4:153,684,280...153,710,637
Ensembl chr 4:153,684,050...153,706,260 		JBrowse link
G TLR4 toll like receptor 4 multiple interactions
affects response to substance
increases expression		 ISO Silymarin inhibits the reaction [Irinotecan results in increased expression of TLR4 protein]; TLR4 protein affects the reaction [Irinotecan affects the expression of IL1B mRNA]; TLR4 protein affects the reaction [Irinotecan affects the expression of NR1I2 mRNA]; TLR4 protein affects the reaction [Irinotecan affects the expression of NR1I3 mRNA]; TLR4 protein affects the reaction [Irinotecan affects the expression of TNF mRNA]; TLR4 protein affects the reaction [Irinotecan results in decreased expression of UGT1A1 mRNA]; TLR4 protein affects the reaction [Irinotecan results in increased expression of IL6 mRNA]
TLR4 protein affects the susceptibility to Irinotecan		 CTD PMID:28454924 PMID:35728726 NCBI chr 9:117,704,403...117,724,735
Ensembl chr 9:117,704,175...117,724,735 		JBrowse link
G TMEM123 transmembrane protein 123 decreases expression EXP Irinotecan analog results in decreased expression of TMEM123 mRNA CTD PMID:18927307 NCBI chr11:102,396,332...102,452,765
Ensembl chr11:102,396,332...102,470,384 		JBrowse link
G TMEM267 transmembrane protein 267 decreases expression EXP Irinotecan analog results in decreased expression of TMEM267 mRNA CTD PMID:18927307 NCBI chr 5:43,444,252...43,484,387
Ensembl chr 5:43,444,252...43,483,893 		JBrowse link
G TMEM37 transmembrane protein 37 affects expression ISO Irinotecan affects the expression of TMEM37 mRNA CTD PMID:20097248 NCBI chr 2:119,429,895...119,438,504
Ensembl chr 2:119,429,901...119,438,504 		JBrowse link
G TMEM41B transmembrane protein 41B decreases expression EXP Irinotecan metabolite results in decreased expression of TMEM41B mRNA; Irinotecan results in decreased expression of TMEM41B mRNA CTD PMID:15956246 NCBI chr11:9,280,654...9,314,593
Ensembl chr11:9,280,654...9,314,636 		JBrowse link
G TMSB4X thymosin beta 4 X-linked multiple interactions ISO [PHY 906 co-treated with Irinotecan] affects the expression of TMSB4X mRNA CTD PMID:32812032 NCBI chr  X:12,975,110...12,977,223
Ensembl chr  X:12,975,110...12,977,227 		JBrowse link
G TMT1B thiol methyltransferase 1B affects expression ISO Irinotecan affects the expression of METTL7B mRNA CTD PMID:20097248 NCBI chr12:55,681,736...55,684,611
Ensembl chr12:55,681,736...55,684,611 		JBrowse link
G TNF tumor necrosis factor increases expression
affects expression
increases secretion
multiple interactions		 ISO
EXP		 Irinotecan results in increased expression of TNF mRNA; Irinotecan results in increased expression of TNF protein
Irinotecan affects the expression of TNF mRNA
Irinotecan results in increased secretion of TNF protein
Luteolin inhibits the reaction [Irinotecan results in increased expression of TNF mRNA]; PPARG protein affects the reaction [Luteolin inhibits the reaction [Irinotecan results in increased expression of TNF mRNA]]; PPARG protein affects the reaction [Rosiglitazone inhibits the reaction [Irinotecan results in increased expression of TNF mRNA]]; Rosiglitazone inhibits the reaction [Irinotecan results in increased expression of TNF mRNA]
[Irinotecan co-treated with Ciprofloxacin] promotes the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Ciprofloxacin inhibits the reaction [Irinotecan promotes the reaction [Mitogens results in increased expression of TNF protein]]; Irinotecan inhibits the reaction [Mitogens results in increased expression of TNF protein]; Irinotecan promotes the reaction [Mitogens results in increased expression of TNF protein]; Thalidomide inhibits the reaction [Irinotecan results in increased expression of TNF mRNA]; Thalidomide inhibits the reaction [Irinotecan results in increased expression of TNF protein]
2-(1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-7H-purin-7-yl)-N-(4-isopropylphenyl)acetamide inhibits the reaction [carvacrol inhibits the reaction [Irinotecan results in increased expression of TNF protein]]; carvacrol inhibits the reaction [Irinotecan results in increased expression of TNF protein]; MYD88 protein affects the reaction [Irinotecan affects the expression of TNF mRNA]; TLR2 protein affects the reaction [Irinotecan affects the expression of TNF mRNA]; TLR4 protein affects the reaction [Irinotecan affects the expression of TNF mRNA]		 CTD PMID:16815871 PMID:18182997 PMID:18535404 PMID:19401694 PMID:26431797 More... NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336 		JBrowse link
G TNFAIP6 TNF alpha induced protein 6 decreases expression EXP Irinotecan metabolite results in decreased expression of TNFAIP6 mRNA; Irinotecan results in decreased expression of TNFAIP6 mRNA CTD PMID:15956246 NCBI chr 2:151,357,592...151,381,340
Ensembl chr 2:151,357,592...151,380,046 		JBrowse link
G TNFRSF12A TNF receptor superfamily member 12A increases expression ISO Irinotecan results in increased expression of TNFRSF12A mRNA CTD PMID:20097248 NCBI chr16:3,020,368...3,022,383
Ensembl chr16:3,018,445...3,022,383 		JBrowse link
G TNFRSF14 TNF receptor superfamily member 14 affects expression ISO Irinotecan affects the expression of TNFRSF14 mRNA CTD PMID:20097248 NCBI chr 1:2,554,234...2,563,829
Ensembl chr 1:2,555,639...2,565,382 		JBrowse link
G TNFRSF1A TNF receptor superfamily member 1A increases expression ISO Irinotecan results in increased expression of TNFRSF1A mRNA CTD PMID:20097248 NCBI chr12:6,328,771...6,342,076
Ensembl chr12:6,328,757...6,342,114 		JBrowse link
G TNFSF10 TNF superfamily member 10 increases activity
multiple interactions		 EXP Irinotecan results in increased activity of TNFSF10 protein
CFLAR protein alternative form inhibits the reaction [Irinotecan results in increased activity of TNFSF10 protein]		 CTD PMID:16373718 NCBI chr 3:172,505,508...172,523,430
Ensembl chr 3:172,505,508...172,523,475 		JBrowse link
G TOB1 transducer of ERBB2, 1 increases expression EXP Irinotecan metabolite results in increased expression of TOB1 mRNA; Irinotecan results in increased expression of TOB1 mRNA CTD PMID:15956246 NCBI chr17:50,862,223...50,867,978
Ensembl chr17:50,862,223...50,867,978 		JBrowse link
G TOB2 transducer of ERBB2, 2 increases expression EXP Irinotecan metabolite results in increased expression of TOB2 mRNA; Irinotecan results in increased expression of TOB2 mRNA CTD PMID:15956246 NCBI chr22:41,433,494...41,446,801
Ensembl chr22:41,433,494...41,446,801 		JBrowse link
G TOP1 DNA topoisomerase I affects response to substance
affects binding
decreases activity		 EXP TOP1 protein affects the susceptibility to Irinotecan
Irinotecan binds to TOP1 protein
Irinotecan results in decreased activity of TOP1 protein		 CTD PMID:11914913 PMID:15041737 PMID:15655543 PMID:18509181 NCBI chr20:41,028,822...41,124,487
Ensembl chr20:41,028,822...41,124,487 		JBrowse link
G TOP2A DNA topoisomerase II alpha decreases expression
increases response to substance		 EXP Irinotecan metabolite results in decreased expression of TOP2A mRNA; Irinotecan results in decreased expression of TOP2A mRNA
TOP2A mRNA results in increased susceptibility to Irinotecan		 CTD PMID:15239142 PMID:15956246 NCBI chr17:40,388,525...40,417,896
Ensembl chr17:40,388,525...40,417,896 		JBrowse link
G TOP6BL TOP6B like initiator of meiotic double strand breaks increases expression EXP Irinotecan analog results in increased expression of TOP6BL mRNA CTD PMID:18927307 NCBI chr11:66,744,736...66,843,516
Ensembl chr11:66,744,451...66,843,516 		JBrowse link
G TOPORS TOP1 binding arginine/serine rich protein, E3 ubiquitin ligase decreases expression EXP Irinotecan metabolite results in decreased expression of TOPORS mRNA; Irinotecan results in decreased expression of TOPORS mRNA CTD PMID:15956246 NCBI chr 9:32,540,544...32,552,586
Ensembl chr 9:32,540,544...32,552,586 		JBrowse link
G TP53 tumor protein p53 increases response to substance
affects activity
increases expression
affects response to substance
increases phosphorylation
multiple interactions		 EXP TP53 results in increased susceptibility to Irinotecan
Irinotecan affects the activity of TP53 protein; Irinotecan metabolite affects the activity of TP53 protein
Irinotecan results in increased expression of TP53 mRNA; Irinotecan results in increased expression of TP53 protein
TP53 protein affects the susceptibility to Irinotecan
Irinotecan results in increased phosphorylation of TP53 protein
[Irinotecan co-treated with Bortezomib] results in increased ubiquitination of TP53 protein; Irinotecan results in increased phosphorylation of and results in increased activity of TP53 protein; Irinotecan results in increased phosphorylation of and results in increased expression of TP53 protein; TP53 protein affects the susceptibility to [Irinotecan co-treated with Bortezomib]; TP53 protein inhibits the reaction [Irinotecan results in increased phosphorylation of STAT1 protein]		 CTD PMID:16204068 PMID:16373703 PMID:16963839 PMID:22510560 PMID:22898888 More... NCBI chr17:7,668,421...7,687,490
Ensembl chr17:7,661,779...7,687,546 		JBrowse link
G TP53INP1 tumor protein p53 inducible nuclear protein 1 increases expression EXP Irinotecan analog results in increased expression of TP53INP1 mRNA CTD PMID:18927307 NCBI chr 8:94,925,972...94,949,378
Ensembl chr 8:94,925,972...94,949,378 		JBrowse link
G TPMT thiopurine S-methyltransferase increases expression
multiple interactions		 EXP Irinotecan analog results in increased expression of TPMT mRNA
TPMT protein affects the susceptibility to [Fluorouracil co-treated with Irinotecan analog]		 CTD PMID:18927307 NCBI chr 6:18,128,311...18,155,169
Ensembl chr 6:18,128,311...18,155,077 		JBrowse link
G TPPP tubulin polymerization promoting protein increases expression EXP Irinotecan analog results in increased expression of TPPP mRNA CTD PMID:18927307 NCBI chr 5:659,862...700,727
Ensembl chr 5:659,862...693,352 		JBrowse link
G TPX2 TPX2 microtubule nucleation factor decreases expression EXP Irinotecan metabolite results in decreased expression of TPX2 mRNA; Irinotecan results in decreased expression of TPX2 mRNA CTD PMID:15956246 NCBI chr20:31,739,290...31,801,800
Ensembl chr20:31,739,271...31,801,805 		JBrowse link
G TRADD TNFRSF1A associated via death domain increases expression EXP Irinotecan metabolite results in increased expression of TRADD mRNA; Irinotecan results in increased expression of TRADD mRNA CTD PMID:15956246 NCBI chr16:67,154,185...67,159,909
Ensembl chr16:67,154,185...67,159,909 		JBrowse link
G TRAF1 TNF receptor associated factor 1 increases expression
decreases expression		 EXP Irinotecan metabolite results in increased expression of TRAF1 mRNA; Irinotecan results in increased expression of TRAF1 mRNA
Irinotecan metabolite results in decreased expression of TRAF1 mRNA; Irinotecan results in decreased expression of TRAF1 mRNA		 CTD PMID:15956246 NCBI chr 9:120,902,393...120,929,171
Ensembl chr 9:120,902,393...120,929,173 		JBrowse link
G TRDMT1 tRNA aspartic acid methyltransferase 1 decreases expression EXP Irinotecan metabolite results in decreased expression of TRDMT1 mRNA; Irinotecan results in decreased expression of TRDMT1 mRNA CTD PMID:15956246 NCBI chr10:17,137,336...17,201,672
Ensembl chr10:17,137,336...17,202,054 		JBrowse link
G TRIB1 tribbles pseudokinase 1 increases expression EXP Irinotecan analog results in increased expression of TRIB1 mRNA CTD PMID:18927307 NCBI chr 8:125,430,358...125,438,403
Ensembl chr 8:125,430,358...125,438,403 		JBrowse link
G TRIB2 tribbles pseudokinase 2 affects expression EXP Irinotecan analog affects the expression of TRIB2 mRNA CTD PMID:18927307 NCBI chr 2:12,716,936...12,742,734
Ensembl chr 2:12,716,910...12,742,734 		JBrowse link
G TRIM4 tripartite motif containing 4 increases expression EXP Irinotecan analog results in increased expression of TRIM4 mRNA CTD PMID:18927307 NCBI chr 7:99,890,403...99,919,530
Ensembl chr 7:99,876,958...99,919,531 		JBrowse link
G TRIM9 tripartite motif containing 9 increases expression EXP Irinotecan analog results in increased expression of TRIM9 mRNA CTD PMID:18927307 NCBI chr14:50,975,266...51,095,105
Ensembl chr14:50,975,262...51,096,061 		JBrowse link
G TRMT13 tRNA methyltransferase 13 homolog decreases expression EXP Irinotecan analog results in decreased expression of TRMT13 mRNA CTD PMID:18927307 NCBI chr 1:100,133,163...100,150,496
Ensembl chr 1:100,133,150...100,150,496 		JBrowse link
G TSEN2 tRNA splicing endonuclease subunit 2 decreases expression EXP Irinotecan results in decreased expression of TSEN2 mRNA CTD PMID:20185912 NCBI chr 3:12,480,231...12,539,624
Ensembl chr 3:12,484,421...12,541,549 		JBrowse link
G TSPAN4 tetraspanin 4 increases expression ISO Irinotecan results in increased expression of TSPAN4 mRNA CTD PMID:20097248 NCBI chr11:842,852...867,111
Ensembl chr11:842,812...867,116 		JBrowse link
G TSPAN8 tetraspanin 8 multiple interactions EXP [Fluorouracil co-treated with Irinotecan] results in decreased expression of TSPAN8 mRNA CTD PMID:16391804 NCBI chr12:71,125,096...71,157,999
Ensembl chr12:71,125,085...71,441,898 		JBrowse link
G TTK TTK protein kinase decreases expression EXP Irinotecan metabolite results in decreased expression of TTK mRNA; Irinotecan results in decreased expression of TTK mRNA CTD PMID:15956246 NCBI chr 6:80,004,649...80,042,527
Ensembl chr 6:80,003,887...80,042,527 		JBrowse link
G TXNIP thioredoxin interacting protein increases expression EXP Irinotecan results in increased expression of TXNIP mRNA CTD PMID:20185912 NCBI chr 1:145,992,435...145,996,579
Ensembl chr 1:145,992,435...145,996,579 		JBrowse link
G TXNRD1 thioredoxin reductase 1 affects expression ISO Irinotecan affects the expression of TXNRD1 mRNA CTD PMID:20097248 NCBI chr12:104,215,779...104,350,307
Ensembl chr12:104,215,779...104,350,307 		JBrowse link
G TYMP thymidine phosphorylase multiple interactions EXP TYMP mRNA affects the susceptibility to [Irinotecan co-treated with Fluorouracil co-treated with Leucovorin] CTD PMID:17454858 NCBI chr22:50,525,752...50,530,085
Ensembl chr22:50,525,752...50,530,032 		JBrowse link
G TYMS thymidylate synthetase multiple interactions EXP TYMS mRNA affects the susceptibility to [Irinotecan co-treated with Fluorouracil co-treated with Leucovorin] CTD PMID:17454858 NCBI chr18:657,653...673,578
Ensembl chr18:657,653...673,578 		JBrowse link
G TYROBP transmembrane immune signaling adaptor TYROBP multiple interactions ISO [PHY 906 co-treated with Irinotecan] affects the expression of TYROBP mRNA CTD PMID:32812032 NCBI chr19:35,904,403...35,908,295
Ensembl chr19:35,904,401...35,908,295 		JBrowse link
G UBD ubiquitin D affects expression ISO Irinotecan affects the expression of UBD mRNA CTD PMID:20097248 NCBI chr 6:29,555,515...29,559,732
Ensembl chr 6:29,555,515...29,559,732 		JBrowse link
G UBE2C ubiquitin conjugating enzyme E2 C decreases expression EXP
ISO		 Irinotecan metabolite results in decreased expression of UBE2C mRNA; Irinotecan results in decreased expression of UBE2C mRNA CTD PMID:15956246 PMID:20097248 NCBI chr20:45,812,644...45,816,952
Ensembl chr20:45,812,576...45,816,957 		JBrowse link
G UBE2E3 ubiquitin conjugating enzyme E2 E3 decreases expression EXP Irinotecan analog results in decreased expression of UBE2E3 mRNA CTD PMID:18927307 NCBI chr 2:180,980,360...181,063,425
Ensembl chr 2:180,967,248...181,076,585 		JBrowse link
G UBE2J2 ubiquitin conjugating enzyme E2 J2 decreases expression EXP Irinotecan analog results in decreased expression of UBE2J2 mRNA CTD PMID:18927307 NCBI chr 1:1,253,912...1,273,854
Ensembl chr 1:1,253,909...1,273,864 		JBrowse link
G UBE2L6 ubiquitin conjugating enzyme E2 L6 affects expression ISO Irinotecan affects the expression of UBE2L6 mRNA CTD PMID:20097248 NCBI chr11:57,551,662...57,567,935
Ensembl chr11:57,551,656...57,568,284 		JBrowse link
G UCHL5 ubiquitin C-terminal hydrolase L5 decreases expression EXP Irinotecan metabolite results in decreased expression of UCHL5 mRNA; Irinotecan results in decreased expression of UCHL5 mRNA CTD PMID:15956246 NCBI chr 1:193,012,254...193,060,076
Ensembl chr 1:193,012,250...193,060,080 		JBrowse link
G UGGT2 UDP-glucose glycoprotein glucosyltransferase 2 decreases expression EXP Irinotecan analog results in decreased expression of UGGT2 mRNA CTD PMID:18927307 NCBI chr13:95,801,580...96,053,401
Ensembl chr13:95,801,580...96,053,482 		JBrowse link
G UGT1A UDP glucuronosyltransferase family 1 member A complex locus affects response to substance
increases response to substance		 EXP UGT1A gene polymorphism affects the susceptibility to Irinotecan
UGT1A protein results in increased susceptibility to Irinotecan		 CTD PMID:22213127 NCBI chr 2:233,585,439...233,773,299 JBrowse link
G UGT1A1 UDP glucuronosyltransferase family 1 member A1 increases glucuronidation
affects glucuronidation
decreases expression
multiple interactions
decreases activity
decreases glucuronidation
increases metabolic processing
affects metabolic processing
affects response to substance		 ISO
EXP		 UGT1A1 protein results in increased glucuronidation of Irinotecan
UGT1A1 protein mutant form affects the glucuronidation of Irinotecan
Irinotecan results in decreased expression of UGT1A1 mRNA
MYD88 protein affects the reaction [Irinotecan results in decreased expression of UGT1A1 mRNA]; TLR2 protein affects the reaction [Irinotecan results in decreased expression of UGT1A1 mRNA]; TLR4 protein affects the reaction [Irinotecan results in decreased expression of UGT1A1 mRNA]
Irinotecan results in decreased activity of UGT1A1 protein
UGT1A1 gene mutant form results in decreased glucuronidation of Irinotecan; UGT1A1 protein polymorphism results in decreased glucuronidation of Irinotecan
[Ketoconazole results in decreased activity of UGT1A1 protein] which results in decreased metabolism of Irinotecan; [UGT1A1 protein mutant form affects the glucuronidation of Irinotecan] which results in decreased abundance of 7-ethyl-10-hydroxycamptothecin beta-glucuronide; [UGT1A1 protein results in increased glucuronidation of Irinotecan] which results in increased abundance of 7-ethyl-10-hydroxycamptothecin beta-glucuronide; UGT1A1 gene polymorphism affects the susceptibility to [Fluorouracil co-treated with Irinotecan]; UGT1A1 protein results in increased glucuronidation of and results in decreased activity of Irinotecan
UGT1A1 protein results in increased metabolism of Irinotecan
UGT1A1 protein affects the metabolism of Irinotecan
UGT1A1 gene polymorphism affects the susceptibility to Irinotecan; UGT1A1 promoter polymorphism affects the susceptibility to Irinotecan; UGT1A1 protein affects the susceptibility to Irinotecan		 CTD PMID:12960109 PMID:15517893 PMID:15523087 PMID:15655543 PMID:15716465 More... NCBI chr 2:233,760,270...233,773,300
Ensembl chr 2:233,760,270...233,773,300 		JBrowse link
G UGT1A10 UDP glucuronosyltransferase family 1 member A10 increases glucuronidation
affects glucuronidation
multiple interactions
affects response to substance
decreases activity		 EXP UGT1A10 protein results in increased glucuronidation of Irinotecan
UGT1A10 protein mutant form affects the glucuronidation of Irinotecan
[UGT1A10 protein mutant form affects the glucuronidation of Irinotecan] which results in decreased abundance of 7-ethyl-10-hydroxycamptothecin beta-glucuronide
UGT1A10 protein affects the susceptibility to Irinotecan
UGT1A10 protein results in decreased activity of Irinotecan		 CTD PMID:15517893 PMID:15716465 PMID:17898154 PMID:35930428 NCBI chr 2:233,636,448...233,773,300
Ensembl chr 2:233,636,448...233,773,300 		JBrowse link
G UGT1A6 UDP glucuronosyltransferase family 1 member A6 increases glucuronidation EXP UGT1A6 protein results in increased glucuronidation of Irinotecan CTD PMID:15716465 PMID:35930428 NCBI chr 2:233,691,702...233,773,300
Ensembl chr 2:233,691,607...233,773,300 		JBrowse link
G UGT1A7 UDP glucuronosyltransferase family 1 member A7 increases glucuronidation
multiple interactions
affects glucuronidation		 EXP UGT1A7 protein results in increased glucuronidation of Irinotecan
[UGT1A7 protein mutant form affects the glucuronidation of Irinotecan] which results in decreased abundance of 7-ethyl-10-hydroxycamptothecin beta-glucuronide		 CTD PMID:15716465 PMID:15833930 PMID:17898154 PMID:35930428 NCBI chr 2:233,681,901...233,773,300
Ensembl chr 2:233,681,901...233,773,300 		JBrowse link
G UGT1A8 UDP glucuronosyltransferase family 1 member A8 increases glucuronidation
affects glucuronidation
multiple interactions		 EXP UGT1A8 protein results in increased glucuronidation of Irinotecan
UGT1A8 protein mutant form affects the glucuronidation of Irinotecan
[UGT1A8 protein mutant form affects the glucuronidation of Irinotecan] which results in decreased abundance of 7-ethyl-10-hydroxycamptothecin beta-glucuronide		 CTD PMID:15833930 PMID:17898154 PMID:35930428 NCBI chr 2:233,617,633...233,773,300
Ensembl chr 2:233,617,633...233,773,300 		JBrowse link
G UGT1A9 UDP glucuronosyltransferase family 1 member A9 increases glucuronidation
multiple interactions
affects glucuronidation		 EXP
ISO		 UGT1A9 protein results in increased glucuronidation of Irinotecan
[UGT1A9 protein mutant form affects the glucuronidation of Irinotecan] which results in decreased abundance of 7-ethyl-10-hydroxycamptothecin beta-glucuronide		 CTD PMID:15833930 PMID:17898154 PMID:35930428 NCBI chr 2:233,671,898...233,773,300
Ensembl chr 2:233,671,898...233,773,300 		JBrowse link
G ULBP2 UL16 binding protein 2 increases expression EXP Irinotecan analog results in increased expression of ULBP2 mRNA CTD PMID:18927307 NCBI chr 6:149,942,014...149,949,235
Ensembl chr 6:149,942,014...149,949,235 		JBrowse link
G ULK4 unc-51 like kinase 4 decreases expression EXP Irinotecan analog results in decreased expression of ULK4 mRNA CTD PMID:18927307 NCBI chr 3:41,246,599...41,962,103
Ensembl chr 3:41,246,599...41,962,130 		JBrowse link
G USO1 USO1 vesicle transport factor decreases expression EXP Irinotecan analog results in decreased expression of USO1 mRNA CTD PMID:18927307 NCBI chr 4:75,724,577...75,814,286
Ensembl chr 4:75,724,577...75,814,286 		JBrowse link
G USP24 ubiquitin specific peptidase 24 decreases expression EXP Irinotecan analog results in decreased expression of USP24 mRNA CTD PMID:18927307 NCBI chr 1:55,066,359...55,215,364
Ensembl chr 1:55,066,359...55,215,378 		JBrowse link
G UTP3 UTP3 small subunit processome component multiple interactions EXP [Fluorouracil co-treated with Irinotecan] results in increased expression of UTP3 mRNA CTD PMID:16391804 NCBI chr 4:70,688,532...70,690,551
Ensembl chr 4:70,688,532...70,690,551 		JBrowse link
G VLDLR very low density lipoprotein receptor affects expression ISO Irinotecan affects the expression of VLDLR mRNA CTD PMID:20097248 NCBI chr 9:2,621,787...2,660,056
Ensembl chr 9:2,621,182...2,660,056 		JBrowse link
G VPS13B vacuolar protein sorting 13 homolog B decreases expression ISO Irinotecan results in decreased expression of VPS13B mRNA CTD PMID:20097248 NCBI chr 8:99,013,274...99,877,580
Ensembl chr 8:99,013,266...99,877,580 		JBrowse link
G VPS4A vacuolar protein sorting 4 homolog A decreases expression EXP Irinotecan analog results in decreased expression of VPS4A mRNA CTD PMID:18927307 NCBI chr16:69,311,350...69,326,939
Ensembl chr16:69,311,336...69,326,939 		JBrowse link
G VTI1A vesicle transport through interaction with t-SNAREs 1A decreases expression EXP Irinotecan analog results in decreased expression of VTI1A mRNA CTD PMID:18927307 NCBI chr10:112,446,988...112,855,368
Ensembl chr10:112,446,998...112,818,744 		JBrowse link
G WAPL WAPL cohesin release factor decreases expression EXP Irinotecan analog results in decreased expression of WAPL mRNA CTD PMID:18927307 NCBI chr10:86,435,256...86,521,792
Ensembl chr10:86,435,256...86,521,792 		JBrowse link
G WASL WASP like actin nucleation promoting factor decreases expression EXP Irinotecan analog results in decreased expression of WASL mRNA CTD PMID:18927307 NCBI chr 7:123,681,943...123,749,003
Ensembl chr 7:123,681,943...123,749,003 		JBrowse link
G WDFY1 WD repeat and FYVE domain containing 1 affects expression ISO Irinotecan affects the expression of WDFY1 mRNA CTD PMID:20097248 NCBI chr 2:223,875,348...223,945,335
Ensembl chr 2:223,855,716...223,945,357 		JBrowse link
G WNT16 Wnt family member 16 increases expression EXP Irinotecan analog results in increased expression of WNT16 mRNA CTD PMID:18927307 NCBI chr 7:121,325,367...121,341,104
Ensembl chr 7:121,325,367...121,341,104 		JBrowse link
G WSB1 WD repeat and SOCS box containing 1 increases expression EXP Irinotecan analog results in increased expression of WSB1 mRNA CTD PMID:18927307 NCBI chr17:27,294,114...27,315,926
Ensembl chr17:27,294,076...27,315,926 		JBrowse link
G XIAP X-linked inhibitor of apoptosis multiple interactions EXP [Irinotecan co-treated with alvocidib] results in increased cleavage of XIAP protein CTD PMID:11751522 NCBI chr  X:123,859,708...123,913,972
Ensembl chr  X:123,859,712...123,913,972 		JBrowse link
G XPA XPA, DNA damage recognition and repair factor decreases expression EXP Irinotecan results in decreased expression of XPA protein CTD PMID:11593056 NCBI chr 9:97,654,398...97,697,340
Ensembl chr 9:97,674,909...97,697,340 		JBrowse link
G XPO7 exportin 7 decreases expression EXP Irinotecan analog results in decreased expression of XPO7 mRNA CTD PMID:18927307 NCBI chr 8:21,919,662...22,006,585
Ensembl chr 8:21,919,662...22,006,585 		JBrowse link
G XRCC4 X-ray repair cross complementing 4 decreases expression EXP Irinotecan metabolite results in decreased expression of XRCC4 mRNA; Irinotecan results in decreased expression of XRCC4 mRNA CTD PMID:15956246 NCBI chr 5:83,077,547...83,374,473
Ensembl chr 5:83,077,498...83,353,787 		JBrowse link
G XRCC5 X-ray repair cross complementing 5 decreases expression EXP Irinotecan analog results in decreased expression of XRCC5 mRNA CTD PMID:18927307 NCBI chr 2:216,109,348...216,206,293
Ensembl chr 2:216,107,464...216,206,303 		JBrowse link
G YAF2 YY1 associated factor 2 decreases expression EXP Irinotecan analog results in decreased expression of YAF2 mRNA CTD PMID:18927307 NCBI chr12:42,157,104...42,238,248
Ensembl chr12:42,157,104...42,238,349 		JBrowse link
G YES1 YES proto-oncogene 1, Src family tyrosine kinase decreases expression EXP Irinotecan metabolite results in decreased expression of YES1 mRNA; Irinotecan results in decreased expression of YES1 mRNA CTD PMID:15956246 NCBI chr18:721,588...812,753
Ensembl chr18:721,588...812,546 		JBrowse link
G ZBTB14 zinc finger and BTB domain containing 14 decreases expression EXP Irinotecan analog results in decreased expression of ZBTB14 mRNA CTD PMID:18927307 NCBI chr18:5,289,022...5,297,053
Ensembl chr18:5,289,019...5,297,053 		JBrowse link
G ZBTB20 zinc finger and BTB domain containing 20 decreases expression EXP Irinotecan analog results in decreased expression of ZBTB20 mRNA CTD PMID:18927307 NCBI chr 3:114,314,500...115,147,288
Ensembl chr 3:114,314,500...115,147,292 		JBrowse link
G ZC3HAV1 zinc finger CCCH-type containing, antiviral 1 decreases expression EXP Irinotecan analog results in decreased expression of ZC3HAV1 mRNA CTD PMID:18927307 NCBI chr 7:139,043,515...139,109,720
Ensembl chr 7:139,043,515...139,132,122 		JBrowse link
G ZCCHC12 zinc finger CCHC-type containing 12 increases expression EXP Irinotecan analog results in increased expression of ZCCHC12 mRNA CTD PMID:18927307 NCBI chr  X:118,823,824...118,826,968
Ensembl chr  X:118,823,824...118,826,968 		JBrowse link
G ZDHHC21 zinc finger DHHC-type palmitoyltransferase 21 decreases expression EXP Irinotecan analog results in decreased expression of ZDHHC21 mRNA CTD PMID:18927307 NCBI chr 9:14,588,797...14,693,432
Ensembl chr 9:14,611,071...14,693,432 		JBrowse link
G ZFP36L2 ZFP36 ring finger protein like 2 decreases expression EXP Irinotecan metabolite results in decreased expression of ZFP36L2 mRNA; Irinotecan results in decreased expression of ZFP36L2 mRNA CTD PMID:15956246 NCBI chr 2:43,222,402...43,226,606
Ensembl chr 2:43,222,402...43,226,606 		JBrowse link
G ZFX zinc finger protein X-linked decreases expression EXP Irinotecan metabolite results in decreased expression of ZFX mRNA; Irinotecan results in decreased expression of ZFX mRNA CTD PMID:15956246 NCBI chr  X:24,148,982...24,216,255
Ensembl chr  X:24,149,173...24,216,255 		JBrowse link
G ZNF207 zinc finger protein 207 decreases expression EXP Irinotecan analog results in decreased expression of ZNF207 mRNA CTD PMID:18927307 NCBI chr17:32,350,157...32,381,885
Ensembl chr17:32,350,132...32,381,885 		JBrowse link
G ZNF32 zinc finger protein 32 multiple interactions EXP ZNF32 mRNA results in increased susceptibility to [Leucovorin co-treated with Fluorouracil co-treated with Irinotecan] CTD PMID:17327601 NCBI chr10:43,643,862...43,648,881
Ensembl chr10:43,643,860...43,648,881 		JBrowse link
G ZNF408 zinc finger protein 408 multiple interactions EXP [Fluorouracil co-treated with Irinotecan] results in increased expression of ZNF408 mRNA CTD PMID:16391804 NCBI chr11:46,701,031...46,705,912
Ensembl chr11:46,701,030...46,705,912 		JBrowse link
G ZNF574 zinc finger protein 574 decreases expression EXP Irinotecan analog results in decreased expression of ZNF574 mRNA CTD PMID:18927307 NCBI chr19:42,068,477...42,081,552
Ensembl chr19:42,068,477...42,081,552 		JBrowse link
G ZNF582 zinc finger protein 582 multiple interactions EXP ZNF582 mRNA results in increased susceptibility to [Leucovorin co-treated with Fluorouracil co-treated with Irinotecan] CTD PMID:17327601 NCBI chr19:56,382,751...56,393,534
Ensembl chr19:56,375,846...56,393,538 		JBrowse link
G ZNF668 zinc finger protein 668 decreases expression EXP Irinotecan analog results in decreased expression of ZNF668 mRNA CTD PMID:18927307 NCBI chr16:31,060,847...31,074,240
Ensembl chr16:31,060,843...31,074,240 		JBrowse link
G ZNRF1 zinc and ring finger 1 decreases expression EXP Irinotecan analog results in decreased expression of ZNRF1 mRNA CTD PMID:18927307 NCBI chr16:74,999,024...75,110,994
Ensembl chr16:74,999,024...75,110,994 		JBrowse link
G ZRSR2 zinc finger CCCH-type, RNA binding motif and serine/arginine rich 2 multiple interactions EXP ZRSR2 mRNA results in increased susceptibility to [Leucovorin co-treated with Fluorouracil co-treated with Irinotecan] CTD PMID:17327601 NCBI chr  X:15,790,484...15,823,260
Ensembl chr  X:15,790,156...15,830,694 		JBrowse link
G ZSCAN31 zinc finger and SCAN domain containing 31 decreases expression EXP Irinotecan analog results in decreased expression of ZSCAN31 mRNA CTD PMID:18927307 NCBI chr 6:28,324,737...28,356,271
Ensembl chr 6:28,324,693...28,356,271 		JBrowse link
Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 26040
    role 25956
      application 25177
        pro-agent 12047
          prodrug 11726
            irinotecan 738
Path 2
Term Annotations click to browse term
  CHEBI ontology 26040
    subatomic particle 26015
      composite particle 26015
        hadron 26015
          baryon 26015
            nucleon 26015
              atomic nucleus 26015
                atom 26015
                  main group element atom 25840
                    p-block element atom 25840
                      carbon group element atom 25437
                        carbon atom 25395
                          organic molecular entity 25395
                            heteroorganic entity 24770
                              organochalcogen compound 24383
                                organooxygen compound 24060
                                  ester 18815
                                    carboxylic ester 17956
                                      lactone 13632
                                        delta-lactone 4055
                                          SN-38 738
                                            irinotecan 738
paths to the root